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ABSTRACT 
 
The most significant determining factor in successful allotransplantation is the 
ability to avert graft rejection.  Innovative transplantation techniques have 
evolved to include presurgical and postsurgical immunosuppressive regimens, 
some of which continue to pose serious short- and long-term health risks.  The 
intrathymic (IT) inoculation of certain donor cell types into an adolescent recipient 
thymus gland in the circumstance of short-term immune ablation with a single 
intraperitoneal injection of antilymphocyte serum has been shown to induce 
tolerance to a variety of subsequent donor-specific grafts in many animal models 
of allogeneic transplantation.  Using this technique of immune re-programming, 
the resultant peripheral immune population has shown long-lasting efficacy in 
tolerance induction even after the withdrawal of non-donor-specific, systemically 
acting immunosuppressive drug regimens.  Cellular inoculates for IT tolerance 
induction have included donor splenocytes, spleen-derived dendritic cells, bone 
marrow cells, bone marrow-derived dendritic cells (included in the class of cells 
known as antigen presenting cells), renal glomeruli, and pancreatic islets of 
Langerhans.  To date, the potential of primary culture-immortalized thymic 
epithelial cells (TECs) to modify the host immune system using a similar 
experimental regimen has not been investigated in a rat model of allogeneic 
1
transplantation.  This may be due to the difficulty in deriving and maintaining 
these cells as a readily available source for extensive experimentation.  
 
Although the mechanism by which IT inoculation of antigenic cells induces 
tolerance has not been fully elucidated, numerous studies have demonstrated 
the efficacy of this technique in inducing specific unresponsiveness in a host.  
These studies have confirmed a significant role for the thymus in immune 
maturation, antigen recognition, and induction of specific unresponsiveness 
(central tolerance).  It is believed that cell/tissue grafts within the thymus allow 
presentation of foreign antigens to immature host T cells, resulting in reeducation 
of the host immune system through clonal deletion of target specific cells by 
apoptosis.  The proven efficacy of IT bone marrow transplantation in tolerance 
induction studies has served as background for the use of bone marrow 
transplantation in several of today’s pre-transplant conditioning regimens for 
human tissue transplantation.  Some of the techniques used for total 
myeloablation prior to allogeneic bone marrow reconstitution in human pre-
transplantation conditioning regimens are associated with significant health risks 
related to a severely immunocompromised state.  Hematopoietic cell 
transplantation is not trivial as bone marrow is also limited in supply.  
Additionally, bone marrow lacks cellular uniformity, sometimes harbors viral 
contaminants, and current technologies aimed at primary bone marrow culture 
are limited.  TECs were chosen for this investigation based on their thymic origin, 
epithelial nature, cellular uniformity, and ability to be maintained and manipulated 
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in vitro.  Bone marrow cannot offer these same benefits.  In light of the ability of 
certain cells to induce intrathymic tolerance, it was initially hypothesized that a 
combination of gene therapy on TECs and intrathymic transplantation of the 
genetically altered TECs might form a new paradigm for the prevention or 
treatment of transplant rejection.  Before embarking on this project, the effects of 
unmanipulated TECs transplanted to the intrathymic environment had to be 
investigated.  It was hypothesized that peripheral reactive lymphocyte depletion 
with antilymphocyte serum followed by TEC transplantation to the thymic 
environment would result in repopulation of the immune repertoire with cells 
recognizing TEC antigens as self.  In such a paradigm, the immunogenic proteins 
expressed by TECs within the host thymus would function as tolerogens, 
resulting in the modification of the host immune repertoire.  This approach would 
allow the host immune system to be specifically modified to accept grafted tissue 
or cells without impinging on its ability to effectively respond to other foreign 
immunogens.   
 
The early studies outlined in this project sought to identify techniques of 
establishing primary cultures of TECs from a variety of donor rat strains.  TEC 
primary cultures were characterized in varying growth medium conditions using 
several parameters, including morphological changes, proliferative capacity, 
junction formation, cell contact, and terminal differentiation.  The best suitable 
culture conditions were defined for the establishment of the primary cultures as a 
cell line.  These TECs were then used in transplantation experiments to 
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determine their ability to induce allogeneic tolerance to subsequent donor 
matched grafts.  The experimental design in this project used a rat model of 
allogeneic tissue transplantation.  Graft rejection was based on rejection scores 
determined by a histological analysis of donor matched and mismatched 
transplanted tissue.  The tolerogenic effects of TECs upon intrathymic 
transplantation were compared to the tolerogenic effects of bone marrow cells 
upon intrathymic transplantation.  The comparison evaluated the ability of the 
intrathymic treatments to modify the natural history of graft rejection as quantified 
by the extent of lymphocytic infiltration, general inflammation, and preservation of 
structural architecture.  On a scale of 0 to 4, with a score of 4 indicative of the 
most aggressive graft rejection processes, intrathymic transplantation 
experiments revealed a reduction in mean graft lymphocytic infiltration from 
1.78±0.47 in the negative control groups (intrathymic saline, IP saline; n=10) and 
1.50±0.60 (intrathymic saline, IP ALS; n=8) to 0.25±0.25 (p < 0.01) in the positive 
control group (intrathymic bone marrow + ALS; n=8).  A reduction in graft mean 
lymphocytic infiltration to 1.00±0.31 in the experimental group (intrathymic TEC, 
IP ALS; n=16) occurred, but the p value did not reach statistical significance.  
Overall, the results revealed that IT inoculation of TECs results in some 
immunomodulation, although not reaching the same effectiveness as bone 
marrow.  This might be related to previous reports of a dual role for the TEC in 
both positive and negative selection.  Overall, it appears that intrathymic 
inoculation of TECs can be used to reeducate the host immune system following 
reactive peripheral lymphocyte depletion and may provide an opportunity for 
4
future research using in vitro cellular manipulation techniques to further 
investigate pre-transplant conditioning regimens employing tolerance induction.   
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CHAPTER 1.  
TRANSPLANTATION, THE IMMUNE SYSTEM, AND THYMIC EPITHELIAL 
CELLS FOR TOLERANCE INDUCTION 
 
 
1.1. INTRODUCTION 
 
Transplantation offers a means of replacing absent or dysfunctional tissue with 
viable cells, tissues, or organs to meet the physiologic demands of the body.  
Autotransplantation involves transplantation within one individual; homogeneic or 
syngeneic transplantation involves transplantation between two histocompatibly 
matched individuals; and allogeneic transplantation (allotransplantation) involves 
transplantation between two histocompatibly mismatched individuals.  Xenogeneic 
transplantation involves transplantation between individuals from separate 
species.  Although there are documented reports of attempts to successfully 
transplant animal organs or tissues to humans dating as early as ancient Egypt 
and China circa 8,000 B.C. [1, 2], allotransplantation has been the mainstay of 
current investigations into successful human transplantation.  Great strides have 
been achieved in the successful replacement of organs, tissues, and cells.  
Advances in surgical techniques and graft treatments prior to transplantation have 
led to technical success in the placement of grafted organs and tissues.  
6
Pharmacological discoveries have led to the development of immunosuppressive 
agents that are almost universally administered to prevent acute and chronic graft 
rejection.  New treatment regimens can even offer the possibility of graft survival in 
the transplantation of a completely genetically mismatched organ.  Nevertheless, 
pharmacological agents used to prevent graft rejection are associated with 
significant complications, indicating a need for an alternative treatment which is as 
effective in reducing immune rejection process. 
 
This chapter will summarize the history of transplantation through the 21st century, 
explain normal immune system development and mechanisms of immune function, 
describe categories of graft rejection and ways of preventing it, and introduce 
tolerance induction mechanisms as a method of bypassing toxic 
immunosuppressive regimens and inducing antigen-specific immune 
unresponsiveness.  
 
 
1.2. THE HISTORY OF TRANSPLANTATION  
 
Blood transfusions and dental transplantation have been documented as far back 
as the 15th century.  Prior to the late 18th century, transplantation focused on 
replacement of limbs and teeth, and transferring skin and other body parts from 
one animal to another.  By the late 19th and early 20th centuries, a number of 
unsuccessful animal transplants were attempted using animal organs, including 
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kidney transplants between dogs.  The first reliable report of a human transplant 
surgery was a skin graft performed by Dr. Carl Bunger in 1823, although it is not 
reported whether this surgery was successful.  It was not until early in the 20th 
century that successful transplants between humans were reported, offering new 
avenues of renewed health.  The concerted efforts of researchers and 
physiologists helped to develop the surgical techniques needed for performing 
successful transplants, but rejection still remained a problem.   
 
Through the late 19th and early 20th centuries, corneal transplants, skin allografts, 
joint and vascular reconstruction, and blood transfusions became commonplace.  
In the 1920’s and 1930’s, the concept of "self versus non-self" was starting to 
become recognized and the field of transplant immunology was born.  Dr. Emile 
Holman, a young Boston surgeon, suggested from his results in skin 
transplantation that host immunity increased after a second grafting from the 
initial donor but not from a third party.  [1]  In 1937, Dr. J. B. Brown transplanted 
skin between identical twins and made a comparison between the indefinite 
survival of these grafts and the gradual “absorption” of maternal skin on burned 
patients.  In 1942, Oxford zoologist, Dr. Peter Medawar, was able to demonstrate 
the impracticality of allografts compared to autografts and reported hastened 
destruction of second allografts, concluding that accelerated rejection involved 
the “destruction of foreign epidermis…brought about by a mechanism of active 
immunization.”  These ingenious perceptions led to the induction of Sir Medawar 
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as “the father of transplantation biology”.  [3]  A more detailed outline of historical 
events in transplantation can be found in tabular form at Table A. 
 
“The replacement of diseased organs by healthy ones has been a milestone of 
medicine in the mid-twentieth century.”  [1]  However, organ transplant success is 
quite limited due to a number of factors, including availability of donor organs, 
immune graft rejection, and the side effects of immunosuppression.  One way to 
eliminate graft rejection is to use the recipient’s own tissue when possible (blood, 
skin, bone marrow, blood vessels).  Although successful experiments in renal 
transplantation in animals can be documented as early as 1902, it was 50 years 
later before the first successful living-related human kidney transplant. [4]  This 
was followed by venous allografts, kidney transplants between genetically 
mismatched siblings, cadaveric kidney, liver, lung, kidney-pancreas, heart, and 
pancreas transplantation.   
 
The accomplishments of early transplant surgeons and the growing popularity of 
organ transplantation led to many practical and ethical issues related to donor 
organ availability.  The establishment of brain death criteria in 1968 served to 
increase the supply of viable donor tissue for transplantation.  [5]  However, most 
of today’s graft recipients still must remain on a waiting list.  (In 2004, according 
to the United Network for Organ Sharing [UNOS], there were approximately 
14,000 donors available for nearly 90,000 recipients on the transplant waiting list 
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in the United States alone.)  The establishment of UNOS in the 1980’s supported 
organ procurement organizations and outlawed the purchase and sale of organs.   
 
Cryopreservation and biologist Dr. Jean-Francois Borel’s discovery of the 
immunosuppressant cyclosporine in 1972 (not clinically used until 1982) have 
been pivotal in the development of modern transplantation techniques.  The 
development of organ preservation solutions (e.g. Viaspan or University of 
Wisconsin [UW] solution) for improved organ preservation during cold storage 
and transport has led to significant improvements and greater success rates in 
transplantation by reducing the incidence of primary graft non-function (heat 
shock, reperfusion injury, ischemia).  [6] Simultaneous multiple organ 
transplantation has also led to increased success.  As success in transplantation 
has progressed, the demand for donors has grown.  In order to supply increasing 
demands, artificial tissue has been used to replace missing or dysfunctional 
tissue.  Through the 1980’s, artificial heart, single-lung, heart-liver, double-lung, 
and liver-small intestine transplantation techniques and protocols were 
established.   
 
Still, the increasing demand for viable transplantable tissues has led researchers 
to explore other avenues, such as advanced immunotherapies that would 
improve transplantation efficacy and xenotransplantation techniques that would 
allow extrahuman expansion of the donor pool.   
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1.2.1. Immunology and Transplantation 
 
In 1863, it became well documented that tissues transplanted from one person to 
another resulted in graft rejection.  Forty years later, this graft rejection was 
classified as immunologic in nature.  Irradiation by X-rays became the first 
available method of immunosuppression in the 1950’s, and after the 1958 
discovery of the histocompatibility gene complex and the development of tissue 
typing and matching, transplantation underwent a transformation from a technical 
science to an immunological science.  Namely, transplant surgeons had 
previously focused on technical aspects of transplantation, but the limited 
success of transplants impeded by the immunologic process of graft rejection led 
to a focus on preventing immune mechanisms that would destroy a technically 
well-placed graft.  Minimizing histocompatibility differences, along with early anti-
rejection medications like prednisone, azathioprine (Imuran), and anti-lymphocyte 
serum, offered some limited protection from rejection, but greatly increased the 
risk of postoperative infection.   
 
Lymphocytes were functionally distinguished and divided into T and B cell 
subsets in the late 1960’s, and not until the 1970’s were subsets of T cells 
defined using antibodies developed with recently discovered monoclonal 
antibody technology.  [1] Overall improvements in graft survival coincided with 
the conceptualization by Dr. Alfred Singer of subpopulations of T helper/inducer 
cells and the T cell receptor-MHC antigen interaction.  Since the FDA’s approval 
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of cyclosporine, there has been significantly reduced graft rejection and longer 
graft survival times with improved quality of life in many transplant recipients.  
The Nobel Prize for Medicine was shared between Dr. Joseph Murray in 1990 for 
his work in kidney transplantation and Dr. George Hitchings for his work in 
chemical immunosuppression.  Dr. E. Donnall Thomas was also awarded the 
Nobel Prize for bone marrow transplantation as a practical therapy in the 
treatment of leukemia.  Transplantation techniques have increased in complexity 
even since the 1990’s, employing newer, more sophisticated immunosuppressive 
agents whose mechanisms of action can be defined at the cellular level, and in 
some cases, the molecular level.  These agents continue to offer improved graft 
survival with fewer side effects.  The later part of the 20th century (1980-1999) 
also brought advances in immunology, tissue typing, and surgical techniques; as 
well as advances in organ donation, distribution, and preservation. In addition, 
the passage of several laws has provided additional support and direction to 
organ donation and transplantation in the United States. The Uniform Anatomical 
Gift Act of 1968 and the National Organ Transplant Act of 1984 began the 
process of establishing the organ donation and transplantation system that we 
know today. [7-9] Over the years, other federal polices and laws have provided 
for Medicare coverage and medication funding for some qualified transplant 
recipients.   
 
Because of the disparity between donor supply and recipient demand, transplant 
waiting lists are rapidly growing.  A combination approach has been developed to 
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curtail this disparity: the expansion of the donor pool and the advancement of 
immunosuppressive therapy, despite its side effects.  Many transplant centers 
have come to accept the use of living, unrelated donors in kidney 
allotransplantation.  The immunosuppressive regimens of today have allowed 
biologically unrelated donors the option of transplantation.   
 
The 21st century holds the promise of many new and exciting advances in the 
field of transplantation which include artificial organs and support devices, stem 
cells as sources of functional transplantable tissue, xenotransplantation (the use 
of animal cells and organs), advances in living and cadaveric organ donation, 
splitting of organs to help multiple recipients, and development of better anti-
rejection medications.  At the forefront of transplantation science, future studies 
may allow a better understanding of the immune system and specific applications 
of immunomodulatory treatments in the prevention of graft rejection.   
 
 
1.3. THE EVOLUTION OF 21ST CENTURY TRANSPLANTATION 
 
1.3.1. Blood Transfusion 
 
The most common form of transplantation performed in modern medicine is the 
blood transfusion.  The first successful blood transfusion was performed in 1818 
by Dr. James Blundell.  Transfusions became more widespread in World War I 
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following the discovery of blood group antigens by Dr. Karl Landsteiner, and the 
first use of an effective anticoagulant for stored blood, sodium citrate, in 1914.  
[10, 11]  Early blood transfusions were associated with transfusion reactions and 
infections, but over the past 90 years, advances in immunology and chemistry 
have transformed blood transfusions from harrowing experiences to a routine 
and relatively safe form of treatment.  The allogeneic blood supply is screened 
for viral antibodies, antigens, and nucleic acids, elevated enzyme levels, and 
evidence of syphilis.  The ability to screen for these particular elements, and to 
remove contaminated blood from the blood supply, has greatly increased the 
success of transfusion.  In terms of transplantation immunology, transfusion may 
elicit the formation of antibodies reactive to antigens on the donor red blood cells, 
leukocytes, or platelets.  Many transfusion recipients will become transiently 
febrile.  Significant transfusion reactions are generally limited to blood group 
antigen disparities, mostly commonly due to human error. 
 
1.3.2. Vascularized Transplantation 
 
An organ is a fully differentiated unit of tissues with specific cellular architecture 
that is specialized to work in concert to perform specific functions.  Each organ’s 
survival and function is dependent upon the provision of an adequate blood 
supply, and transplanted organs require the maintenance of patent vascularity 
following transplantation.   
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Among the most frequently transplanted single organs are the kidney, heart, liver, 
pancreas and lung.  An alternative to multiple single organ transplantation is the 
option of combined organ transplantation.  Combined organ transplants are 
designed to share a common, extensive vascular supply, and are therefore more 
likely to survive.  Frequently combined transplants include heart-lung.  
Bowel/cluster transplants or multivisceral transplants can be used to replace the 
function of multiple organs including the small bowel.  Additionally, large flaps of 
tissue (full thickness skin, muscle) that require an extensive blood supply can be 
successfully transplanted with vascular anastomoses.  While graft rejection 
following vascularized transplantation is still a common complication, the major 
cause of hospitalization during the first post-transplant year is infection [12], with 
graft versus host disease a significant complication in cluster transplantation. 
 
Immunosuppressive drug regimens that include multiple agents, each working 
through a different mechanism of action, have evolved to effectively reduce graft 
rejection and support survival of transplanted organs.  Although conventional 
immunosuppression includes triple therapy with sirolimus, cyclosporine, and 
prednisone, the specifics of which will be discussed in following sections, individual 
drug-related toxicity, recipient-related risk factors, and donor organ characteristics 
are all taken into account when deciding upon an immunosuppressive treatment 
regimen [13].  Most protocols combine a primary immunosuppressant (e.g. 
cyclosporine or tacrolimus) with one or two adjunctive agents (e.g. azathioprine, 
mycophenolate mofetil, sirolimus, corticosteroids).  These improvements in 
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immunosuppression have made allograft rejection “the exception rather than the 
rule” [14], reducing acute cellular rejections to about 10-20%.  [15] The reduced 
incidence of acute and chronic renal graft rejection has allowed renal 
transplantation to replace hemodialysis as the preferred hemofiltration option in 
end-stage renal disease.  [14]   
 
Heart, lung, and combined heart-lung transplants have been clinical options for 
resuming adequate circulation and gaseous exchange in congenital heart disease 
patients and those patients with end-stage heart and lung disease, and have been 
a standard part of the treatment paradigm for selected patients with these 
diseases over the past 35 years.  Emphysema and chronic obstructive pulmonary 
disease account for the pathology associated with the majority of single lung 
transplants, while the most frequently reported indication for heart transplantation 
in the United States is coronary artery disease.  The recipient’s medical condition 
is the most important factor in patient survival following lung transplantation, while 
the recipient’s age, gender, and race are the significant determining factors for 
successful heart transplant outcomes. [12] 
 
The indications for liver transplantation have expanded greatly, and techniques 
have been simplified over the years.  As the waiting list for liver transplantation 
continues to grow, and numbers of cadaveric donors remains static, the 
availability of transplantable livers cannot keep up with need.  The proliferative 
capacity of hepatocytes has made the use of live donors and the procurement of 
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split-liver grafts for two recipients a scientifically and medically sound approach 
towards reducing the shortage of donor organs.  [16] For unknown reasons, the 
liver is known to be associated with a downregulated immune response and 
excellent graft survival.  Although it has been reported that up to 70% of patients 
develop acute liver rejection, this often spontaneously resolves and chronic 
rejection is rarely seen.  [17] Because of the relatively forgiving nature of liver 
transplantation, cadaveric donors, living-unrelated related donors, and older 
donors with co-morbidities and moderate elevations in liver function tests can be 
added to the relatively small pool of living related donors to address the 
increasing demands for donors.  [16] Exploring beyond the realm of human 
transplantation, xenotransplantation (transplantation of tissue between disparate 
species) has been attempted to expand the donor pool for heart, liver, and kidney 
transplantation.  Attempts at xenotransplantation from chimpanzees and baboons 
to humans have been limited by hyperacute rejection due to preformed 
antibodies.  Molecular genetic techniques offer the option of knocking out genes 
that encode cell surface antigens prior to xenotransplantation.  Large offspring 
numbers and appropriate organ size for human transplantation make porcine to 
human xenotransplantation a realistic option for meeting increased demands for 
donors.  There is still concern about the threat of latent viruses in animal tissue.   
 
In diabetic patients, pancreas transplantation is routinely performed along with the 
scheduled kidney transplantation (often due to renal failure secondary to diabetes) 
and dramatically improves the quality of life of the patient.  The probability of 
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success of pancreas transplantation has reached that of other organ transplants.  
However, the inherent cotransplantation of surrounding exocrine pancreatic tissue 
along with the endocrine pancreatic islets is unnecessary and associated with 
complications such as enzymatic tissue damage.  Isolated islet transplantation, as 
will be described below, offers a more specific means of resupplying the recipient 
with needed insulin producing beta cells.   
 
1.3.3. Nonvascularized Transplantation 
 
Tissues are composed of uniform cells which are organized to perform a specific 
function.  Unlike an organ, a tissue’s viability does not depend on an organized 
vascular supply.  When faced with removal from its source of vascular perfusion, a 
tissue, if placed in a nurturing environment, will be infiltrated and perfused by 
surrounding blood vessels through the process of neovascularization.  Commonly 
transplanted tissues include skin, bones, ligaments/tendons, corneas, and heart 
valves.   
 
Skin transplantation is usually used to replace epidermal regions damaged by 
trauma (e.g. burns) or by disease (e.g. cancer).  Split thickness skin grafting 
involves a skin harvest which is processed to form a mesh, allowing expansion of 
the graft for greater surface area coverage compared to a full thickness skin graft.  
The prognosis for autologous skin engraftment is usually excellent but allogeneic 
skin engraftment still presents a challenge.   
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Bone transplantation may involve the use of live autologous cortical bone 
harvested from the ilium of the patient.  However, the recovery from this procedure 
is painful and associated with excessive bleeding.  Cryopreserved bone matrix 
(fibular strut) allografts are commonly used as structural support for osteogenesis 
in spinal fusion surgery.  The recipient’s blood is used to infiltrate the non-living 
graft with autologous cells.  Minimal graft rejection is associated with this process. 
 
Structural reinforcement can be accomplished with the proper placement of dense 
connective tissue, such as ligaments or tendons.  Most of the time this involves 
autologous grafting.  These tissue allografts are associated with very little 
complications other than ischemia. 
 
Corneal transplantation is used to replace a damaged cornea.  The avascularity of 
the cornea is the principal feature which determines its immunologic privilege.  The 
trauma of corneal transplantation surgery can compromise this privilege, exposing 
the graft to the host immune system. Studies over the past 50 years have 
demonstrated that inflammation and neovascularization predispose a corneal graft 
to the cell-mediated immune rejection response.  Fortunately, the antigenicity of 
corneal cells is comparatively low.  Topically applied immunosuppressive 
compounds can be used to prevent inflammation and vascularization, thus 
blocking T cell activation.  Blocking antibodies (to CTLA4, for example) and soluble  
coreceptor blocking agents have led to a considerable reduction of corneal 
allograft rejection.  [18] 
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Although the procedure is associated with significant mortality risks, replacement 
of the native aortic valve with a heart valve prosthesis has become one of the most 
frequently performed procedures in cardiac surgery. [19] Biologic valve 
prostheses, although limited in durability, offer an alternative to lifelong 
anticoagulation associated with mechanical prostheses. 
 
1.3.4. Cellular Transplantation 
 
Individual cells or cell clusters can be transplanted to a recipient to replace 
important physiologic roles lost to disease or damage.  When applicable, cellular 
transplantation offers a safer, less costly alternative to organ transplantation.  
Cellular transplantation involves the transplantation of such small volumes that 
the benefits of immunologically privileged site placement can be exploited.  
Immunologically privileged sites are parts of the body where the immune system 
is prevented from mounting an effective attack. They include the eye, testis, 
brain, placenta, and thymus gland, but only the eye's privileged status has so far 
been exploited (for corneal grafting) in humans. Many factors are involved in 
immune privilege, such as tight junctions between the cells of the tissue, little 
expression of MHC Class I molecules, and expression of the apoptotic-inducing 
ligands on the cell surface (such as Fas).   
 
Although pancreatic islets of Langerhans may be considered as tissues, or even 
as organs, due to their variety of interacting cell types and independent vascular 
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supply, they are included in this section.  Islet transplantation is a more specific 
alternative to pancreas transplantation for the replacement of insulin producing 
beta cells and can significantly reduce surgical morbidity.  Unfortunately, reduced 
beta cell mass occurs with organ dispersal and islet purification.  Recent progress 
in the field of pancreatic islet transplantation, most notably in Edmonton, Canada, 
has led to recipient insulin independence following single donor islet 
transplantation.  [20] However, current immunosuppressive drug regimens are 
complicated by the potential of dangerous systemic comorbidities associated with 
a non-specific mode of action.  Many immunosuppressive agents also 
demonstrate significant islet cell toxicity.  (Chaib, 1994) Diabetogenic 
immunosuppressants should be eliminated in order to allow optimal survival and 
function of the grafted islets, since lack of glycemic control can influence the 
survival of newly transplanted islets.  [21] Immunosuppressants such as 
mycophenolate mofetil and rapamycin do not appear to be as toxic as 
corticosteroids and cyclosporine.  [15] Cellular transplantation also offers the 
possibility of donor-specific tolerance induction.   
 
Other cellular transplants include bone marrow, epithelial cells, neural cells, 
myoblasts, and hepatocytes.  Bone marrow transplantation is performed to replace 
the hematogenous cell population.  This is most commonly secondary to 
myeloablative diseases.  Bone marrow has also been shown to induce donor-
specific tolerance in a variety of transplantation models, as will be discussed 
further in Chapter 4.  Neural cell and myoblast replacement procedures are still in 
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experimental stages.  Hepatocyte transplantation through the inferior mesenteric 
vein is growing in popularity as an alternative to liver transplantation for the 
correction of acute liver failure, inherited liver based metabolic diseases and 
coagulopathies, and  
chronic liver diseases.  [22-24]  
 
 
1.4. COMMON CHARACTERISTICS OF TRANSPLANTATION 
 
Successful transplantation of organs, tissues, or cells requires adequate tissue 
perfusion and reduced graft rejection.  Tissue perfusion in organ transplantation is 
dependent upon the infusion technique used to reduce intravascular debris, the 
skilled surgical anastomosis of the donor and host vessels, and the ability to 
maintain an unimpeded vascular supply to the graft.  Tissue perfusion in non-
vascularized transplantation is dependent upon a supportive nutritive environment 
and an accommodating immune milieu that allows the development of a new 
vascular supply.  Reduction of graft rejection in most cases is achieved by ABO 
blood type matching between the donor and the recipient and by prevention of 
immune mechanisms involved in infiltration of the graft by effector cells. 
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1.5. THE MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) 
 
Antigen presentation in allogeneic transplantation and discussions of the MHC go 
hand in hand.  This section is included to review the MHC complex as it relates to 
allogeneic transplantation.  The MHC is an array of genes on the small segment 
of chromosome 6 that encodes three structurally, functionally, and distributionally 
different products: 1) cell surface glycoprotein antigens designated as MHC 
Class I antigens, 2) cell surface glycoprotein antigens designated as MHC Class 
II antigens, and 3) soluble protein components of the complement system.  The 
MHC gene is designated Rt1 in the rat and H-2 in the mouse.   
 
The rat MHC was discovered at the turn of the 19th century when the growth of 
rat tumor cell lines could not be supported across mismatched strains.  [25] The 
genes of the MHC are the most polymorphic known, and it was not until 1999 
that the MHC of humans was sequenced.   
 
The principal physiologic function of class I and class II cell surface MHC 
molecules is to "present" antigenic peptides of foreign proteins to the appropriate 
antigen-specific T cells of the immune system.  T cells can recognize only 
membrane bound antigens (as opposed to B cells).  The MHC antigen is 
structured to form a small groove which holds a very small antigenic peptide in 
place on the surface of an antigen presenting cell for signal recognition by a T 
cell receptor (TcR).  [25] The antigenic peptide, usually about 9 amino acids long, 
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fits into a groove at the surface of either an MHC Class I or MHC Class II 
molecule.  The TcR is not able to recognize these small antigenic peptides 
without presentation in the context of an MHC because of the many stepwise 
signals involved in the TcR-MHC binding that are necessary for antigen 
presentation.  These peptides can include fragments of protein antigens derived 
from intracellular or extracellular parasites (viruses, bacteria, etc.).   
 
1.5.1. Presentation Through MHC Class II 
 
The Class II molecules consist of two transmembrane polypeptides: an alpha 
chain and a beta chain, and a groove is formed by the interaction of these 2 
chains.  Class II molecules are not as widely expressed in the body as the class I 
molecules are, being constitutively expressed primarily on hematogenously 
derived cells.  However, cells where inflammation is occurring may be induced to 
express class II strongly and provide a powerful stimulus to the immune system.   
 
In general, class II molecules present exogenous antigens (e.g. extracellular 
microbes, soluble proteins) that are first internalized and processed in the 
endosomes or lysosomes.  Peptides resulting from proteolytic cleavage then 
associate with class II heterodimers assembled in the endoplasmic reticulum (ER).  
Finally, the peptide MHC complex is transported to the cell surface, where it can 
be recognized by CD4+ helper T cells.  In this interaction, the CD4 molecule acts 
as a coreceptor.  Because CD4+ T cells can recognize antigens only in the context 
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of self class II molecules, they are referred to as “class II restricted.”  The role of 
class II antigens in the induction of helper T cells has an important bearing on the 
genetic regulation of the immune response.  The absence of MHC Class II positive 
APCs reduces islet graft immunogenicity.  [26] 
 
1.5.2. Presentation Through MHC Class I 
 
The Class I molecule consists of a transmembrane protein heterodimer that 
noncovalently binds a polymorphic molecule of beta-2 microglobulin to a 
polymorphic short alpha peptide chain.  A groove is formed in its quaternary 
structure.  Class I molecules are expressed at the surface of platelets and almost 
all the nucleated cells of the body.  They are not expressed in RBCs or the 
central nervous system.   
 
Biochemical analyses of several different class I alleles have revealed that 
almost all polymorphic residues line the sides or the base of the peptide binding 
groove.  As a result, different class I alleles bind to different peptide fragments.  
In general, class I MHC molecules bind to those peptides that are derived from 
proteins, such as viral antigens, synthesized within the cell.  The generation of 
peptide fragments within cells, their association with MHC molecules, and 
transport to the cell surface is a complex process.  Analogous to CD4+ T cell 
restriction to the MHC Class II antigen, the CD8 molecule acts as a coreceptor in 
MHC Class I antigen binding to the T cell receptor.   
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The human MHC antigen is known as the HLA (Human Leukocyte Antigen) 
complex.  The HLA was initially detected on leukocytes, hence its name.  The 
HLA system is highly polymorphic.  Class I HLA antigens (HLA A, B, and Cw) 
and class II HLA antigens (HLA DR, DQ, & DP) are further subdivided into types.  
There are 22 different HLA A, 42 different HLA B, 9 different HLA Cw, and 18 
different HLA DR antigens.  The great diversity of class I and class II HLA alleles, 
including ones that result in increased resistance to developing certain diseases, 
has helped to ensure that no single parasite can eliminate the entire human 
population, but such diversity also has made a perfectly compatible tissue match 
for transplantation between two humans almost nearly impossible (except in the 
case of identical twins).  The detection of antigens (genetic markers) such as the 
HLA on the surface of lymphocytes, known as tissue typing, was developed in 
efforts to overcome barriers in human organ transplantation, and has helped to 
reduce the incidence of graft rejection prior to the development of more effective 
immunosuppressive drug regimens.  Serologic and DNA-based methods can be 
used for tissue typing.  Serological methods are used most commonly and work 
to identify tissue cells that are reactive to antibodies specific for known HLA-A, 
HLA-B, and HLA-DR antigens.  DNA typing is being used to improve the 
sensitivity and specificity of tissue typing, especially with the HLA-D antigens.  
The United Network for Organ Sharing (UNOS) screens organs using 6 HLA 
antigens: two each at HLA-A, HLA-B, and HLA-DR.   
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Even if it were possible to match the donor and recipient at every locus of the 
MHC, some tissue incompatibility would still remain and immune rejection would 
occur because of minor histocompatibility antigens.  Few of these antigens have 
been identified, but they include: H-Y, an antigen encoded on the Y chromosome 
and thus present in male, but not female, tissue, and HA-2, an antigen derived 
from the molecular motor protein myosin.  Therefore, even transplantation of an 
MHC-matched organ to a non-identical host requires some degree of 
immunosuppression to avoid graft rejection.  This is why many pre-
transplantation protocols are ignoring tissue typing mismatches and maintaining 
their attention on ABO matching and immunosuppression.  
 
 
1.6. OVERVIEW OF IMMUNE SYSTEM DEVELOPMENT  
 
The process by which circulating hematopoietic stem cells emigrate from the 
bone marrow and take residence in the thymus gland is known as thymopoiesis.  
[27, 28]  The commitment of these stem cells to the T cell lineage is based upon 
a response to signals from the cellular microenvironment within the gland.  [29] 
Following commitment to the T cell lineage, these cells will undergo changes 
induced by close associations with discrete thymic epithelial cell 
microenvironments or compartments.  The specific sequence of events 
experienced by each T cell will determine its compartmentalization into a 
particular T cell subset.  These processes are surveyed in a series of physiologic 
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checkpoints prior to release of the T cell into the circulating pool of mature 
lymphocytes.  If the T cell does not meet standards deemed necessary by the 
thymic epithelium, it will not be rescued from apoptosis; instead, it will be 
destroyed via apoptosis as part of the process of positive selection.  [30-34]   
 
There are different types of thymic epithelial cells (TECs), and their classification 
is location based.  [35] Ultrastructural studies have demonstrated at least four 
types of TECs: those found at the cortical surface, those found within the cortex, 
those found in the medulla, and those within Hassall’s corpuscles.  [36] Those 
found in the thymic medulla are referred to as medullary TECs.  Similarly, those 
found in the thymic cortex are referred to as cortical TECs.  Both the cortical 
TECs and medullary TECs have been shown to present antigens in the context 
of the MHC, but the medullary TECs may do so more rapidly.  [37] It appears that 
in terms of MHC class II-restricted CD4 T cell development, the cortical 
epithelium functions to regulate positive selection, whereas a particular subset of 
medullary epithelium regulates negative selection.  [38]  
 
Specificities of the interactions between T cells and the thymic stroma determine 
the fate of immature T cells.  The thymic stroma includes TECs, interdigitating 
reticular cells, macrophages, and fibroblasts.  It is suggested that the thymic 
stromal environment is mutually dependent upon the differentiation status of 
developing T cells, “a phenomenon designated as 'crosstalk'.”  [39] Namely, 
thymocyte subsets are believed to influence the development and organization of 
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the thymic epithelium: the organization of the thymic medulla “depends upon 
activating signals provided by mature thymocytes to epithelial and dendritic 
cells.”  [40] Disorganization of the corticomedullary thymic epithelial junction and 
abnormal clonal selection was found to occur as a consequence of lack of these 
important activating signals even in the presence of normal thymocyte 
maturation.  [40]   
 
Although lymphocyte clonal selection occurs as a consequence of both thymic 
epithelial and bone marrow cell participation [41], the focus of this review will be 
immune system development and responsiveness as it relates to the thymus 
gland and thymic epithelium.    
 
1.6.1. Arrangement of the Thymus Gland  
 
In the neonate, the thymus gland is a bilobed structure that occupies almost the 
entire mediastinal space, is situated anterior to the great vessels, and is 
separated laterally from the lungs by mediastinal pleura and from the heart 
inferiorly by pericardium.  Each lobe is characterized by a superior prominence of 
tissue referred to as a horn, with the right lobe being characteristically larger than 
the left.   
 
The thymus gland is largest relative to body size at birth.  At puberty or during an 
illness early in life, the human thymus reaches its greatest size, weighing 
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approximately 40 grams.  In the adult, the thymus is seen as a remnant located 
within the retrosternal fat pad.  The atrophy of the gland is attributed to depletion 
of T cells, primarily by the process of apoptosis.   
 
The name “thymus” originates from the Greek language, meaning “warty-bumpy” 
and “feel good.”  This warty consistency occurs due to a fibrous capsule from 
which fibrous septa extend, dividing the gland into lobules.  The thymic 
parenchyma is divided into a cortical region and a medullary region, and does not 
contain lymphoid nodules.  The primary vascular supply to the thymus is from the 
internal thoracic arteries, with venous drainage via the internal thoracic veins.  
Small arteries follow the septa, branching into arterioles running between the 
cortex and medulla of the thymus.  Capillary loops enter the substance of the 
cortex.  A few small efferent lymphatics flow within the walls of blood vessels and 
in connective tissue septae.   
 
The thymus gland is derived from embryonic endoderm (TECs or epithelial 
reticular cells) and mesoderm (lymphocytes).  During embryogenesis, the thymus 
develops from the third and fourth pharyngeal pouches.  Connective tissue growth 
factor (CTGF) is involved in cellular “proliferation, survival, migration, adhesion, 
and extracellular matrix production” during embryogenesis, with specific detection 
by day 13.5 in mice.  [42] Epidermal growth factor (EGF) also modulates fetal 
thymocyte growth and differentiation.  [43] Non-thymic lymphoid tissue is derived 
solely from mesoderm. 
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 The thymic cortex (“bark”) is the layer directly beneath the capsule and consists 
of mostly tightly packed small (resting) lymphocytes and some capillaries 
surrounded by spaces consisting of a mixture of immune cells surrounded by 
cuboidal-shaped TECs possessing a single large, ovoid, light staining nucleus 
which often displays a nucleolus.  The space around the endothelium-lined 
capillaries is bound by a thin layer of collagen (perivascular connective tissue) 
and a complete covering of TEC processes with their basal laminae.  This 
layered coating prohibits blood from directly contacting cortical T cells.  This 
coating is also known as the blood-thymus barrier and prevents large 
macromolecules from traversing the vessel wall and entering the cortex.  The 
blood-thymus barrier exists in the cortex only, making it immunologically 
protected from connective tissue septae and from the thymic medulla.  This 
ensures that antigens escaping from the bloodstream do not reach developing T 
cells in the thymic cortex.  Large numbers of immature T cells (thymocytes) are 
found in various stages of differentiation within the thymic cortex.  The influx of 
thymocytes into the thymus gland induces the formation and extension of cellular 
processes from these TECs, which form the thymic stromal network or 
cytoreticulum that helps to segregate thymocytes from antigens during their 
maturation.  TEC-induced apoptosis of immature thymocytes that have been 
exposed to antigens involves a unique apoptotic pathway, while acceptable 
thymocytes, rescued from apoptosis by the TECs, migrate toward the medulla as 
they mature.  [44] Medullary TECs have a particular receptor associated with 
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apoptosis.  Binding of this Fas medullary cell membrane receptor to its ligand 
results in cellular apoptosis.  [45] The majority of thymocytes in the cortex are 
eventually phagocytosed by macrophages. 
 
The medulla is the central portion of the thymus and is where T cells complete 
their maturation and exit the thymus via venules and efferent lymphatic vessels.  
The T cells then migrate to non-thymic lymphoid structures.  The medulla is 
continuous throughout the gland and is not separated by lobules.  It consists of a 
variety of cell types, but TECs, small T cells, macrophages, dendritic cells, 
eosinophils, and plasma cells are among the more commonly observed in this 
region of the thymus.  Hassall’s corpuscles are concentrically arranged whorl-like 
nests of squamous thymic epithelium that increase in number and size with age.  
They display various stages of keratinization and their specific function, if any, 
remains unclear.  In contrast to vessels within the thymic cortex, there is no 
barrier around capillaries in the medulla.  These medullary thymic capillaries, or 
sinusoids, allow trafficking to occur freely throughout the medulla.  Large 
numbers of TECs and loosely packed mature T cells cause the medulla to stain 
differently from the cortex.   
 
1.6.2. Origin of TECs 
 
TECs are endodermally and ectodermally derived from the third pharyngeal 
pouch and branchial cleft.  They are also derived from cranial neural crest cells.  
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Because vascularization of the primordial thymus gland has not yet occurred, 
early hematopoietic populants of the thymic rudiment must extravasate through 
the pharyngeal vessels and home to the thymus through the perithymic 
mesenchyme.  This suggests that the stem cells are “responding to a gradient 
of…diffusible chemoattractant factors” that are reported to originate from fetal 
MHC class II+ TECs.  “A number of chemokine receptors expressed by thymic 
precursors and several chemokines, including thymus-expressed chemokine 
(TECK), are expressed by thymic epithelial cells, resulting in chemotactic activity 
for isolated thymic precursors.”  [27, 46]  
 
1.6.3. TEC Function in Immune System Development  
 
The TECs of the thymic cortex are believed to positively select thymocytes, so that 
only cells with a self MHC-restricted T cell receptor (TcR) are allowed to mature. 
[47] The bone marrow-derived antigen presenting cells (APCs) found mainly at the 
corticomedullary junction, are believed to be largely responsible for negative 
selection, which leads to deletion of T cells with high affinity for self MHC and/or 
self antigen/self MHC complexes.  However, recent studies both in vitro using TEC 
cultures [48], and in vivo, using thymic transplantation models in mice, [41, 49] 
suggest that the thymic epithelium may also be involved in negative selection.  
Lymphocytes have long been known to reside in close contact with TECs, and 
have even been found within TEC vacuoles months following initial harvesting of 
thymic tissue.  [50]   
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1.6.4. Positive and Negative Thymic Selection  
 
The MHC restricted, two-signal model of antigen recognition serves as the 
framework for understanding cellular immunity.  [51-53] The thymus plays a 
significant role in developing and maturing T cells which exhibit this pattern of 
specific MHC restriction.  [54-56]; [57] Thymocytes develop this specificity by 
undergoing selective elimination during their maturation and differentiation.  [58] 
In the process of thymocyte development, bone marrow stem cells migrate to the 
thymus, are retained there by binding of the CD2 molecule, and commit to the T 
cell lineage under the influence of the thymic microenvironment.  [29] The 
expression of co-receptor molecules CD4 and CD8 characterize the major 
lineages of T cells thereafter.  The earliest precursors are CD4-/CD8- (double 
negative), which later become CD4+/CD8+ (double positive) cells.  Immature 
CD4+/CD8+ T cells able to interact in a productive manner with self-MHC 
molecules are retained through the process of positive selection.  It is believed 
that MHC molecules on the surface of the thymic epithelium select which of the 
double positive cells will mature into CD4+/CD8- or CD8+/CD4- (single positive) 
cells.  [59] [60] Positive selection involves the “positive” recognition by developing 
T cells of self-MHC proteins expressed on non-lymphoid cells resident within the 
thymus, particularly TECs.  [34, 59, 61, 62].  Bone marrow derived cells or 
fibroblasts have also been shown to participate in positive selection.  [34]   
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Thymocytes recognizing and targeting self-proteins bound by self-MHC are 
eliminated by negative selection.  Negative selection occurs via the high-affinity 
recognition by developing T cells of self-peptides bound to MHC proteins 
expressed on IT APCs, specifically thymic dendritic cells and macrophages.  [63] 
 
 
1.7. OVERVIEW OF HUMORAL AND CELL-MEDIATED IMMUNITY 
 
The lymphatic system consists of several discrete organs (thymus, spleen, 
tonsils, and lymph nodes), diffuse lymphoid tissue, and cells including T cells, B 
cells, and macrophages.  This system functions to defend the organism by 
mounting humoral immune responses against foreign substances (antigens) and 
cell-mediated immune responses against microorganisms, tumor and 
transplanted cells, and virus-infected cells.  An allogeneic immune response 
involves the coordination of many cell types.  There are both general and specific 
responses to this stimulus.  The three main cell types involved in this response 
are T cells, B cells, and APCs.  Other cell types include eosinophils for 
opsonization of antigens and neutrophils for local inflammation to enhance the 
overall immune response.  Cellular infiltration at the rejection site occurs early in 
the process of allogeneic graft rejection.  The general properties and functions of 
specific immune cells will be reviewed as background material for the 
descriptions and evaluations of cellular infiltrates found upon histological 
evaluations of tissue grafts in this project.  
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APCs may degrade antigens into small peptides during “processing”.  These 
antigenic peptides are then linked to an MHC molecule expressed within or on 
the surface of the APC.   
 
In 1961, studies demonstrated that thymectomized neonatal mice never 
underwent normal lymphoid tissue development, exhibited weak immune 
responsiveness, and easily developed infection.  Because of the B cell 
response from the intact bone marrow in these animals, antibody responses 
remained, but the absence of T cells resulted in an immunocompromised 
state.  In 1967, it was shown that antigen-stimulated lymphocyte populations, 
now known to be T cells, responded by proliferating, but that these cells did 
not secrete antibodies.  The cells of the immune system include exponential 
numbers of clones of T- and B cells that are able to recognize and respond to 
a single antigenic determinant (epitope), or a small group of closely related 
epitopes.  Exposure to an antigen and a second signal (one or more 
cytokines) induces activation of resting T and B cells, leading to their 
proliferation and differentiation into effector cells.  The population of effector 
cells may also include APCs (e.g. macrophages, lymphoid dendritic cells, 
Langerhans’ cells, follicular dendritic cells, M cells, and B cells) as well as 
mast cells and granulocytes.  Although B cells can present antigenic epitopes 
to T cells, and thus are APCs, their role in this function probably is limited to 
the secondary (anamnestic) immune response rather than the primary immune 
response. 
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As described above, T cell maturation occurs in the thymus and involves 
immunoincompetent progenitor T cells migrating from the bone marrow to the 
thymus, where they are termed thymocytes.  Within the thymic cortex, 
thymocytes undergo gene rearrangements and begin to express antigen-
specific T cell receptors, which are integral membrane proteins.  Hence, the 
cells are now immunocompetent.  The cortical thymocytes also begin to 
express thymus-induced CD (cluster of differentiation) markers, designated 
CD2, CD3, CD4, and CD8 on their surface.  In the thymic medulla, some 
thymocytes lose CD4 and develop into CD8+ cells; others lose CD8 and 
develop into CD4+ cells.  Medullary thymocytes also develop class I or class II 
MHC antigens. 
 
T cell subtypes include T helper (Th) and T cytotoxic (Tc) cells.  T helper (Th) 
cells are CD4+ cells which synthesize and release numerous growth factors, 
known as cytokines (lymphokines), following their activation.  The cytokines 
interleukin 2 (IL-2) and interleukin 4 (IL-4) induce B cells to respond to an 
antigenic stimulus.   
 
T cytotoxic cells (Tc) are CD8+ cells.  They also produce cytokines, and are 
involved in the effector stage of graft rejection.   
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Suppressor T cells (Ts) are also CD8+ cells that can modulate the extent of 
the immune response by suppressing the activity of Th cells.  They may serve 
an important role in preventing autoimmune responses.   
 
T memory cells are long-lived, committed, immunocompetent cells that are 
formed during proliferation in response to an antigenic challenge.  They 
remain relatively dormant in the circulation or in specific regions of the 
lymphoid system, and when activated, function to increase the size of the 
original clone and thereby provide a faster and greater anamnestic response 
against a future challenge by the same antigen.   
 
B cells originate and mature into immunocompetent cells within the bone 
marrow.  They have surface immunoglobulins (antibodies) attached to the 
external aspect of their plasma membrane; all the immunoglobulin (Ig) 
molecules on a given B cell clone recognize and bind to the same antigen 
determinant, or epitope.  They are responsible for the humoral immune 
response.  They proliferate and differentiate following an antigenic challenge 
to form plasma cells and B memory cells.  Plasma cells actively synthesize 
and secrete antibody specific for the challenging antigen.  B memory cells 
have the same properties as T memory cells.   
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Null cells, designated Th0, are part of a small selection of peripheral 
lymphocytes that lack antigens which would characterize them as T or B cells.  
Natural killer (NK) cells are one type of null cell, exhibiting nonspecific 
cytotoxicity against tumor cells and virus-infected cells.  The mechanism by 
which NK cells recognize these target cells is not yet understood.  They also 
can kill specific target cells that have antibodies bound to their surface 
antigens in a process known as antibody-dependent cell-mediated cytotoxicity 
(ADCC).   
 
Macrophages function as both APCs and as cytotoxic effector cells in ADCC.  
They produce IL-1 which helps activate TH cells, and several other cytokines 
that influence the immune response or hematopoiesis.  They also secrete 
prostaglandin E2 which decreases certain immune responses.  They are 
activated by interferon gamma which is also known as macrophage activating 
factor; this activation increases the phagocytic and cytotoxic activity of 
macrophages.  Macrophages recognize foreign cells, cellular debris, foreign 
material, and apoptotic cells through the process of target recognition.  
Phagocytosis is triggered by binding of macrophage surface receptors to 
target ligands, and accomplished by the formation of a coated pit which 
creates a vesicle known as a phagosome.  The phagosome fuses to a 
lysosome, exposing the engulfed material to hydrolytic enzymes.  [64]   
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The major histocompatibility complex, as described previously, encodes two 
main classes of antigenic molecules: class I molecules, which are expressed 
by nearly all nucleated cells, and class II molecules, which are expressed by 
the various cells that function as APCs.  Antigens are molecules that have the 
capability of inducing an immune response.  The word antigen comes from 
“generating antibody.”  Immunogens are antigenic molecules that can react 
with an antibody or a T cell receptor.  Some exogenous antigens are 
endocytosed or phagocytosed by APCs and degraded intracellularly.  Involved 
in this sequence are proteolytic complexes, proteasomes, which digest 
antigenic proteins into short peptides, and transport proteins, which ferry 
peptide fragments from the cytoplasm to the ER.  Within the ER, antigenic 
peptides bind to the antigen binding cleft of newly synthesized class I heavy 
chains, which will associate with beta 2 microglobulin to form a stable trimer.  
(MHC alloantigens do not require intracellular degradation for antigen 
presentation.)  The epitope-class II HLA complexes are transported to the cell 
surface for epitope presentation, where they are presented to CD8+ cytotoxic 
T cells.  Endogenous immunogens are produced within host cells (e.g. viral 
proteins synthesized within virus-infected cells and tumor proteins synthesized 
within cancerous cells).  They are degraded within host cells, yielding antigen 
peptides that associate with class I HLA molecules.  The peptide-class I HLA 
complexes are transported to the cell surface, where they are displayed 
(presented) to T cells.   
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T cells exhibit HLA restriction: T cells of each type (except T memory cells) 
only recognize epitopes that are associated with either class I or class II HLA 
molecules as follows.  Th cells recognize class II HLA molecules.  Tc cells and 
the majority of Ts cells recognize class I HLA molecules.  T memory cells 
recognize both class I and class II HLA molecules.   
 
1.7.1. Requirement of Antigen Presentation  
 
Before any pro-inflammatory cells infiltrate an area (monocytes, lymphocytes), 
there must be an immune stimulus.  This stimulus is either mismatched MHC 
antigen or a minor histocompatibility antigen difference strong enough to elicit a 
response.  This antigen must be properly “presented” to the immune system to in 
the context of MHC and followed by a co-stimulatory ligand binding signal.  A 
strong and organized immune response will not occur without the second signal.  
APCs may degrade antigen into small peptides during “processing”.  These 
antigens are then linked to an MHC molecule expressed within or on the surface 
of the APC.  Almost simultaneously, release of the second signal of activation by 
costimulatory ligand binding of the TcR-MHC on the APC elicits an immune 
response.  This second step is crucial.  Non-APCs are capable of presenting 
antigen per se, but they are not capable of eliciting an immune response 
because the second signal remains absent. 
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1.7.1.a. Presentation of Alloantigens  
 
During “presentation”, allogeneic MHC on a graft cell can act as an antigen 
without the intracellular processing and transport back to the cell surface that 
other antigens must undergo.  Generally, the MHC molecules of allograft tissue 
belong to Class I, but the Class II MHC antigen expressed by enough donor cells 
carried into the host site within the parenchyma of a graft can elicit a significant 
rejection response.  In terms of non-MHC antigens, they may be bound to either 
MHC Class I or Class II, but are restricted to whichever one is bound.  As a 
general rule, if the antigen is found within the cell (endogenous), then that 
antigen will be bound to a Class I MHC molecule, and exogenous antigens are 
bound to Class II molecules.  Dendritic cells are the most potent of the APCs. 
 
Antigen presentation restricted to Class I MHC involves antigen degradation by 
proteasomes.  The antigens are marked for degradation by two mechanisms: 1) 
natural degradation and 2) labeling by ubiquitin.  There are gene-encoded 
endopeptidases that provide the phagocytic cell with molecules to assist with 
degradation.   
 
APCs (B cells, macrophages, dendritic cells, and Langerhans cells), together 
with TECs, endothelial cells, and activated T cells are the only cells in the body 
that naturally express MHC II proteins on their surface, although almost any cell 
can be induced to express MHC II molecules by cytokines, namely γ-interferon 
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[65].  Exogenous antigens, usually recruited by phagocytosis or endocytosis, are 
bound to MHC Class II molecules within the cell and this complex is transported 
to the cell surface, where it is made available for interaction with a T cell receptor 
(TcR).  When this MHC II molecule-antigen complex surfaces on the APC, it is 
recognized by a TcR.  This is referred to as the “First Signal.”  There are other 
first signal binding complexes than the MHC-TcR.  But again, this first signal(s) 
cannot provide enough of stimulus to activate T cells.   
 
1.7.1.b. The Second Signal or Costimulatory Factor  
 
There are co-stimulatory molecules on the APC that induce activation of T cells.  
This is referred to as the “Second Signal.”  The second signal may be a chemical 
signal, such as interleukin 1, or the binding of B7-1 on the antigen presenting cell 
with CD28 on the T cell.  This binding will lead to the production of IL-2 (also 
known as T cell growth factor), initially from APCs and later in greater amounts 
from T cells.  The end product of this cascade is the mass proliferation of a 
particular clone of T cells due to interleukin stimulated activation of transcription 
factors.  
 
There are other molecules that do not directly participate in antigen presentation, 
but assist in the process.  Two main types of cluster designation (or CD) 
molecules are present on T cells.  CD4 and CD8 (depending on the MHC 
molecule class) stimulate intercellular events and lead to T cell activation.  CD4 
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molecules help to anchor the bond between MHC Class I molecules and antigen 
with the TcR and CD8 molecules help to anchor the bond between MHC Class II 
molecules and antigen with the TcR.  These events promote greater affinity in 
TcR-MHC binding, stimulating T cell activation and proliferation.  Other 
molecules that assist with this binding are LFA-1 (on T cell) with ICAM-1 (on 
APCs) and LFA-3 (on APCs) with CD2 (found on all T cells).   
 
Both CD8+ cytotoxic and CD4+ helper T cells are needed for complete rejection.  
Helper T cells express the CD4 molecule and assist in the clonal expansion of 
more T cells and B cells by the secretion of various interleukins.  Helper T cells 
can either participate in cell-mediate immunity (Th1 cells) or antibody-mediated 
immunity (Th2 cells).  The main chemical mediators involved in cell-mediate 
immunity are IL-12 and interferon-γ.  The main chemical mediators of antibody-
mediated immunity are IL-4, IL-5, and IL-10.   
 
Cytotoxic and suppressor T cells express CD8 molecules.  Cytotoxic T cells 
destroy cells which express the antigen that they recognize, and suppressor T 
cells lower cytotoxic T cell activity.  Cellular killing is accomplished in part with 
the pore-forming lytic protein, perforin. 
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1.7.2. Cells Capable of Antigen Presentation  
 
1.7.2.a. Cell Types and Their Distribution 
 
Bone marrow derived macrophages, monocytes, B cells, and dendritic cells are 
characterized by the relevant costimulatory molecules (B7-1 and B7-2) required for 
antigen presentation to T cells bearing an MHC-restricted TcR.  These cells mostly 
originate from the bone marrow and the thymus gland, and are mostly present in 
lymphoid organs, the circulating lymph, and the skin.  Other MHC Class Ia-positive 
macrophages are found in the peritoneum, the liver, the lungs, and the blood.  
“Non-professional” APCs include cells of epithelial origin that are able to present 
antigens when activated.”  [66]   
 
1.7.2.b. Origin of APCs 
 
Dendritic cells, included in the class of APCs, were discovered in both skin (termed 
Langerhans cells) and lymphoid tissues in 1973, and found to be up to 100 times 
as efficient as B cells in antigen presentation.  [67] These cells, also known as 
passenger leukocytes, are capable of transferring antigens from peripheral tissues 
back to lymphoid tissues where they present these antigens to naive antigen-
specific T cells within lymphoid tissue, initiating an immune response.  Dendritic 
cells are involved in the initiation of autoimmune diseases and are largely 
responsible for the initiation of graft rejection.  [68, 69]  Like other APCs, dendritic 
45
cells express MHC Class II antigens.  Splenic dendritic cells are believed to derive 
from a “thymus-independent bone marrow precursor”.  [70] 
 
1.7.3. Function of TECs in Antigen Presentation  
 
Immature thymocytes able to express MHC-restricted T cell receptors (TcR) on 
their cell surfaces are selected to mature.  [71-73] Likewise, immature CD4+ and 
CD8+ T cells must also express appropriate MHC-TcR interactions to continue in 
the process of thymic maturation and survival following release to the periphery.  
A sufficient naive thymocyte population is regulated by cytokine signals that 
induce a baseline level of expansion.  Weak TcR-MHC interactions allow 
constant immune surveillance feedback between circulating T cells and the 
thymus gland, signifying the expansion of reactive clones when necessary.  For T 
cells to be surveyed on a constant basis, they must remain free for split second 
interactions with MHC expressing cells.  This requires a combination of high TcR-
MHC specificity and low affinity.  Taking advantage of peripheral immune 
surveillance mechanisms, investigators have used intravenous infusion of 
specific T cell populations as a modality to influence T cell subset selection in 
models of autoimmune disease.  [74] The diversity of the mature T cell 
population can be attributed by the diversity of self-peptides bound to MHC.  [75] 
The long-term maintenance of a peripheral T cell population that remains 
sensitive to the self-peptide/MHC complex suggests that extrathymic surveillance 
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continues long after positive selection of mature lymphocytes by TECs has taken 
place.  [76] 
 
The thymus gland, as discussed, is key to the establishment of self-recognition 
and self-tolerance.  [54] [57].  This is evidenced by the fact that neonatal 
thymectomy has been shown to induce autoimmune disease.  [77, 78]  In the 
establishment of tolerance to peripheral tissue-specific antigens, the interaction of 
the thymus gland with the periphery has not been fully explained, since clonal 
ignorance, deletion, and anergy can occur independent of thymic selection.  The 
mechanism of thymic dependent active suppression of aggressive responses to 
autoantigens that are not expressed intrathymically, also known as infectious 
tolerance, still remains unknown.  [79-81] In any case, the thymus gland is 
important in immune surveillance as evidenced by in vivo studies showing that the 
intravenous administration of various molecular weight antigens results in  
their rapid transit to the thymus gland for antigen presentation. [82]   
 
 
1.8. OVERVIEW OF THE IMMUNE RESPONSE TO TRANSPLANTATION 
 
1.8.1. The Normal Physiologic Response to Graft Placement  
 
Anatomical and physiological events following transplantation or other 
immunological stimulus include massive shifts in lymphocyte migration to host 
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lymphoid tissues and away from nonlymphoid tissues.  Under normal conditions, 
T cells recirculate continuously between blood, various native tissues, and the 
lymph system.  In the event of an antigenic stimulus, whether via the gut, from a 
site of skin inflammation such as a delayed hypersensitivity response, or from 
placement of a vascularized graft, these recirculation patterns change to allow 
dissemination of the antigenic message as widely and promptly as possible 
throughout the host immune system.  A few lymphocytes will appear in 
perivascular areas, ready for interaction with APCs.  Lymphoid tissues are an 
important point of interaction between circulating lymphocytes and graft antigen 
brought by APCs, or with cytokines released into the circulation from the graft 
site by antigen-activated immune and, potentially, non-immune cells.  They also 
facilitate antigen recognition and activation by naive host immune cells.  Also, 
some of the prompt changes in lymphocyte migration patterns following an 
antigenic stimulus can be attributed to the activity of adhesion molecules, both on 
antigenic cell surfaces and on lymphocyte membranes.  For instance, 
upregulated LFA-1 expression causes lymphocyte binding to high endothelial 
venules, allowing lymphocytic infiltration into lymph nodes by diapedesis.  It has 
been suggested that there are high endothelial venular-like structures in the 
vessels of organs which allow leukocyte migration at particular sites.  Other such 
molecules on endothelial surfaces, endothelial-leukocyte adhesion molecules, or 
intracellular adhesion molecules, may also alter migration of recirculating 
lymphocytes, increasing the immunological message to the entire host. Over the 
span of two to four days, large numbers of lymphocytes and macrophages enter 
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the area(s) of graft tissue.  As progressive disruption of vessels and other 
structures associated with tissue necrosis occurs, lymphocytic cells fill recipient 
lymphoid compartments.  A general inflammatory response occurs to the surgical 
trauma.  Tissue damage resulting from the actual transplantation procedure is 
surveyed by T cells, while pathogen eradication occurs via cell-mediated 
immunity.  Release of proinflammatory factors, like Hageman factor (factor XII), 
triggers a cascade of events such as the clotting cascade.  Fibrinopeptides 
promote vascular permeability and attract neutrophils and macrophages with 
subsequent cytokine production.  Antigen-antibody complexes target pathogens 
for phagocytosis and stimulate macrophages to secrete cytokines (tumor 
necrosis factor β or cachectin, and tumor necrosis factor, interferon γ released 
locally by infiltrating cells, and interleukin-1), stimulating proinflammatory 
endothelial responses.  Nitric oxide may also be involved in the inflammatory 
response.  T cells activate the classical complement cascade (e.g. C3a and 
C5a), while mast cell degranulation (histamine, 5-hydroxytryptamine) increases 
vascular permeability.  In the absence of pathogens, macrophages promote 
repair and structural reinforcement of damaged tissues (regeneration and 
neovascularization).  Endothelial cells, smooth muscle cells, fibroblasts 
stimulated by fibroblast growth factor, extracellular matrix with its integrin 
adhesion molecules, interleukin-1, interleukin-6, transforming growth factor, and 
platelet derived growth factor, all aid in tissue repair. 
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1.8.2.The Immunologic Process of Graft Rejection  
 
Graft rejection is a cell-mediated response to alloantigens.  Based upon its 
stimulus, severity, and timing, graft rejection can be classified as hyperacute, 
acute, and chronic.  These stages of graft rejection do not necessarily follow a 
chronological course.   
 
Normally, T cells recognize the foreign peptides presented in the context of a 
self-MHC molecule. Different individual T cells, or T cell clones, recognize 
different peptides. After a transplant, the foreign (allogeneic) MHC molecules, 
with or without peptide ligands, are recognized as non-self-MHC-peptide 
complexes by many types of T cells.  CD8+ and CD4+ cell subsets proliferate in 
response to the alloantigens on the surface of the foreign cells.  The activation of 
these specific T cell clones triggers the effector stage. 
 
These activated lymphocytes that accumulated by active proliferation in the host 
lymphoid tissue during early phases of immune responsiveness then migrate to 
the graft site to act in an effector role toward its destruction.  The effector stage 
involves a large influx of macrophages and T cells to the graft site.  Cytolytic T 
cells lyse cells bearing the specific MHC alloantigen target, in this case the 
endothelial and parenchymal cells of the graft.  Helper T cells, mostly CD4+ cells, 
activate macrophages and initiate a delayed-type hypersensitivity reaction. 
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Finally, graft blood vessels are compromised by alloantibodies that bind to the 
endothelium. 
 
1.8.2.a. Hyperacute Graft Rejection 
 
Hyperacute rejection may occur as early as minutes following transplantation.  In 
general, rejection that occurs up to 24 hours following transplantation is classified 
as hyperacute.  In these cases, the etiology is usually associated with a 
significant number of preformed antibodies, either generated from memory cells 
in the case of specific sensitization, or from non-specific cross-reactivity with the 
graft alloantigens.  Once antibodies present in the host encounter donor MHC 
antigens, particularly on a donor organ’s surface endothelial cells, antigen 
binding triggers the complement system.  Neutrophils flood the grafted tissue and 
platelets aggregate.  The graft soon fails as massive inflammation and emboli 
block the blood flow to the grafted tissue.  
 
The severity of antibody-mediated rejection can vary from case to case.  In fact, 
not all transplant recipients with donor-specific antibodies actually go on to 
develop hyperacute rejection.  In the worst cases, it begins immediately after 
establishing vascular reperfusion of the allograft.  This may be as early as 20 
minutes following transplantation.  A blood group (ABO) mismatch could cause a 
hyperacute graft rejection even in the presence of immunosuppressive drug 
therapy, but such a mistake rarely occurs. [83] The transplanted organ becomes 
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grossly mottled, cyanotic, and loses its previous function.  The organ may 
enlarge due to marked edema and rupture of the graft may occur.  A 
multisystemic syndrome such as shock may be the first signal that hyperacute 
graft rejection is occurring. 
 
1.8.2.b. Acute and Delayed Accelerated Acute Graft Rejection 
 
Acute rejection is a T cell mediated response which typically occurs within the 
first week following transplantation.  The most characteristic feature involves the 
progressive infiltration of the site by host mononuclear cells.  Early experiments 
have shown that this inflammatory immune response, consisting of diffuse 
lymphocytic infiltration with CD8+ cytotoxic T cells (Tc cells) and CD4+ T helper 
cells (Th cells), is capable of stimulating acute destruction of an allogeneic graft.  
Additional supportive evidence includes the fact that neonatal thymectomy 
results in a blunting of the rejection response to allogeneic skin transplantation, 
while injection of normal T cells can restore this capacity.  Extensive damage 
occurs to the blood vessels and effector mechanisms cause massive tissue 
destruction.  The two-signal process of lymphocyte activation involves binding of 
transplantation antigens to the T cell surface receptors (signal 1), which receive, 
at the same time, a co-stimulatory signal 2 from an antigen-presenting cell (e.g. 
macrophage, dendritic cell, B cell, etc.).  The co-stimulatory signal(s), CD28 and 
B7 ligand binding, are increased by the adhesion molecules CD2, LFA-1, and 
VLA-4 and act to stimulate interleukin-2 (IL-2) production.  The CTLA4 adhesion 
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molecule present on activated Th and Tc cells is structurally similar to CD28 and 
also binds to the B7 ligand.  Extracellular matrix basement membrane proteins 
serve as a substratum for cell adhesion, stimulating lymphocyte migration and 
exerting co-mitogenic effects upon lymphocyte activation.  T cell activation can 
be increased in vivo by the co-mitogenic effects and can be influenced by factors 
affecting extracellular matrix components.  Antigen binding alone without the co-
stimulatory signal is not sufficient for activation and differentiation of CD8+ T 
cells.  T cell proliferation follows IL-2 stimulation.  T cell subsets are MHC 
restricted, in that Tc cell precursors are activated by class I MHC antigens and 
Th cell precursors are activated by class II MHC antigens.  IL-1 produced by 
antigen-activated antigen presenting cells stimulates the proliferation of Th cells.  
IL-2 produced by the T-helper cells in turn stimulates the differentiation and 
proliferation of Tc cells.  Tc cells recruited secondarily to the site complete the 
acute rejection process. Cell killing may occur via specific T cell products, 
granzyme B, a serine esterase protein, and perforin.  Alloantigen-stimulated B 
cells differentiate into antibody-producing plasma cells, secreting both specific 
and non-specific anti-donor antibodies.  Macrophages act as both APCs early in 
the immune cascade and later as aggressive effector cells contributing to graft 
destruction.  As previously mentioned, products such as IL-1, which activates Th 
lymphocytes to produce their own cytokines, particularly IL-2, and other 
macrophage-derived cytokines, upregulating donor MHC antigens on graft cells, 
leading to even more effective target recognition as the graft response ensues.  
Pro-inflammatory cytokines may directly injure graft tissue, while IL-4 and IL-10 
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may counteract these effects.  Two myelomonocyte differentiation antigens 
(MRP8 and MRP14) are expressed during acute rejection and act as calcium-
binding proteins with cell activation and differentiation.  Natural killer cells, a 
population of cytotoxic non-T, non-B immune cells, have been found adhering to 
exposed Fc portions of molecules during antigen-antibody interactions. 
 
Vasculitis results from antibody formation.  The T cell mediated response is 
followed by destruction of the tissue by invading effector cells such as 
macrophages and lymphocytes.   The pathogenesis of antibody-mediated 
rejection occurring within the first few days of transplantation is believed to be 
due to preformed antibodies reactive against donor antigens. These antibodies 
develop during a prior exposure of the recipient to donor-derived antigens in 
connection with a blood transfusion, pregnancy or abortion.  If the titer of these 
antibodies has dropped, a few days or even weeks may elapse before an 
amnestic immune response can develop.  Antibody mediated rejection in such 
cases may be somewhat delayed and less severe.   
 
Cytokine production plays an important role in the immune response.  In 
addition to graft parenchymal cells, both donor and host activated immune 
cells and APCs can participate in the immune response by producing 
cytokines.  Proinflammatory cytokines include Th1 derived IL-1, IL-3, IL-5, IL-
6, interferon gamma (IFN-γ), and tumor necrosis factor (TNF).  In 
transplantation, cytokines produced locally by injured vascular endothelium, 
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particularly IFN-γ and TNF-α, work in many ways to stimulate the immune 
response.  These cytokines work by increasing MHC Class II expression and 
detection of the T cell receptors on infiltrating host lymphocytes, upregulating 
both donor (target) and host (recognition) molecules.  Adhesion molecules and 
other mediators expressed or upregulated on vascular endothelium may 
influence both early and late graft behavior.  Selectins are a family of 
molecules which are associated with the rolling phase of leukocyte adhesion.  
Intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 
(VCAM-1), LFA-3, and endothelial-leukocyte adhesion molecule-1 (ELAM-1) 
are all molecules associated with a proinflammatory response and allograft 
rejection.   
 
The diagnosis and treatment of acute rejection can be extremely difficult at times, 
as it may even occur in the first 6 to 12 months following transplantation.  
Rejection is related to levels of adequate immunosuppression, and may be 
delayed by several weeks if sensitization to donor antigens has occurred in the 
remote past.  For most organs, the only way to show unequivocally that rejection 
is occurring is by organ biopsy.   
 
1.8.2.c. Chronic Graft Rejection  
 
Chronic rejection has taken the lead in graft rejection since routine preventive 
and immunosuppressive techniques commonly prevent hyperacute and acute 
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rejection, respectively.  Unfortunately, there are still many undiscovered concepts 
in the multifactorial process of chronic graft rejection.  There may be multiple 
etiologies resulting in delayed and long-term immune compromise of a graft.  The 
definitive diagnosis of chronic rejection is generally made by organ biopsy.  
Chronic cardiac graft rejection is often manifest, as in many other grafts, by 
accelerated graft atherosclerosis caused by smooth muscle cell proliferation. 
This may be a form of delayed-type hypersensitivity caused by recipient 
macrophage smooth muscle cell growth factor stimulation.  Chronic renal graft 
rejection is characterized by fibrosis and damage to the microscopic blood 
vessels in the substance of the kidney.  Livers with chronic rejection have a 
decreased number of bile ducts on biopsy, a condition known as "vanishing bile 
duct syndrome". Transplanted lungs with chronic rejection are said to have 
"bronchiolitis obliterans", a type of fibrosis of the lung.   
 
1.8.2.d. Graft vs. Host Disease 
 
When a graft containing enough lymphocytes is placed, donor lymphocyte clonal 
expansion can occur and result in an immunologic response by donor cells 
directed against host cells and tissues.
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1.9. PREVENTING GRAFT REJECTION  
 
The first method used to lower the risk of graft rejection is cross matching 
between a particular donor and recipient to decrease the likelihood of acute 
rejection.  Because a perfect match is rarely available, other techniques for 
preventing graft rejection are included in the transplantation treatment regimen.  
Despite precautionary measures, chronic rejection can occur weeks or years 
after the initial graft was accepted.  Various immunosuppressive drugs, including 
mitotic inhibitors such as azathioprine, lymphocyte migration inhibitors such as 
corticosteroids, and generalized immunosuppressives such as cyclosporine A, 
FK 506, and rapamycin, can be used to effectively reduce graft rejection.  The 
first successful long-term kidney transplants were between monozygotic twins, 
biological clones known to inherit the same histocompatibility antigens.  
Transplants were therefore donor matched.  Using a relative and therefore 
someone with similar inherited histocompatibility antigens as the donor can also 
reduce graft rejection.  Many techniques have been developed to widen the 
donor pool.  One of the most widely used methods of achieving renal allograft 
success is the use of routine tissue typing on cadaver organs to select matches 
with the closest histocompatibility.  Although retrospective studies comparing 5 
year kidney graft survival rates show direct proportionality to lack of HLA 
mismatches, techniques used to prevent graft rejection have resulted in 80% of 
all kidneys functioning by the end of the first year, even with mismatches of all 6 
HLA antigens.  Most transplantation protocols today depend on ABO blood group 
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matching but have eliminated tissue typing.  While reducing the severity of graft 
rejection, many of these highly potent immunosuppressive drugs are cytotoxic to 
both the recipient and sometimes to the graft of interest.   Even if a recipient can 
survive potentially lethal side effects due to toxicity, the effects of long-term 
generalized immunosuppression leave the recipient vulnerable to disease 
secondary to infectious pathogens and cancer secondary to blunted immunologic 
surveillance mechanisms.  From 1% to 5% or more of transplant recipients will 
develop cancer within a few years of receiving their allograft.  This represents a 
100-fold increase in risk compared to the general population. Allograft recipients 
are particularly prone to developing B cell lymphomas.  Their risk is 350 times 
higher than that of the general population.  In most cases, stopping the 
immunosuppression leads to regression of the cancer, but often rejection of the 
transplant as well.  More precise methods of immunosuppression would prevent 
rejection without the dangerous side effects of infection and cancer.  
Immunosuppressive drugs are also responsible for a significant financial and 
psychological burden to the recipient.  Patient compliance is another significant 
factor. 
 
Solid organ transplantation success continues to improve, allowing for longer 
periods of graft survival.  Unfortunately, the longer the graft survives in the host, 
the greater the chances for adverse events and comorbidities.  [84] Most 
protocols combine a primary immunosuppressant (cyclosporine or tacrolimus) 
with one or two adjunctive agents (azathioprine, mycophenolate mofetil, 
58
sirolimus, corticosteroids).  While the benefits of today’s immunosuppressive 
regimens essentially guarantee graft survival, and are necessary and vital to the 
successful outcome of the transplant, immunosuppressive agents taken over 
long periods may be associated with the onset of hypertension, hyperlipidemia, 
osteoporosis, nephrotoxicity, islet cell toxicity, neoplasia, and may possibly 
contribute to other comorbid conditions.  Immunosuppressive treatments may 
also cause cosmetic changes, such as gingival hyperplasia, hirsuitism, alopecia, 
and weight gain, leading to patient noncompliance.  [84] When toxic levels are 
reached, both cyclosporine and tacrolimus may cause neurological symptoms 
such as major speech or language abnormalities, delirium, seizures, tremors, or 
even coma.  Vasogenic white matter edema (as seen on MRI) may lead to 
apoptosis and cytotoxic edema.  Enhanced nitric oxide production may cause 
blood-brain barrier dysfunction and may inhibit drug clearing from the central 
nervous system.  Drug interactions are common and the source of significant 
complications/comorbidities.  These drug side effects have traditionally been so 
significant that ethical arguments against their usage have sometimes 
outweighed arguments supporting transplantation in non-life threatening 
diseases.   
 
1.9.1. Immunosuppression 
 
Immunosuppressive agents are used to inhibit the recipient's immunological 
response against the transplanted antigens.  The application of generalized 
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immunosuppressive drugs in transplantation has dated since the commencement 
of azathioprine and steroid use in the early 1950’s, and has continued with the 
development of antilymphocyte globulin in 1960, and the first specific 
immunosuppressive agent, cyclosporine, discovered in 1970.  [85] Over recent 
years, “improved knowledge of the immune mechanisms underlying 
transplantation rejection has resulted in the development of new 
immunosuppressive agents capable of selectively blocking various steps of the 
immune response.” [86] Specifically acting immunosuppressive agents are 
associated with fewer side effects, maintaining the necessary balance between 
immunosuppression and immunocompetence (preservation of general immune 
protective mechanisms) in order to maintain the general health of the transplant 
recipient.  A regimen which is effective, easy to follow, less costly, and has fewer 
side effects can dramatically improve patient compliance and morale.   
 
Acute graft rejection is the most significant factor in short-term graft outcome.  
Real-time ultrasound-guided allograft biopsy and routine histological evaluation 
using Banff criteria has permitted close monitoring of each graft. [14] The use of 
erythropoietin to treat anemia allows patients to avoid transfusions, thereby 
reducing potential immune sensitization which could trigger acute and/or 
hyperacute rejection episodes.  Sirolimus and everolimus have antiproliferative 
effects on smooth muscle that retard vascular remodeling that is characteristic of 
chronic allograft nephropathy.  Avoiding drug-drug interactions, especially in 
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pregnancy, intravenous dosing, and caring for minority patients [87], is of extreme 
importance.   
 
Triple immunosuppressive therapy is a common strategy used to reduce the 
incidence and severity of graft rejection, and includes the use of a calcineurin 
inhibitor such as cyclosporine A (CsA, trade name Sandimmune, Neoral), 
Tacrolimus (FK-506, trade name Prograf), or Sirolimus (Rapamycin, trade name 
Rapamune); an antimetabolite such as mycophenolate mofetil (MMF, trade name 
CellCept) or azathioprine (trade name Imuran); and a corticosteroid, such as 
prednisone, methylprednisolone, or hydroxycorticosone.   
 
Calcineurin inhibitors are natural products isolated from microbial fungal cultures of 
Streptomyces tsukubaensis (CsA and FK-506) and actinomycetes found in the 
fermented soil of Rapa Nui (Rapamycin).  These macrolide immunosuppressants 
inhibit the signaling pathway used by T cells to turn on their genes for activation, 
e.g. IL-2 secretion.  They work by forming complexes with intracellular receptors 
(cyclophilins or FK-506 binding proteins [FKBPs]).  These complexes block the 
calcium/calmodulin dependent serine-threonine protein phosphatase, or 
calcineurin (CaN), lymphocyte activation pathway, preventing activation of specific 
T cell transcription factors involved in cytokine (IL-2) production and thus signal 
transduction.  [86]   
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Antimetabolite purine analogs are potent, selective, non-competitive, reversible 
inhibitors of inosine monophosphate dehydrogenase (IMPDH), inhibiting DNA de 
novo synthesis, and thus lymphocyte proliferation, without incorporation.  Like 
cancer drugs, purine analogs may induce side effects associated with rapidly 
dividing cells (e.g., lining of the intestine, hair follicles) and myelosuppression.  The 
active metabolite of MMF, mycophenolic acid (MPA), “selectively targets activated 
lymphocytes” and works to augment the actions of standard immunosuppressive 
agents without adding to toxicity.  It works by inhibiting purine synthesis and thus B 
and T cell proliferation.  The addition of MMF will allow a dose reduction of 
cyclosporine, tacrolimus, or corticosteroids while still avoiding acute graft rejection.  
MMF is also used in the definitive and prophylactic treatment of graft versus host 
disease (GVHD).  [88]   
 
Prior to the development of the latest pharmaceuticals, corticosteroid 
immunosuppression was a mainstay in triple therapy treatment of graft rejection.  
Corticosteroids are still sometimes administered at high intravenous doses 
intraoperatively, and at moderately high intravenous doses 1 to 2 days 
postoperatively.  Higher doses initially induce lymphocyte migration to the 
extravascular space through effects on adhesion molecules and impedance of 
leukocyte rolling.  Later, there is non-specific blockage of antigen recognition by 
the reduction of IL-1, TNF, and IL-6 through transcriptional inhibition of 
macrophage mRNA, and modulation of T cell, B cell, and monocyte activity by 
glucocorticoid receptor effects.  High doses can result in lymphocyte death with 
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resultant shrinkage of lymphoid tissues, decreased cytokine production, decreased 
antibody synthesis, and inhibition of the complement pathway due to increased cell 
membrane lipid accumulation.  Corticosteroids are tapered to moderate oral doses 
over the postoperative week, and further tapered over the following two to three 
months.  Lower doses are actually associated with elevated antibody synthesis, 
possibly accounting for rebound graft rejection following discontinuation of 
steroids.  The final dose is usually 0.2 to 0.3 mg/kg/day, which is still associated 
with significant clinical comorbidities.   
 
Table 1.1. Side Effects of Corticosteroid Therapy.  Multisystemic side effects can 
occur in transplant patients with long-term steroid treatment. 
 
Side Effect Features 
Cushing’s syndrome  (excess glucocorticoids stimulate lipogenesis in face,
neck, and trunk) 
Osteoporosis  (increased osteoclast:osteoblast activity; reduced 
gastrointestinal calcium absorption) 
Myopathy  (fluorinated steroids) 
Cataracts  (toxicity) 
Peptic ulcers  (mucosal irritation) 
Skin fragility  (atrophy) 
Adrenal suppression  
Hypertension  (mineralocorticoids) 
Insulin resistance/Diabetes  
 
 
 
Despite improved renal allograft survival over the past 30 years, drug-related 
nephrotoxicity and chronic rejection remain obstacles in successful kidney 
transplantation in a significant number of cases.  Development of laboratory 
assays focused on identifying patients with donor antigen-specific hyporeactivity 
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may help to customize the immunosuppressive drug regimen in stable renal 
allograft patients.  [14]  
 
Antilymphocyte serum (ALS) is antibody-rich serum derived from an animal that 
has been immunized against lymphocytes.  It is used as a potent, non-
specifically-acting immunosuppressive agent that destroys circulating 
lymphocytes.  Because of its lot-to-lot variability in potency, it is generally used 
for animal research.  The gamma globulin component of ALS is antithymocyte 
globulin (ATG, or thymoglobulin, trade name Atgam).  Antithymocyte globulin has 
been used clinically to modulate the immune response.  However, due to its 
relatively non-specific mechanism of action, it has been replaced by more 
targeted immunosuppressive agents.   
 
New drugs available offer the potential to achieve optimal immunosuppression 
while reducing toxicity by combining lower doses of toxic drugs or replacing them.  
[85, 86, 89]  Newest to the armamentarium against graft rejection are the 
monoclonal antibodies directed against specific molecules key to the 2-signal 
model of T cell activation.  Immunosuppressants as well as treatments that recruit 
leukocytes to allografts are some of the strategies used to study allograft tolerance 
[17], and many of these studies have led to the development of new monoclonal 
antibodies for the inhibition of T cell signaling in graft rejection.  
Modern immunosuppressants, such as basilixumab (trade name Simulect) and 
daclizumab (trade name Zenepax), are monoclonal antibodies that target specific 
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receptors ligands in the immune response (such as IL-2), and other soluble 
receptor hybrid molecules may serve to reduce required doses of toxic chemical 
immunosuppressants and provide more specific immune suppression.  [14, 17, 86]  
Moromonab-CD3 (OKT3, trade name OrthocloneCD3) targets the CD3 
component of T cell receptors, inhibiting the Signal 1 of T cell activation.  [90]  
Daclizumab targets the IL-2 receptor and thus inhibits only activated T cells.  
Efalizumab (trade name Raptiva) is a humanized monoclonal antibody that targets 
the T cell lymphocyte function-associated antigen-1 (LFA-1) receptor through the 
CD11a side chain.  [91] Monoclonal antibodies that inhibit B7-1 and CD28 ligand 
binding are being developed to inhibit Signal 2 of T cell activation.  [92]   
 
1.9.2. Immunomodulation and Donor-Specific Immune Tolerance  
 
Immunosuppressive agents are invariably required for all allografts as of today, 
although immunologic tolerance induction techniques may reduce or perhaps 
someday eliminate the need for these agents.  With continued improvements in 
transplantation outcomes, the drawbacks associated with conventional 
immunosuppression regimens become increasingly apparent.  If allograft tolerance 
could be established, immunosuppression and its accompanying risks could be 
withdrawn.  Further identification and development of novel agents that target 
specific components of the allograft response will help achieve greater target-
specific immunosuppression, and will aid in the development of true donor-specific 
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tolerance, “the Holy Grail of solid organ transplantation,” as described by Luke and 
Jordan. 
 
Generally, the introduction of an immunogen at a period following the completion 
of immune development in the presence of some inflammatory stimulus will 
sensitize the recipient to subsequent exposures of that immunogen.  However, IT 
inoculation of antigenic tissue with concomitant depletion of the extent of the 
peripheral lymphocyte population has been shown to specifically modify recipient 
immunity, although the mechanism by which immune reeducation occurs has not 
been fully elucidated.  Numerous studies have demonstrated that the introduction 
of specific polypeptide sequences to the immunologically privileged IT site with 
depletion of circulating and noncirculating peripheral lymphocytes will induce 
tolerance. 
 
The ability to induce donor-specific tolerance in an allogeneic host raises the 
possibility of introducing specific antigens into the thymus to study the ability of 
these known antigens to act as tolerogens, and induce antigen specific 
unresponsiveness.  [93-96] By altering conditions such as the timing and route of 
administration of antigenic peptides or the genes encoding them, it may be 
possible to induce specific tolerance to subsequent exposure to that same antigen.   
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1.9.2.a. Intrathymic (IT) Transplantation and Central Tolerance Induction Through 
Thymic Reeducation 
 
Selection processes that occur within the thymus, prior to T cell differentiation, 
are referred to as “central” selection processes, while post-differentiation T cell 
regulatory mechanisms on the effective immunological repertoire of lymphocytes 
are referred to as “peripheral” selection processes.  It has been concluded that 
“only recent thymic emigrants, but not peripheral resident mature T cells are 
susceptible to this process of functional education, which also requires exposure 
to specific antigens and occurs entirely in the periphery.” [97] Based upon the 
cellular type, timing, and route of administration, cellular inoculation treatments 
can be used to harness natural central or peripheral tolerance induction 
mechanisms.  [47] The thymus is of great importance in T cell development and 
self-recognition, but its function was unknown until the current century.  [54] [57].  
It plays an essential role in the establishment of self-tolerance to antigens 
expressed on its stroma by clonal elimination or functional inactivation of self-
reactive T cells.  [98] Cortical TECs are believed to positively select self-MHC-
restricted thymocytes for maturation.  [47] The bone marrow-derived APCs found 
mainly at the corticomedullary junction are believed to be largely responsible for 
negative selection [99], which leads to deletion of T cells with high affinity for self 
MHC and/or self antigen/self MHC complexes.  This hypothesis is supported by  
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recent studies demonstrating that TECs can regulate the functional maturation of 
CD4+ thymocytes.  [100, 101] 
 
1.9.2.a.1. Maintenance of the T Cell Repertoire 
 
Models of autoimmune disease serve to elucidate mechanisms of immune 
function.  In these models, autoantigens serve as naturally occurring foreign 
antigen representatives, and are classified as either intrathymic or extrathymic.  
[74] The binding of immature autoreactive T cells signals a process that results in 
apoptosis and thus clonal deletion [98].  In comparing the autoimmune response 
to the normal cell-mediated immune response, antigen presentation studies have 
been used to detect abnormalities in the normal 2-signal model of antigen 
recognition.  Cells bearing autoantigens are thought to be presented to T cell 
receptors by APCs that are missing key costimulatory molecules.  [102] [66]  
Activation of signal 1 without coactive signal 2 renders autoreactive T cells either 
anergic or indifferent.  [103-105]  
 
This is how passive self-tolerance is said to occur.  However, self-tolerance to 
autoantigens may also require active suppression mechanisms to address the 
autoreactive potential of cells that somehow are neither clonally deleted nor 
rendered anergic.  [106, 107]  Likewise, it has been shown that IT selection of the 
T cell repertoire is dependent upon peripheral fallback mechanisms regulated by 
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circulating mature suppressor T cells, answering the question of how tolerance to 
peripheral self-antigens is achieved.  [74] 
 
In terms of tolerance induction, if deletion (anergic) mechanisms were 
responsible for unresponsiveness, the persistence of thymic tissue unexposed to 
donor alloantigen would permit normal maturation of alloreactive T cells, 
preventing donor-specific tolerance.  Donor alloantigen introduced into one 
thymic lobe would result in clonal reeducation in that part of the thymus, but the 
remainder of the thymus gland would remain naive to the donor alloantigen.  This 
would indicate why it would be important to inoculate both lobes with antigenic 
tissue for successful tolerance induction.  If a suppression mechanism were 
responsible unresponsiveness, then the presence of alloantigen-naive thymic 
tissue would not affect the IT induction of tolerance.  IT tolerance induction 
studies support the clonal deletion mechanism.  It was shown that “inoculation of 
bone marrow into only one lobe of the native thymus and/or ectopic thymus did 
not promote consistent survival of subsequent…cardiac allografts.”  [108] 
Tolerant hosts actually had reduced numbers of precursor cytotoxic lymphocytes 
targeted against donor alloantigens.  “Adoptive transfer of spleen cells from 
tolerant WF hosts harboring longstanding cardiac allografts led to permanent 
survival of LEW cardiac allografts in secondary recipients, indicating that the 
unresponsive state after IT inoculation of bone marrow cells is primarily mediated 
by deletion and/or inactivation of donor-specific T cell precursors maturing in a 
chimeric thymus.”  [108] These findings reflect that persistence of donor 
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alloantigen supplied by cells in the allograft is key to the maintenance of an 
unresponsive state.  “Adoptive transfer of spleen cells from tolerant WF hosts 
treated with LEW bone marrow but not transplanted with cardiac allografts did 
not lead to permanent survival of LEW cardiac allografts in naive secondary 
recipients.”  [108] Immune mechanisms are never quite so straightforward, 
however.   
 
The intravenous infusion of specific T cell populations to induce tolerance or to 
prevent autoimmune disease takes advantage of the immune surveillance capacity 
of these cells in the peripheral immune system.  It has been shown that as few as 
600,000 CD4+/CD8- cells collected from the donor thoracic duct and injected 
intravenously into lymphopenic rats can protect approximately half of the animals 
from diabetes.  [74] The mechanisms of immunomodulation associated with 
peripheral administration of lymphocyte populations may not fall under the 
category of tolerance induction per se, as T cell-mediated suppression of immunity 
may be the cause of perceived donor-specific unresponsiveness.   
 
Transplantation biology remains a very complicated science.  The very same 
immunosuppressive methods used to treat one of the major obstacles in the 
success of transplantation, graft rejection, may also lead to graft failure and other 
intolerable side effects.  Familiarity with current techniques in transplantation 
combined with an intricate understanding of the immune response will guide the 
development of modern strategies to reduce graft rejection, and at the forefront of 
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this field, to induce transplantation tolerance.  It is hypothesized that more 
specifically targeted approaches towards reducing immune graft rejection that 
avoid chronic therapy would eliminate both the threat of graft rejection and the 
secondary complications of long-term immunosuppression. 
 
1.9.2.b. Intrathymic Inoculation of Soluble Proteins and Non-Viable Cells and 
Tolerance Induction  
 
In the establishment of tolerance to peripheral tissue-specific antigens, the role of 
the thymus is much less clear, since recessive mechanisms of peripheral 
tolerance (ignorance, deletion, anergy, immunodeviation) do not require thymic 
selection.  The mechanism of thymic dependent specific suppression of 
aggressive responses to autoantigens that are not expressed intrathymically still 
remains unknown.  [79-81] It is known that the expression of autoantigen mRNA 
and protein in the thymus correlates with resistance to autoimmune disease, 
supporting the idea that introduction of antigens into the thymus could be used to 
establish central tolerance. [109] Allogeneic and xenogeneic murine thymic 
tissue transplantation has been shown to induce donor-specific tolerance.  
Similarly, allogeneic thymic tissue transplantation in a euthymic miniature swine 
model supported host thymopoiesis.  These studies suggested that thymic 
transplantation could be adapted into a donor-specific xenogeneic tolerance 
induction regimen.  [110] The specific mechanism by which tolerance induction 
occurs has not been characterized, but it has been proposed that TECs are 
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primarily responsible for imprinting MHC-restricted specificity, and bone marrow 
derived macrophages or dendritic cells are responsible for the elimination of high 
affinity bound self-reactive T cells.   
 
IT inoculation of soluble alloantigens, including MHC, has been shown to induce 
donor-specific tolerance to murine cardiac allograft, [93, 111-114] and IT 
inoculation of sonicated cells has also been shown to induce donor-specific 
allograft tolerance via the oral route in a mouse model of corneal 
allotransplantation.  [115] Allograft tissue presented intrathymically in this fashion 
is not recognized as foreign and rejection processes are avoided.  The exact 
mechanisms behind IT soluble alloantigen inoculation induced tolerance 
induction are not well explained, and the IT inoculation of specifically functioning 
cells bearing antigens may be a more targeted approach towards tolerance 
induction. 
 
Further studies have demonstrated that this thymic reeducation is also 
efficacious in an autoimmune setting.  In some models of autoimmune disease, 
such as experimental autoimmune uveoretinitis, a correlation has been shown 
between “constitutive expression of autoantigens in the thymus (mRNA and 
protein)” and resistance to disease.  [109] This naturally occurring central 
tolerance to the “relevant autoantigen” could explain why certain individuals are 
more susceptible to autoimmune diseases than others.  [109, 122] 
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1.9.2.c. Intrathymic Inoculation of Viable Cells and Tolerance Induction  
 
1.9.2.c.1. Tolerance Induction with Islets of Langerhans 
 
IT islet transplantation in prediabetic BB/Wor rats was shown in several studies 
to inhibit the progression towards the diabetic state.  [116-121]  These historical 
studies are further discussed in Chapter 4. 
 
In many of the studies involving IT cell transplantation for tolerance induction, it is 
difficult to determine whether the reduced immunogenicity is related to the type of 
cells transplanted or simply due the presence of allogeneic antigens in the 
transplantation milieu.  It is hypothesized that genetically altering and then 
transplanting a specific cell type would further specify the mechanism by which 
tolerance induction occurs. 
 
1.9.2.c.2. Tolerance Induction with Renal Glomeruli 
 
An IT glomerular inoculation study was published just after a similar study showing 
that IT inoculation of donor islet cells induced tolerance to subsequent donor 
matched islet grafts, as described above.  [123] The IT inoculation of isolated renal 
glomeruli into the thymus of MHC incompatible rats pretreated with cyclosporine 
was shown to induce long-term donor-specific tolerance to subsequently 
transplanted kidney grafts while medium only injected rats rejected their grafts 
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within 7 to 9 days.  [124] This study expanded upon the specificity of tolerance 
induction because it demonstrated that the tolerance induction was not only MHC-
specific, but it was tissue-specific.   
 
1.9.2.c.3. Tolerance Induction with Bone Marrow  
 
Donor-matched tolerance to a variety of tissues, including skin, has been 
achieved following the IT injection of donor-matched bone marrow cells into each 
lobe of the thymus coadministered with a single 1 mL intraperitoneal injection of 
ALS. [125-128]  Studies supporting this tolerance induction strategy are 
discussed in greater detail in Chapter 4. 
 
1.9.2.c.4. Tolerance Induction with Spleen Cells 
 
IT inoculation of MHC mismatched splenocytes with a concomitant single 
intraperitoneal dose of ALS led to donor-specific unresponsiveness in a model of 
rat cardiac allotransplantation.  Graft survival was dependent upon the route of 
inoculation (intravenous splenocytes did not induce tolerance) and the present of 
ALS coadministration. [129]  
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1.9.2.d. Use of TECs in Thymic Reeducation  
 
TECs were chosen for this investigation based on their thymic origin, epithelial 
nature, and their ability to be maintained and manipulated in vitro.  It is 
hypothesized that TEC expression and presentation of an antigenic gene product 
in the thymic environment will result in the recognition of the antigen as self, 
preventing immune targeting of this antigen.  In such a paradigm the immunogenic 
proteins within the host thymus, whether native products such as allogeneic MHC, 
or transgenic products from novel transferred genes, would function as tolerogens, 
resulting in the modification of the host’s immune repertoire.  It is hypothesized 
that this approach would allow the host immune system to be specifically modified 
to accept transplanted tissues or cells without impinging on its ability to effectively 
respond to other foreign immunogens.   
 
1.9.2.d.1. Primary Culture of Mammalian TECs  
 
1.9.2.d.1.a. The Demand for Interest in Primary Keratinocyte Cell Lines and 
Application to TEC Cultures  
 
It is hypothesized that deriving and culturing TECs would allow for studies on the 
role of TECs in thymic education and tolerance induction.  The development of 
new and intriguing in vitro manipulation techniques which function to isolate and 
effectively maintain cells in prolonged culture have allowed more efficient 
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individual and throughput research protocols to materialize.  Harvesting and 
culturing primary cells is a tedious process associated with inconsistency, 
inconvenience, and expense.  Consistency depends upon the reliability of a 
harvesting source, sensitivity of specific processing techniques, timing of crucial 
steps in the harvesting process, and technical skill of the tissue harvesting team.  
Tissue and cell harvesting can be labor intensive, sometimes requiring repeated 
mid-process sampling to ensure adequate product yields.  To maintain genetic 
consistency between harvest sources, littermates of the same gender are often 
chosen.  Therefore, many other factors, including the reproductive capacity of an 
animal colony and the availability of appropriately sexed offspring can be 
technically and financially limiting.  Even when the protocols for high yield 
harvesting from multiple animals have been established, some technologies are 
not suited for tissues or cells from multiple animals.  For example, the gene 
therapeutic techniques that might potentially be used on cells require that they 
originate from a single animal source and that the cells are “carried for multiple 
passages”.  The ability to cryopreserve the cells would also be advantageous for 
repeating experiments and comparing results among primary cell lines.  [130] To 
obtain sufficient numbers of cells for experimental manipulation and evaluation, 
the development of a method allowing continuous culture of thymus-derived 
epithelial cells becomes necessary [131-133].  Typically, culture protocols for 
epithelial-derived cells require a high density of cells to sustain viability in primary 
culture.   
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Epidermal keratinocytes are an epithelial-derived cell type which have been 
extensively studied in in vitro systems, and when plated at a high density, 
demonstrate proliferation and improved overall viability compared to cells cultured 
at low density [134].  Studies also demonstrate increased plating efficiency for 
human epidermal keratinocytes derived from newborn as compared to adult 
donors, signifying the advantage of using partially undifferentiated or immature 
cells for establishing cell lines.  It is reported that even though some keratinocyte 
cultures can be established and subcultured, there is a limited lifetime in culture 
ranging from 20 to 50 cell generations.  [135] 
 
While the culture and subculture of human keratinocytes from a single biopsy 
have been well documented, culture techniques for murine keratinocytes have 
required plating at high density for seeding of sufficient numbers of cells, and 
poor division capacity has necessitated pooling from several animals.  [135] [136]  
[137]  These limitations in murine keratinocyte culture highlight the demand for 
an interest in primary keratinocyte cell lines.   
 
General aspects of primary keratinocyte culture can be applied to TEC culture, 
as TECs may be included in the category of keratinocytes.  TECs express keratin 
in the form of keratin intermediate filament bundles, or tonofilaments, and 
desmosomes, defining them as epithelial in nature.  [36] Additionally TECs 
express an endocrine function, secreting thymosin, serum thymic factor, and 
thymopoietin in cytoplasmic secretory granules.  These hormones all function in 
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the transformation of immature T cells into immunocompetent T cells, though 
they may have other functions.  Thymosin has been connected to functions in 
reproductive physiology, wound repair, angiogenesis, and tumorigenesis.   
 
The thymic microenvironment controls IT T cell differentiation via influence by 
prolactin (PRL) and growth hormone (GH).  Both of these hormones, along with 
thyroid stimulating hormone, stimulate thymulin secretion by TECs. [138] 
Thymulin, also a hormone, has been shown to regulate GH secretion [139] while 
inducing T cell differentiation [140], and is controlled by TEC negative feedback 
mechanisms.  [141] Insulin-like growth factor 1 (IGF-1) works synergistically with 
GH to upregulate thymulin secretion.  Prolactin and GH receptors have been 
located on both TECs and thymocytes.  [142] Established TEC lines secrete 
thymic hormones and promote thymocyte proliferation in vitro.  One group refers 
to these secretory products as thymic hormonal factors (THFs).  [143] 
 
Minced human thymic tissue has been cultured with and without trypsinization.  
Cuboidal shaped epithelial cells can appear in a layer within the first 24 to 48 
hours, and the in vitro thymic epithelial cells were able to influence thymocyte 
proliferation for at least two weeks.  [144]   
 
The differentiation of TECs toward a “neural-oriented cell fate” occurs under the 
influence of epidermal growth factor (EGF).  [145] Neural-oriented differentiation 
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also appears to be calcium dependent.  [146] This could be related to TEC 
derivation from cranial neural crest cells.   
 
1.9.2.d.1.b. Previous Reports of TEC Isolation  
 
The isolation and culture of TECs in humans, mice, and rats has been described 
previously.  Many of the advances in TEC isolation and culture have resulted from 
studies aimed at the characterization of monoclonal antibodies for immunology 
research.  These studies are discussed further in Chapter 2. 
 
1.9.2.d.1.c. Culture Conditions and Media Supplements  
 
Many techniques for isolation and culture of TECs have been described, mostly 
employing conventional primary tissue culture techniques combined with 
hormonal supplementation and intermittent chelation therapy to reduce fibroblast 
overgrowth.  Other manipulations used to enhance specific growth of this cell 
type include the deletion of serum from the culture medium, supplementation of 
the medium with D-valine [147-149], growth of cells on extracellular matrix-
coated surfaces [150], growth of cells over “irradiated fibroblasts as filler cells” 
[135, 149], and culture of cells in low calcium medium.  [146, 151-155]  Using this 
background knowledge, it is hypothesized that TEC culture isolation can be 
developed to supply the need for proliferative TEC lines (Chapter 2).   
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TECs may be distinguished from other thymic cells based on characteristics 
specific to epithelial-derived cells.  The presence of cytoplasmic keratin 
intermediate filaments (IFs) or tonofilaments interacting with desmosomal 
junctions are the primary morphological features allowing identification and 
characterization of TECs. [156, 157] 
 
Thymic epithelial cell cultures are highly susceptible to overgrowth by fibroblasts.  
The substitution of horse serum for fetal calf serum has been shown to reduce 
fibroblast overgrowth. [158]  Various serum-free methods of primary keratinocyte 
culture have proven effective in establishing and maintaining cells through 
several passages.  Types of keratinocytes studied have included but are not 
limited to epidermal keratinocytes and prostatic epithelial cells.  Supplements 
used in prostatic epithelial cultures include transferrin (1 microgram/mL), EGF 
(10 ng/mL) and insulin (3.7 micrograms/mL or 0.1 IU/mL).  Glucocorticoids like 
dexamethasone and retinoids like retinyl acetate have also been added as 
supplements to regulate epithelial proliferation by dose dependent synergism 
with the effects of insulin and EGF. [159, 160]  It is suggested that the TECs 
exhibit paracrine glucocorticoid activity on thymocytes [161] and that reduction of 
glucocorticoid production by TECs with age may be the cause of thymic 
involution.  [162] It has been shown that hydrocortisone treatment of 
glucocorticoid expressing TECs augments their adhesion to thymocytes, thymic 
hormone secretion, cytokeratin expression, and extracellular matrix production.  
These cells have been shown to express glucocorticoid receptors and are 
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sensitive to hydrocortisone in terms of thymic hormone secretion, cytokeratin 
expression, and ECM production.  Additionally, dexamethasone treatment in vitro 
has been shown to induce keratin distribution changes in vitro in TECs.  [163] It 
is not known how these effects correlate with in vitro primary culture per se, 
although several growth factors have been used to maintain cultured 
keratinocytes.  [164]; [146, 165] [166]  Insulin-like growth factor-1, GH, and PRL 
have been shown to enhance in vivo expression of high molecular weight 
cytokeratins and to stimulate in vitro TEC proliferation.  [142]. 
 
Already employing serum-free methods of primary keratinocyte culture, one group 
investigated the effects of glucose and electrolytes.  Titration experiments showed 
that optimal glucose concentration is 0.8 mM and sodium chloride concentration is 
100 mM.  There appeared to be an abnormal lipid profile in keratinocytes in 
primary culture, but the lipid profile normalized with the adjustment of glucose and 
sodium chloride levels. [167] The accumulation of lipid granules within TECs might 
indicate a need for culture medium glucose and electrolyte optimization.  
 
A common denominator in the formulation of culture medium for the development 
of primary murine cell lines has been the maintenance of cells in medium 
containing low levels of calcium.  Several studies report on the impact of reduced 
medium calcium concentration on the proliferation and effortless passaging of 
epidermal keratinocytes [146, 151-155].  Media containing calcium 
concentrations less than 0.09mM supported continued growth and proliferation of 
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keratinocytes, while higher calcium levels initiated terminal differentiation and 
decreased cell proliferation.  [165] Further, the expression of biochemical 
markers indicative of late stage epidermal differentiation occurred following 
culture of cells in media depleted of growth factors and containing calcium at a 
high concentration (0.15mM) [168].  Keratinocytes from newborn mice were 
grown on dishes coated with collagen IV and maintained in fibroblast-conditioned 
medium containing 0.06 mM calcium and added growth factors.  By removing 
growth factors and increasing the medium calcium level to 0.15 mM, 
keratinocytes were induced to produce mouse keratin I.  However, this 
expression was lost by the 15th passage.  [130] Other groups also reported that 
higher calcium levels initiated terminal differentiation and decreased cellular 
proliferation.  [146] [169]  The calcium-induced response of TECs is discussed in 
Chapter 3. 
 
Another supportive investigation showed that monolayers of human prostatic 
epithelial cells have been grown to the 4th passage using collagenase digestion 
of prostatic acini, low calcium concentrations, supplementation with “a growth 
factor that is concentrated in bovine neural tissue” and subculturing before 
confluence reaches a certain threshold.  [170] Trypsinization with EDTA may not 
be as effective in passaging cells due to their tight adherence to growth surfaces 
and to each other.  Gentle collagenase IV digestion for 5 minutes at 37° C, then 
rinsing with PBS and 0.02% EDTA, followed by pelleting at 600 to 800 rpm and 
replating can allow passaging of especially adherent cells.   
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Limited dilution cloning is a technique that has been used to isolate and expand 
small numbers of epithelial cells.  (Figure 2.1.)  [171] Additionally, the reduction 
of incubation temperatures from the usual 37° C to 31° C has been shown to 
increase epidermal cell proliferation.  [164] 
 
1.9.2.d.2. Immortalization (Transformation vs. Nontransformation)  
 
“Subculturable cell lines” can be established with the cellular application of 
carcinogen treatments.  [164] TEC lines derived from thymomas and malignant 
thymomas were compared to those derived from normal rat thymus tissue and 
shown to exhibit differential expression of proto-oncogenes and tumor suppressor 
genes in vitro.  [172] These thymoma-derived cell lines produced cells of a larger 
size than cells derived from normal thymic culture, and were “stabilized” to a fully 
differentiated TEC phenotype with the addition of 1µm dexamethasone.  [163, 173]  
Alternately, TEC lines have been transformed using oncogenic viral vectors, such 
as SV40, an oncogenic simian polyoma virus.  [174-176]  Because of the 
differences between TEC lines derived by induced transformation vs. spontaneous 
transformation, a spontaneously transformed cell line might be preferable.  It was 
hypothesized that altering culture conditions would allow the cultivation of 
spontaneously transformed primary TEC lines for further use.  The isolation and 
culture of several TEC lines, one of which spontaneously transformed, is covered 
in Chapter 2. 
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1.9.2.e. Tolerance Induction and Gene Therapy  
 
Statistical analyses of the number of transplantation recipients suffering from 
significant systemic side effects of routine immunosuppressive agents would 
lead one to conclude that an alternative to current strategies should be closely 
investigated.  Induction of specific immunologic tolerance to subsequent grafts 
would offer a safe alternative to long-term immunosuppression and combat 
donor organ shortage.  Tolerance induction would be an ideal way to treat 
autoimmune diseases.  The possibility of imparting specific immunologic 
tolerance to autoimmune diseases such as diabetes mellitus, autoimmune 
thyroiditis, or system lupus erythematosus serves as a great impetus for 
working towards a new treatment paradigm that would simply and effectively 
prevent some of the world’s most common diseases.  [177] Gene therapy has 
been and continues to be examined as a means to introduce novel genes into 
the cells of a graft in an effort to modify graft immunogenicity, introduce 
localized/microlocalized immunosuppression, modify the graft environment to 
improve engraftment, and/or modify the function of transplanted cells/tissues.  
One method of introducing a protein antigen within the thymic 
microenvironment is via the insertion of genetic material encoding that antigen 
using gene transfer techniques.  [178] 
 
“Gene therapy is currently being used in attempts to induce immune tolerance to 
a variety of immune mediated diseases.  In transplantation, gene therapy 
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strategies to prolong graft survival involve gene transfer and expression of 
immunomodulatory or graft-protecting molecules.”  [179] Induction of 
immunologic tolerance to alloantigens is a major goal in the field of 
transplantation.  The recent addition of stable gene transfer vectors that can be 
expressed in a controlled manner has allowed focus towards clinical applications 
of gene therapy in transplantation of various organs, including the heart.  [179] 
 
While many studies support the IT route of administration for inoculation of 
genetically modified cells for tolerance induction, one showed that neither 
intraperitoneal nor intrathymic inoculation of genetically modified fibroblasts 
induced recipient tolerance to the protein encoded by the transgene without the 
use of immunosupression (cyclosporine A).  In fact, when later compared to the 
intraperitoneal/cyclosporine A treated control group, recipients of intrathymic cells 
mounted a heightened antibody response to the protein, suggesting sensitization 
rather than tolerance induction.  [180] 
 
It is hypothesized that the combination of gene therapy and tolerance induction 
strategies, resulting in the production and expression of specific novel proteins 
and their expression as tolerogens within the thymus, offers a highly attractive 
paradigm for developing novel therapeutic approaches to transplantation 
immunology, autoimmune disease(s), and potentially other immune-related 
issues.  [182] The desire to use genetic manipulation necessitates a method 
allowing continuous TEC culture.  [135-137]   
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CHAPTER 2.  
ESTABLISHMENT AND MAINTAINANCE OF A RAT PRIMARY THYMIC 
EPITHELIAL CELL LINE  
 
 
2.1. INTRODUCTION 
 
Induction of specific unresponsiveness has been demonstrated following IT 
transplantation of whole cells, cell clusters (i.e. islets), and IT inoculation of 
soluble proteins and non-viable cells.  It was hypothesized that the IT injection of 
donor MHC-mismatched TECs, native residents of the thymic environment, 
would demonstrate improved transplantability and survivability at the transplant 
site, and, as demonstrated for other cell types, would induce donor-specific 
tolerance.  The successful establishment of a proliferating population of TECs 
would be the first step in demonstrating the feasibility of this hypothesis.  The 
desire to utilize large numbers of TECs for in vitro manipulation and 
characterization, transplantation experiments, and for other future studies 
including genetic manipulation in a rat model necessitated the establishment of at 
least one primary TEC line.  The best suitable conditions for isolation of TECs 
and establishment of a TEC line were investigated by modifying previously 
published techniques, and by varying culture and medium conditions.  
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Previously, studies focusing on ontogeny of the thymus gland and defining the in 
vitro effects of TECs on T cell maturation in normal and diseased animal and 
human models required the ability to establish and maintain TECs in primary 
culture. [183-188] Some groups applied the results of research on thymomas to 
normal TEC responses.  [189-194] Other studies focused on raising monoclonal 
hybridoma antibodies against TECs for studies characterizing the in situ 
architecture of the thymic cortex as it related to the blood-thymus barrier and 
clonal selection.  [195-209] Murine-derived TECs and other cells which express 
keratin intermediate filaments are reported as difficult to establish and maintain, 
possibly explaining why a primary rat TEC line has not been made commercially 
available.  [135] [136]  [137]  Like primary TEC cultures, primary keratinocyte 
cultures are often complicated by fibroblast overgrowth.  [158] Additionally, 
primary keratinocyte cultures have been established using serum free and low 
calcium growth conditions [146, 151-155].  These varied conditions of primary 
culture, common to keratin-expressing cells, were applied to the primary TEC 
cultures derived from four different rat strains, the Lewis, Dark-Agouti, LDA 
(Lewis x Dark Agouti), and Wistar Furth strains, outlined below.   
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2.2. MATERIALS AND METHODS  
 
2.2.1. Animals  
 
Three to fourteen day old Wistar Furth (WF, RT1u), Lewis (Lew, RT1l), Dark 
Agouti (DA, RT1a), and Lewis-Dark Agouti (LDA, RT1a,l, F1 offspring of Lew x 
DA) rat perinates were used as tissue donors.   
 
2.2.2. Neonatal Thymus Gland Excision 
 
Perinates were sacrificed using craniocervical dislocation, the neck and thoracic 
regions were prepared with 70% ethanol, and thymic dissection was performed in 
an aseptic environment.  Using aseptic technique, a midline vertical skin incision 
was made beginning in the mid epigastric region and extending towards the 
neck.  The skin was retracted laterally.  Forceps were used to lift the epigastric 
musculature and scissors were used to puncture the musculature of the 
diaphragm, and an incision was made through both the musculature and the ribs, 
just lateral to the sternum, extending cranially all the way through the clavicle.  
The ribs were retracted laterally, and the gray, bilobed thymus gland was 
identified overlying the great vessels.  Microforceps were used to separate the 
thymus tissue from the great vessels.  To minimize cellular autolytic changes, the 
fresh thymic tissue was placed in 15 to 20 mL of cold (0°C) Ca++/Mg++ free 
Hank’s balanced salt solution in a glass Petri dish over ice.   
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2.2.3. Preparation of Thymic Cell Suspension – Enzymatic In Vitro TEC Isolation  
 
Freshly harvested neonatal thymi were placed in a sterile glass microconcavity 
slide with a small volume of Ca++/Mg++ free HBSS. (Fisher Scientific, St. Louis, 
MO)  Sharp dissection with microforceps and a microscalpel under a dissecting 
microscope, was used to remove any visible capsular and pericapsular 
connective tissue, fat, coagulum, blood vessels, and debris.  Under a positive 
pressure laminar flow hood, the tissue was minced in the sterile microconcavity 
slide using curved 9 cm surgical scissors, producing approximately 2-3 mm2 
particles in a viscous cellular mix.  Occasionally rinsing the scissors with a small 
volume of Ca++/Mg++ free HBSS helped to clean it of adherent tissue.  The 
minced particles were pipetted into a 50 mL centrifuge tube containing a sterile-
filtered collagenase (Boehringer Mannheim, Mannheim, Germany) solution (15 
mL, 1 mL solution/perinate, 1 mg/mL collagenase in Ca++/Mg++ free HBSS) and 
incubated for 30 minutes at 37°C in a water bath with vigorous agitation every 10 
minutes.  The addition of cold Ca++/Mg++ free HBSS was used to arrest 
enzymatic activity, and the digest was centrifuged at 1500 rpm for 5 minutes.  
Following centrifugation, the supernatant was removed and the digested tissue 
washed and centrifuged with Ca++/Mg++ free HBSS two additional times.  A 
pipette was used to remove the supernatant from the pellet of minced thymic 
tissue.  (Depending on the donor strain, cells were treated with 0.05% EDTA in 
Ca++/Mg++ free HBSS.)  The pellet was resuspended to a total of 7 mL in 
growth medium (type varied with strain of rat), and plated to T25 tissue culture 
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flasks (approximately 3 thymi per flask).  (Falcon, Fisher Scientific, St. Louis, 
MO)  Plated thymic explants were maintained in a water-jacketed incubator at 
37°C with an atmosphere of 5% CO2 in air.  On day 7 of culture, the tissue was 
refed by removing and replenishing approximately half the media volume.  
Depending on the donor strain, 0.05% EDTA in Ca++/Mg++ free HBSS or PBS 
was used to chelate calcium from the culture medium, inhibiting fibroblast 
overgrowth.  Unattached thymic cells and tissue explants removed with the 
media change were pelleted by centrifugation for 5 minutes at 1500 RPM, the 
supernatant discarded, and the pellet resuspended and replated to a new flask in 
fresh media.  
 
All flasks were refed and EDTA-treated every 3 days thereafter.  The thymic cells 
attached to the culture dish surface and cellular outgrowth occurred, eventually 
forming a monolayer.  Culture supernatants were collected daily for one week 
and used for subculture to conserve any unattached cells, providing them further 
opportunity to settle down, attach, and thrive.  The cultures were observed daily 
under an inverted tissue culture microscope.  Unattached non-epithelial thymic 
cells such as thymocytes were discarded with the supernatant and attached 
fibroblasts were eliminated over a period of approximately 3 weeks by exclusion 
of supplements required for their growth and by differential trypsinization of 
cultures.   
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2.2.4. Pure Thymic Epithelial Cell Culture 
 
Initial culture techniques included collagenase and EDTA treatment followed by 
plating of minced tissue for two hours, re-plating of collected centrifuged 
supernatant mixture (500 rpm), and refeeding with fresh medium.  The effects of 
collagenase and EDTA treatment of the thymic suspension and the supernatant 
were evaluated.  The medium used for the initial plating was adjusted over time 
to optimize primary TEC culture.  (Table 2.1)  Evaluation of early cell populations 
revealed a majority of cells with a fibroblast-like phenotype, with a minority of 
epithelial-appearing cells.  Sterile poly-L-lysine was used to treat the growth 
surface of tissue culture flasks in attempts to increase cellular attachment.  
Incubation settings were also optimized.  Re-evaluation of the culture techniques 
eventually led to the following modifications in the protocol:  The collagenase and 
EDTA-treated minced tissue was plated into T25 culture flasks containing the 
medium best suited for each rat strain and maintained at incubation settings of 
37°C, 5% CO2.  The strain-specific optimization of media was empirically 
determined using a variety of media and media combinations (Table 2.1.).  
Depending on the rat strain, the tissue was again EDTA treated on day 7 and 
every 3 days thereafter until the epithelial nature of the monolayered cells was 
confirmed using light microscopy, immunocytochemical staining, and electron 
microscopy.   
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Table 2.1. Media Formulations Assayed for Applications in Primary TEC Culture.  
Various formulations with differing concentrations of medium components.  
GWAJC supplements = cholera toxin, EGF, insulin, transferrin, and DM. 
 
 
Base 
medium 
2° medium 
(conc.) 
serum  
(conc.) 
Buffer 
(conc.) 
antibiotic  
(conc.) 
1% 
Supplements
(conc.) 
DMEM N/A equine (15%) HEPES (1%) PSF  NaPy (1%) 
DMEM Ham’s F12 
(50%) 
N/A NaHCO3 PSF  N/A 
WISH  fetal calf (15%) NaHCO3 PSF  L-glutamine 
(1%) 
GWAJC DMEM 
(7.5%) 
fetal calf (7.5%) HEPES and 
NaHCO3 
PSF  GWAJC  
GWAJC DMEM 
(2.5%) 
supplemental calf (2%) HEPES and 
NaHCO3 
PSF  GWAJC  
GWAJC DMEM 
(7.5%) 
supplemental calf (2%) HEPES and 
NaHCO3 
PSF  GWAJC  
GWAJC DMEM 
(2.5%) 
supplemental calf (7.5) HEPES and 
NaHCO3 
PSF  GWAJC  
DMEM N/A N/A NaHCO3 PSF  GWAJC  
DMEM N/A supplemental calf (2%) NaHCO3 PSF  GWAJC  
DMEM N/A supplemental calf 
(7.5%) 
NaHCO3 PSF  GWAJC  
DMEM N/A supplemental calf 
(10%) 
NaHCO3 PSF  GWAJC  
DMEM N/A fetal calf (10%) NaHCO3 PSF  GWAJC  
Ham’s F12 N/A supplemental calf (2%) NaHCO3 PSF  GWAJC  
Ham’s F12 N/A fetal calf (7.5%) NaHCO3 PSF  GWAJC  
Ham’s F12 N/A fetal calf (10%) NaHCO3 PSF  GWAJC  
Ham’s F12 N/A supplemental calf 
(10%) 
NaHCO3 PSF  GWAJC  
GWAJC DMEM 
(50%) 
supplemental calf (5%) HEPES and 
NaHCO3 
PSF  GWAJC  
GWAJC DMEM 
(50%) 
supplemental calf 
(7.5%) 
HEPES and 
NaHCO3 
PSF  GWAJC  
GWAJC DMEM 
(50%) 
supplemental calf 
(10%) 
HEPES and 
NaHCO3 
PSF  GWAJC  
Promocell N/A N/A N/A PSF  N/A 
GWAJC N/A N/A HEPES and 
NaHCO3 
PSF  Promocell  
Promocell N/A N/A N/A PSF  GWAJC 
Promocell N/A supplemental calf (2%) N/A PSF  Promocell  
Promocell N/A supplemental calf (5%) N/A PSF  Promocell  
Promocell N/A supplemental calf 
(7.5%) 
N/A PSF  Promocell  
Promocell N/A supplemental calf 
(7.5%) 
N/A PSF  Promocell + 
D-valine 
Promocell N/A supplemental calf (2%) N/A PSF  GWAJC  
Promocell N/A supplemental calf (5%) N/A PSF  GWAJC  
Promocell N/A supplemental calf 
(7.5%) 
N/A PSF  GWAJC  
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A culture isolation technique using sterile vacuum grease and cloning cylinders 
was used to isolate and expand cuboidal, epithelial appearing cells or cell 
clusters.  (Figure 2.1.)  When a small cluster of adherent cells was found in early 
stages of primary culture, the area was marked, medium volume was reduced, 
sterile vacuum grease was applied to one end of the cloning cylinder, and under 
sterile conditions, the cylinder was applied with the cylinder lumen surrounding 
the cell cluster.  The isolated cells were lightly trypsinized, and they were passed 
to a new growth surface, thereby increasing their purity and relative 
concentration.  This technique was used to increase cell-to-cell contact and 
maintain a pure population of cells. 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Isolation of TEC
showing isolation technique
large culture plate using a c
 
The primary cell line and cu
developed and maintained is with Cloning Cylinders.  Schematic diagram 
 used to concentrate a small TEC cluster within a 
loning cylinder (aka cloning ring). 
ltures from the different rat strains that were 
n this project were refed every 3 days with the 
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medium that supported their continuous growth.  Cells were maintained in T25 
tissue culture flasks at 37° C in 5% CO2.  Doubling times were approximately 48 
hours long.  A completely confluent flask of TECs usually contained 1 x 106 
TECs, as shown by cytometric analysis.  During the in vitro experiments, the 
isolated cells from thymic suspensions were regularly investigated for the 
presence of cytoskeletal cytokeratin.   
 
2.2.4.a. Passaging of Thymic Epithelial Cells 
 
Adherent cells were passaged when they approached confluence, with replating 
at a density of approximately 2 x 105 cells per T25 flask.  For trypsinization, 
media was removed and cells were rinsed with room temperature calcium free 
PBS.  Trypsin was prepared by adding 20 mL of calcium free PBS to 5 mL 
aliquots of thawed 0.25% stock solution.  Cells were immersed in this 0.05% 
trypsin solution for 10 minutes at 37° C.  Cold calcium free PBS was used to 
inactivate the trypsin.  Cells were agitated off of the flask by jet pipetting, then 
collected and centrifuged in 50 mL centrifuge tubes at 1500 RPM for 5 minutes.  
The supernatant was removed from the pellet and the cells were suspended in 
25 cc flasks in fresh supplemented GWAJC medium.  LDA cells were trypsinized 
and reseeded at a 1:2 or 1:3 concentration, while WF, Lewis, and DA cells were 
reseeded at a 1:1 concentration.   
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2.2.4.b. Cryopreservation and Cryogenic Storage of Thymic Epithelial Cells 
 
Cells from the continuous cell line were stored at a density of 1 x 106 TECs in 
GWAJC medium supplemented with 10% cryoprotectant, DMSO.  Nearly 
confluent LDA TECs grown in antibiotic free media for 3 passages were 
trypsinized, triple washed in calcium free saline solution, and 1 x 106 cells were 
frozen in a vial containing 1 cc of GWAJC media containing 10% DMSO, and 
stored at –80° C.  For reconstitution, the vial was thawed at room temperature, 
cells and media were transferred to a T25 flask, and 6 mL of GWAJC medium 
added to the flask for incubation at 25° C, 5% CO2.  Cells were refed every 3 to 4 
days with fresh GWAJC medium. 
 
2.2.5. Morphological Analysis of Thymic Epithelial Cells by Light Microscopy  
 
2.2.5.a. Immunocytochemical Labeling of Thymic Epithelial Cells for Keratin 
 
The immunocytochemical labeling of keratin within epithelial-appearing cells 
derived from the rat thymus was used to determine whether the neonatal rat 
thymic tissue cultures included TECs.  Like other endodermally-derived epithelial 
cells, TECs should express cytoplasmic keratin IFs.  A modified avidin-biotin-
peroxidase immunocytochemical technique was used.  [210, 211]  Early attempts 
at staining had been performed using a mouse anti-human anti-keratin 
monoclonal antibody. (DAKO N Series Mouse anti-human cytokeratin, MNF 
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1166, class IgG, kappa, Carpenteria, CA); however, experimental results and 
negative controls (monoclonal mouse antibody, isotype IgG1, kappa, clone DAK-
GO1, toward Aspergillus niger glucose oxidase, code no X 0931, Lot 047, 100 
mg/L) were poorly differentiated when using an avidin biotin complex-
diaminobenzidine (ABC-DAB) staining technique with the DAKO LSAB 2 kit 
(Carpenteria, CA).  Therefore, the cytokeratin antigen was labeled with a rabbit 
anti-bovine polyclonal anti-cytokeratin antibody (keratin wide spectrum screening 
20622, DAKO, Carpenteria, CA).   
 
Immunocytochemical staining was successfully performed using a modified 
avidin-biotin-horse radish peroxidase technique with the polyclonal anti-
cytokeratin primary antibody described above to characterize adherent primary 
cultured thymic cells.   
 
Thymic epithelial cells were cultured in filter-top culture flasks (Fisher Scientific, 
St. Louis, MO) over a period of 5 to 6 weeks.  Attempts to lift the cells by 
trypsinization and subsequently passage them into chamber slides did not initially 
yield adequate numbers of adherent cells for staining.  Thus, following the 
establishment of a confluent monolayer of cells, staining was performed within 
the culture flasks.  Cells on the flask’s growth surface were not allowed to dry at 
any time.  All reagents were equilibrated to room temperature prior to usage, 
except as specified. 
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Monolayered cells adhering to the bottom of the plates were washed 3 times with 
calcium-free phosphate buffered saline (PBS) (Fisher Scientific, St. Louis, MO).  
Cells were fixed by the addition of absolute methanol (2 mL per flask) at –4°C for 
5 to 6 minutes, then washed with PBS, and treated with peroxide (0.1 mL of 3% 
H202 in 10 mL of methanol at room temperature for 5 minutes) to quench 
endogenous peroxidase activity, after which cells were again washed with PBS.  
Whole goat serum (diluted 1:50 with PBS, 2 mL per flask) was applied to fixed 
cells for 15 minutes at 37° C to block non-specific binding by the secondary 
antibody, followed immediately by application of primary antibody diluted 1:250 in 
PBS for one hour at 37°C.  PBS was used in place of the primary antibody to 
control for non-specific binding of the secondary antibody or the avidin-HRP 
complex.  After removal of the primary antibody solution, cells were washed in 
PBS for 10 minutes, followed by application of a goat anti-rabbit biotinylated 
secondary link antibody (2 mL per flask) for 1 hour at 37° C, after which cells 
were washed again with PBS for 10 minutes.  Avidin (streptavidin conjugated to 
horseradish peroxidase [HRP]) (2 mL per flask) was then applied to the cells for 
15 minutes at 37°C to allow binding to the biotinylated secondary antibody.  Cells 
were again washed and then immersed in PBS before the staining procedure. 
 
2.2.5.b. Immunocytochemical Labeling of Thymic Epithelial Cells for Vimentin 
 
The same modified avidin-biotin-peroxidase immunocytochemical technique was 
used for vimentin staining of TECs.  A monoclonal anti-mouse vimentin antibody 
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(DAKO V9 vimentin, MO 725) diluted 1:10 in PBS was applied using the same 
ABC-DAB technique as described above.  Equine serum was used to block non-
specific secondary antibody staining. 
 
2.2.5.c. Staining Procedure using Diaminobenzidine as Chromogen 
 
3,3-Diaminobenzidine (DAB, DAKO, code k3465, Carpenteria, CA) was used as 
the chromogenic substrate to react with HRP.  [210, 212, 213]  For TEC staining, 
DAB was diluted (80 microliters of DAB in 3.92 mL of buffer) approximately 30 
minutes prior to use.  Excess solution was removed from the cells and 2 mL of 
the DAB solution were placed in each flask to react with the avidin-conjugated 
HRP at room temperature.  Flasks were observed under the microscope for 
deposition of the DAB reaction product.  Development was continued until 
optimum staining was achieved, usually in approximately 5 minutes.  Gentle 
rinsing with distilled water helped to wash away unbound excess reaction product 
in each flask.  For cells stained in flasks, initial viewing was accomplished with an 
inverted light microscope.  For counterstaining and coverslipping of thymic 
epithelial cells stained in flasks, the growth surface of the flask that contained 
DAB-stained cells was removed, a hematoxylin counterstain was applied for 2 
minutes and then rinsed.  The flask surface was glued face up over a glass slide 
with melted gelatin (28-30°C) and a coverslip was applied over the cells with a 
few drops of fructose mounting media (Fisher Sci., prepared by heating a 3:1 
solution of fructose in distilled water, to 55°C and then chilled) containing thymol 
98
(J.T. Baker) as an antifungal preservative.  Subsequently, optimization of culture 
techniques and conditions allowed the successful adherence and growth of TECs 
on chamber slides, which greatly simplified the immunocytochemical processing 
of culture TECs, and allowed coverslipping with Permount mounting medium.  
 
2.2.6. Morphological Analysis of Thymic Epithelial Cells by Phase Contrast 
Microscopy 
 
The growth surface of flasks containing living media fed cell cultures was 
visualized using an inverted microscope using Hoffman phase contrast 
illumination.  Cells were photographed using a digital camera.   
 
2.2.7. Morphological Analysis of Thymic Epithelial Cells by Transmission Electron 
Microscopy  
 
Transmission electron microscopy of TECs allows detection of cytoplasmic 
keratin IFs and a desmosomal type of intercellular junction between cells.  
Cultured TECs were evaluated as either cell monolayers grown on coverslips, or 
as a pelleted cell mass.   
 
For cells grown on coverslips, approximately 1x106 cells suspended in 0.5mL low 
calcium medium (WAJC with standard supplements) were plated onto Thermanox 
coverslips in 30mm tissue culture plates and incubated for 2hr (37°C, 5% CO2).  
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This allowed for a concentrated number of TECs to seed to the coverslip surface.  
After the 2hr incubation, an additional 1.5mL of WAJC medium was added to each 
plate, and cells were incubated an additional 24hr, after which time cells were fixed 
and embedded for transmission electron microscopy.  Coverslips were released, 
fragmented, glued to Polybed812 bullets, sectioned at 70nm, and stained with 
uranyl acetate and lead citrate.   
 
Alternately, Bouin’s fixative was extracted from previously fixed cells using 2 
washes of 70% ETOH, followed by rehydration in graded solutions of 50% 
ETOH, 25% ETOH, and buffer.  These fixed cells were then pelleted into a 
microfuge tube by centrifugation, and infiltrated with 10% neutral buffer 
formaldehyde (NBF), rinsed with buffer, submerged in gelatin at 37° C for 1-2 
hours, and cooled in ice.  The hardened gelatin was overlaid with toluene 
saturated with Polybed embedding medium.  After baking, the cell button was cut 
out of the microfuge tube for sectioning.   
 
 
2.3. RESULTS  
 
Thymic cells, derived from neonatal WF, Lew, DA, and/or LDA rats were isolated 
and primary cultures were established under reduced calcium conditions.  Cells 
derived from Lew, WF, and DA strains were maintained up to the 5th passage, 
while cells derived from LDA rats were maintained through over 65 passages.  
100
Cultures were refed at varying intervals and subcultured at varying levels of 
confluence, as empirically determined to be appropriate by experimentation.   
 
2.3.1. Establishing Primary Cultures of WF Thymic Epithelial Cells  
 
Initial attempts toward TEC isolation and culture in the WF strain employed the 
use of thymic fragmentation, in vitro enzymatic dissociation, and plating in either 
Nutrient Mixture (Ham’s) F12 medium or Dulbecco’s Modified Eagle Medium.  
(Figure 2.2.)  These high calcium medium formulations resulted in the growth of a 
variety of cell types with limited proliferative capacity.  Some cells appeared 
cuboidal, while others appeared more fusiform (fibroblast-like), with the majority 
of cells appearing as anuclear, membrane bound ghostlike structures adherent to 
the flask growth surfaces. (Figure 2.3.)  After cells grew to a higher confluence, 
trypsinization and replating resulted in a morphologic change of cells from 
epithelioid to a more fibroblast-like appearance.  Plating into glass chamber 
slides resulted in minimal to no adhesion.  Likewise, replating into plastic 
chamber slides resulted in insufficient cell adhesion to allow processing of the 
cells for microscopy.  It was concluded that greater numbers of adherent cells 
were required in the initial phases of culture establishment, and that once 
cultures had been established, expansion of small cell clones was not a feasible 
approach.   
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spite of improvements in the initial yields of WF TECs from primary cultures, 
 proliferative capacity of these cells remained limited.  However, following a 
itch in culture medium within a week of plating from the DMEM with 10% SCS 
d supplements, used for the initial plating process, to WAJC medium, a low 
cium formulation from the W. Alton Jones Cell Research Center, the cells 
monstrated a continued proliferation, producing sufficient numbers of cells for 
ssaging without dilution.  This represented a considerable improvement in the 
ablishment of primary cultures of WF TECs compared to initial results. 
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2.3.1.a. Maintaining Primary Cultures of WF Thymic Epithelial Cells 
 
Established cells were maintained in WAJC media.  Cells were refed by 
aspiration of spent medium and replacement with fresh medium.  Due to the 
relatively limited proliferative capacity of TECs of the WF strain, completely 
confluent TECs were lightly trypsinized and reseeded without dilution.  Cell 
numbers diminished over the span of approximately 5 passages, with eventual 
loss of cellular colonies due to lack of proliferation and terminal differentiation.  
Because thinning of cell numbers resulted in loss of cellular colonies, populations 
of cells grown in several flasks were consolidated, centrifuged, and subcultured 
into a single new flask.  This failure of the cells to thrive in conditions of low cell 
density seemed to indicate that a certain amount of intercellular contact was 
necessary to induce proliferation, and proliferative rates of this cell population 
were never sufficient enough to allow the spontaneous transformation of the WF 
TECs into a cell line.   
 
2.3.2. Establishing Primary Cultures of LDA Thymic Epithelial Cells  
 
LDA TECs were isolated by the in vitro enzymatic tissue digestion technique with 
tissue plating in specialized low calcium medium (WAJC) supplemented with 2% 
Supplemental Calf Serum (SCS, Hyclone, Logan, UT), cholera toxin, 
dexamethasone, insulin, transferrin, and EGF.  WAJC medium has previously 
been used for the isolation and maintenance of the TEA3A1 primary cell line 
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derived from LDA rats.  [132] Both the TEA3A1 cell line and WAJC medium were 
donated as generous gifts by Dr. Jun Hayashi at the University of Maryland to aid 
in the derivation and characterization of new primary TEC lines.  This medium 
formulation was later custom ordered through GibcoBRL.  Gibco WAJC 
(GWAJC) supplemented with 2% SCS, 2.5% DMEM, cholera toxin 20 ng/mL, 
dexamethasone 10 nM, insulin 10 µg/mL, transferrin 10 mg/mL, and EGF 10 
ng/mL was used to establish a primary LDA TEC line for this project.  (Figure 
2.4.) 
 
The initial protocol for establishing LDA TEC primary cultures involved surgical 
excision and enzymatic digestion of the thymus, and culture in WAJC media (low 
calcium, 0.098mM), supplemented as described above.  Later, primary cultures 
of LDA TECs were maintained in GWAJC (GibcoBRL, Gaithersburg, MD) 
supplemented with 2% SCS.  Each T25 flask was able to accommodate thymic 
fragments for 3 neonatal rats.  Contact inhibition was noted with tissue densities 
which exceeded this level.  
 
The above techniques resulted in establishment and proliferation of partially 
differentiated epithelial cells with concomitant depletion of lymphocytes and other 
non-epithelial cells.  Cells were refed after the formation of a sufficient cell 
monolayer and maintained proliferative capacity indefinitely.  Upon microscopic 
examination, cells cultured in low calcium medium displayed round to spindle 
shaped morphology and failed to establish physical contact between cells even 
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at confluence.  In passaging cells, single cell suspensions were easily obtained 
by light trypsinization, further indicating a paucity of intercellular contact.  Isolated 
LDA TECs maintained under reduced calcium conditions (using WAJC media 
supplemented with growth factors) retained a high in vitro mitotic frequency and 
spontaneously transformed into a cell line, designated OKTE4-01.   
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Eigure 2.4. Monolayer of Proliferative TECs from the LDA Hybrid Strain.  
hymus-derived cells displayed the above morphology in primary culture at high 
onfluence.  These cells remained proliferative when maintained in GWAJC 
edium supplemented with 2% SCS and growth factors.  135 X. 
.3.2.a. Maintaining Primary Cultures of LDA Thymic Epithelial Cells 
nce LDA TEC primary culture was established, cells were maintained in T25 
lasks containing 7 cc’s of medium until subculture became necessary.  
assaging of the cells was imperative before they became overly confluent.  
ven though these cells normally appeared to have increased intercellular 
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spacing, a morphological change resulted from excessive confluence, and the 
cells began to exhibit cobblestoning and occasionally some cellular inclusions, 
typical of TECs from other strains which had lost proliferative capacity.  The 
cause of this was unknown, although it was speculated that release of calcium 
from intracellular stores in cultures of overpopulated cells might have been the 
causative factor.  Thus, cells were gently trypsinized at approximately 80% 
confluence (i.e. approximately 80% of the growth surface was occupied by cells). 
 
Cells were cryopreserved for storage and future use at multiple passages.  
Frozen cells were easily reconstituted, and appeared to be relatively unaffected 
by the cryogenic procedure.  No changes in morphology or proliferative capacity 
were observed following cryopreservation. 
 
2.3.2.b. Effects of Cholera Toxin Concentration  
 
Cholera toxin levels were increased to determine their effects on TEC 
morphology.  The original concentration of cholera toxin in the WAJC solution 
was 20 ng/mL.  No significant changes in TEC morphology were seen at cholera 
toxin concentrations of 40, 80, and 200 ng/mL.  However, primary culture of 
TECs was dependent on maintaining minimal cholera toxin concentrations of at 
least 20 ng/mL in the growth medium.  Exclusion of this supplement from the 
medium used for initial plating resulted in the inability to establish TEC primary 
culture.  Once TECs were established in primary culture, the cholera toxin could 
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be excluded from the medium without any apparent deleterious effects on TEC 
morphology or proliferative capacity.   
 
2.3.3. Establishing Primary Cultures of Lewis Thymic Epithelial Cells  
 
Using a calcium free thymic tissue fragmentation and collagenase digestion 
method, numerous media types were tested for their capacity to allow 
establishment of Lewis TEC colonization and proliferation.  Each media type was 
supplemented with cholera toxin, EGF, insulin, dexamethasone, and transferrin.  
GWAJC and Promocell media, despite supplementation with 2%, 5%, 7.5%, and 
10% serum, were the least permissive medium for initial Lewis TEC survival.  
The use of equine serum resulted in fibroblast overgrowth and limited TEC 
proliferation.  Cells initially collagenase-digested and then chelated with EDTA 
appeared to retain a greater proliferative capacity and could be maintained for 
longer periods than cells initially treated with collagenase but never exposed to 
EDTA treatment.   
 
The EDTA chelation of the medium is believed to have reduced available 
calcium, thereby preventing cell/tissue exposure to calcium levels high enough to 
induce irreversible terminal differentiation.  Serum free WAJC resulted in minimal 
to no growth while supplementation with 7.5% SCS allowed the formation of 
minimal cell colonies.  Serum free DMEM with hormonal supplements initially 
allowed small numbers of scattered cells and cellular remnants to attach, but 
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within a week, there was differentiation of some cells and almost complete loss of 
attached cellular material.  Interestingly, use of calcium-free medias did not 
improve initial culture success as much as EDTA chelation of calcium from 
higher calcium medias. 
 
Primary culture of Lewis TECs was possible following comparative studies using 
DMEM with 2% to 10% SCS and Ham’s F12 with 2% to 10% SCS.  DMEM with 
2% SCS and supplements allowed the formation of small nests of TECs that 
expanded over the first week of culture.  DMEM with 7.5% SCS and supplements 
had similar results.  DMEM with 10% SCS and supplements allowed the initial 
formation of even larger nests of TECs, but these cells became less well 
organized over time and were eventually overgrown by fibroblasts.  Similarly, use 
of Ham’s F12 and WAJC supplements with 2% SCS resulted in some scattered 
nests of cells, and with 10% SCS exhibited larger nests containing mitotic figures 
despite increased fibroblast contamination compared to other media types.  Both 
DMEM and Ham’s F12 with 10% SCS and supplements allowed the formation of 
larger, better organized TEC colonies.  This might have been due to the higher 
serum concentrations in the media, although this would not explain why GWAJC 
with 10% serum did not support Lewis TEC colonization.  Unfortunately, over 
time, even the most robust TEC colonies dwindled in number due to loss of 
proliferative capacity and terminal differentiation.  As time passed, some cells 
appeared to display effects of toxicity, as reflected by accumulation of lipid 
droplets.  Cells cultured in Ham’s F12 transformed into dendritic appearing cells.  
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Eventually, mitotic cells disappeared and all of the cells appeared to be 
senescent.   
 
DMEM was mixed 50/50 with GWAJC to take advantage of the positive effects of 
both types of media; however no beneficial effect as evidenced by TEC growth 
was observed with serum supplementation of 5%, 7.5%, or 10% SCS.  The 
application of extracellular matrix (ECM) or poly-L-lysine (PLL) to the cellular 
surface prior to thymic tissue seeding did not improve cellular attachment over 
control flasks without ECM or PLL.   
 
Finally, it was hypothesized that an initial establishment of TEC colonies using 
DMEM with high serum followed by a switch to GWAJC media containing only 
2% SCS at a critical stage in the establishment of primary TEC culture would 
prevent or minimize loss of proliferative capacity.  Lewis TEC primary cultures 
were established by initially plating the tissue in DMEM with 10% SCS.  After a 
period of approximately 7 days when colonies of cuboidal cells appeared, the 
medium was switched to GWAJC, the low calcium medium used to establish 
LDA TECs.  This switch allowed the establishment of TEC colonies in high 
calcium and the subsequent proliferation of TECs in low calcium medium.  Once 
Lewis TEC culture was established, TECs were maintained by refeeding with 
GWAJC every 3 to 4 days.  (Figure 2.5.)  However, Lewis TECs did not 
spontaneously transform into a cell line. 
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2.3.3.a. Maintaining Primary Cultures of Lewis Thymic Epithelial Cells 
 
After colonies of TECs were established with DMEM containing 10% SCS and 
supplements, switching the media to CGWAJC prolonged cell survival of these 
primary TECs to the 7th passage.  The ability to establish colonies in one type of 
medium and maintain them in another type of medium suggested that this 
medium switching technique could be applied to the establishment of TEC 
culture from other rat strains.  It also suggested that application of this strategy 
might make feasible the establishment of primary cultures of other keratinocyte 
types not previously shown to be amenable to primary culture.   
 
 
 
 
 
 
 
Figure 2.5. Lewis TECs in Primary Culture.  Cells derived from Lewis thymic are 
polygonal in shape and are moderately flattened.  135 X. 
 
2.3.4. Establishing Primary Cultures of DA Thymic Epithelial Cells  
 
Primary culture of TECs from the DA strain initially demonstrated similar 
responses, as did primary cultures of Lewis and WF TECs.  Like TECs derived 
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from WF and Lewis strains, TECs derived from the DA strain did not demonstrate 
growth and proliferation in response to initial culture in either high calcium or low 
calcium medium.  After the first passaging, cells terminally differentiated into 
fibroblast-like cells.  Some cells had a dendritic appearance.  Employing the 
medium switch strategy in which initial plating was accomplished using high 
calcium medium (DMEM with 10% SCS and supplements) and then after 
establishment of TEC colonies, switched to low calcium medium (GWAJC) within 
the first week of tissue culture, the cells maintained an epithelial cell morphology, 
retained some proliferative capacity, and could be passaged without dilution.  
This represented a significant improvement in DA TEC primary culture over initial 
attempts, allowing the establishment of monolayers of adherent DA TECs, 
although the cultures did not spontaneously transform into a primary TEC line.   
 
Figure 2.6. DA TECs at Moderate Density.  A pyknotic cellular outline (arrow), 
with blebbing at the upper right hand corner, and scattered cuboidal cells at a 
late passage of TEC culture derived from the DA strain.  135 X. 
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2.3.4.a. Maintaining Primary Cultures of DA Thymic Epithelial Cells 
 
As with TECs from other rat strains, once TEC culture from the DA strain was 
established, cells were refed every 3 days with low calcium GWAJC medium with 
supplements and 2% SCS. 
 
2.3.5. Immunocytochemistry and Verification of TECs 
 
The purpose of immunocytochemical evaluation of established TEC colonies was 
to demonstrate definitive epithelial cell characteristics in the isolated cells 
obtained from neonatal rat thymic tissue harvests, thereby validating that these 
cells were indeed TECs.  The definitive identification of cultured thymic cells as 
epithelial was of interest in related studies that would take advantage of both the 
thymic origin and the epithelial nature of these cells.  Keratin IFs are known to 
exist within epithelial or epithelial-derived cells of ectodermal origin in the form of 
intracytoplasmic bundles and are also known to insert into desmosomes.  Other 
thymus-derived cells would express IFs of a different type, uncharacteristic of 
endodermally derived epithelial cells, and would not be characterized by 
desmosomes.  Therefore, the expression of cytokeratin within these cells, as 
visualized by light microscopic immunostaining, was used as the defining 
characteristic to identify these thymus-derived cells as epithelial.  Because TECs 
contain the antigen cytokeratin, this demonstration was accomplished by staining 
with anti-cytokeratin antibodies.  Positive specific staining would definitely 
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establish the thymus-derived cells to be epithelial in nature, and thus TECs.  
(Figure 2.7.) 
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ith DAB-labeled TECs throughout with prominent cytoplasmic uptake in a 
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AB staining.  425 X. 
ot shown, immunocytochemistry on TECs with an anti-vimentin primary 
ntibody was also negative.  
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2.3.6. Electron Microscopy and Verification of TECs 
 
Electron microscopy of cultured thymic cells was also used to discriminate 
thymus-derived epithelial cells from other thymic cell types, including non-
ectodermally derived epithelial (e.g. endothelial) cells.  Since these cells were 
isolated from the thymus gland, demonstration of characteristics unique to 
epithelial cells would define the cells as TECs.  In previous studies examining 
thymic epithelium [149, 214, 215], both in situ and in vitro, characteristics of 
TECs have been described.  Common to many epithelial-derived cells, these 
cells demonstrate keratin IFs and desmosomes (as described above) and display 
undulating cell membranes that possess microvilli.  Further, TECs have been 
noted to possess significant numbers of intracytoplasmic lipid droplets, 
lysosomes, and residual bodies.   
 
The presence of individual keratin intermediate filaments and filament bundles 
indicates the epithelial derivation of these cells. [157] Endothelial cells, 
fibroblasts, and other connective tissue cells do not demonstrate these 
characteristic filament bundles.  [31, 35, 156, 158]  Rather, they express vimentin 
as individual IFs, the appearance of which tend to be more curved or spiral in EM 
examination than keratin IFs.  The EM demonstration of desmosomes also 
indicates the epithelial derivation of these cells.  These desmosomes, or macular 
adherens junctions, are associated with keratin IFs which insert into components 
of the junction.   
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All of these characteristics, distinctive for epithelial cells, and specifically for 
TECs, have been observed within both the TEA-3A1 and OKTE4-01 cell lines, 
confirming these thymus-derived cells as TECs.  Standard TEM was performed 
using methanol fixed, osmium/lead stained cell clusters to localize ultrastructural 
characteristics definitive of epithelial cells.  (Figures 2.8. and 2.9.)  The definitive 
identification of cultured cells as TECs was important in establishing the ability to 
isolate and maintain a thymic specific cell.   
 
 
 
 
 
 
 
 
 
 
Figure 2.8. Electron Microscopy of TEC Intermediate Filaments.  Cells cultured 
in high calcium WAJC media contained individual and bundled cytoplasmic 
keratin IFs coursing through the cytoplasm (arrow).  42,500 X. 
 
 
 
Cells grown in high calcium medium were adjoined by desmosomes, further 
confirming their TEC nature.  (Figure 2.9.)   
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Figure 2.9. Electron Microscopy of TEC Desmosomes.  A typical desmosome 
with keratin IFs (arrow) attaching into dense plaques.  80,000 X. 
 
Maintenance of TECs in low calcium medium was not associated with the typical 
arrangement of keratin IFs and formation desmosome structures.  Cytosolic 
keratin IF bundles were considerably less numerous although individual IFs 
remained visible and were scattered throughout the cytoplasm.   
 
An incidental finding noted in the evaluation of electron micrographs of TECs 
grown in low calcium media was the presence of IFs arranged in whorls, 
complete and incomplete concentric rings, and other curvilinear bundles.  
Some of these structures demonstrated a dense laminar structure, while 
others appeared to possess more diffuse laminae.  These unique IF 
arrangements were observed in regions containing linear keratin filaments, 
present as either individual filaments or as filament bundles.  (Figure 2.10.) 
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Figure 2.10. TECs Maintained in Low Calcium Medium.  Concentric whorls 
and curvilinear structures (arrows) are visible throughout the cytoplasm of 
TECs maintained in medium containing low calcium levels.  37,500 X. 
 
 
2.4. DISCUSSION 
 
As noted by authors of previous reports, TECs are difficult to obtain and maintain 
in culture.  While LDA TECs spontaneously transformed into a cell line when 
plated and maintained in low calcium medium, WF, Lewis, and DA TECs 
required plating in high calcium medium (DMEM with 10% SCS) and switching to 
low calcium medium (WAJC) for maintenance.  Though not previously reported, it 
appears that rat TEC primary culture is dependent upon the specific strain from 
which the thymic tissue is derived.  These calcium-dependent characteristics of 
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rat TECs are further evaluated by morphological and functional studies in 
Chapter 3. 
 
Because the ability to obtain sufficient TECs was limited to the LDA rat strain and 
its MHC expression, further studies using an allogeneic model of rat 
transplantation tolerance induction were directed towards respectively MHC 
mismatched donors and recipients (Chapter 4).  Additionally, preliminary studies 
on in vitro manipulation and genetic transfection of TECs (discussed briefly in 
Chapter 5) were also limited to LDA TECs. 
 
It is hypothesized that it may be of value to employ a medium change like the 
one used to expand upon the proliferative capacity of WF, Lewis, and DA TECs 
during the crucial period of cellular attachment in primary cultures of other cell 
types that could not previously be established using other techniques.   
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CHAPTER 3.  
EVALUATION OF INDUCED MORPHOLOGICAL CHANGES IN THYMIC 
EPITHELIAL CELLS 
 
 
3.1. INTRODUCTION 
 
The common denominator which led to the successful culture of TECs was 
knowledge of the TEC response to medium calcium levels.  To establish and 
maintain cell populations proportionate to the demands of this project, the 
calcium-related morphological and proliferative responses of TECs became a 
primary focus.  These responses of TECs to varying medium calcium 
concentrations were evaluated in great detail following the establishment of their 
primary culture.   
 
Attempts at primary culture of TECs derived from WF, LDA, Lewis, and DA rat 
strains revealed that there were strain dependent differences in responses to cell 
culture conditions, and only the LDA derived TECs spontaneously transformed 
into a cell line.  It is known that there is a causal relationship between medium 
calcium levels and desmosome formation.  Desmosomes, or macular adherens, 
are structures composed of protein plaques with attaching keratin IFs, and they 
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function in maintaining structural enforcement between keratin-expressing cells.  
“The IF bundle system in epidermal cells appears to be involved in shape 
formation, shape maintenance, the establishment of desmosomes, nuclear 
centration, and cell-cell contact.”  [216] A relationship between desmosome 
formation and calcium exposure has been demonstrated in many cell types [217-
219], but this relationship has not been defined in TECs.  It was hypothesized 
that TEC proliferative capacity was dependent upon desmosome formation.  The 
morphological studies that ensued were aimed at interrelating the effects of 
medium calcium levels, TEC proliferative capacity, and desmosome formation.    
 
 
3.2. MATERIALS AND METHODS 
 
3.2.1. Phase Contrast Microscopy of TECs 
 
The growth surface of a flask containing living media fed cell cultures was 
visualized using an inverted Hoffman phase contrast microscope.  Cells were 
photographed using a digital camera.   
 
3.2.2. Light Microscopy and Immunocytochemistry  
 
The immunostaining protocol using a modified ABC-DAB technique was 
previously described in Chapter 5, and was used on TECs maintained in varying 
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culture conditions.  Cells were maintained and treated in chamber slides.  
Primary cultured LDA TECs maintained in WAJC medium with 2% DMEM were 
compared to LDA TECs which had originally been maintained in WAJC medium 
with 2% DMEM and then switched to a higher calcium medium (WAJC with 7.5% 
DMEM).  During the immunocytochemical labeling process, cells were not 
allowed to dry at any time.  All reagents were equilibrated to room temperature 
prior to usage, except as specified.  Immunocytochemical staining was 
performed using an avidin-biotin-horse radish peroxidase technique with 
polyclonal rabbit anti-bovine anti-cytokeratin primary antibody (keratin wide 
spectrum screening 20622, DAKO, Carpenteria, CA) and DAB as chromogen to 
characterize adherent primary cultured thymic cells.  Cells in chamber slides 
were fixed in absolute methanol at –4°C for 5 to 6 minutes and treated with 
peroxide (0.1 mL of 3% H202 in 10 mL of methanol at room temperature for 5 
minutes) to quench endogenous peroxidase activity, after which cells were again 
washed with PBS.  Fixed cells were treated with blocking serum diluted 1:50 with 
PBS for 15 minutes, incubated with rabbit anti-bovine cytokeratin polyclonal 
primary antibody diluted 1:250 in PBS for one hour at 37°C, washed again, 
incubated with goat anti-rabbit biotinylated secondary antibody diluted 1:250 in 
PBS, washed again, and incubated with avidin HRP solution for 15 minutes at 
37°C.  DAB was used as the chromogenic substrate, and hematoxylin 
counterstaining was also applied. 
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3.2.2.a. Staining Procedure using Diaminobenzidine as Chromogen 
 
The same DAB staining technique described in Chapter 5 was used to stain 
TECs exposed to varied medium calcium concentrations.  Briefly, DAB was 
diluted (80 microliters of DAB in 3.92 mL of buffer) approximately 30 minutes 
prior to use.  Excess solution was removed from the cells and 2 mL of the DAB 
solution were placed in each flask.  Flasks were observed under the microscope 
for deposition of the DAB reaction product.  Gentle rinsing with distilled water 
was used to wash away excess reaction product.  Cells were counterstained for 
2 minutes with hematoxylin and then rinsed, and a coverslip was applied with 
Permount mounting medium. 
 
3.2.3. Transmission Electron Microscopy  
 
As described in Chapter 5, TEM of TECs allowed detection of a desmosomal 
type of junction between cells and cytoplasmic IFs.  Quantitative analysis of 
these calcium-dependent morphologic structures in TECs could therefore be 
compared in TECs exposed to varying calcium concentrations with a TEM study 
on cells grown on coverslips. 
 
Approximately 1x106 cells suspended in 0.5mL low calcium medium (GWAJC with 
standard supplements) were plated onto Thermanox coverslips in 30mm tissue 
culture plates and incubated for 2hr (37°C, 5% CO2).  This allowed for a 
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concentrated number of TECs to seed to the Thermanox coverslip.  After the 2hr 
incubation, an additional 1.5mL of GWAJC medium was added to each plate.  
Cells were allowed to adhere for 18hr, at which time medium calcium levels were 
adjusted, as appropriate, to 0.0925 mM for the low calcium condition by 
maintaining cells in GWAJC with 2% SCS and 2.5% DMEM, and to 0.188mM for 
the high calcium condition by maintaining cells in GWJAC with 2% SCS and 7.5% 
DMEM.  Cells were incubated an additional 24hr, after which time cells were fixed 
and coverslips were embedded for transmission electron microscopy.  Embedded 
coverslips were released, fragmented, glued to Polybed812 bullets, sectioned at 
70nm, and stained with uranyl acetate and lead citrate.   
 
3.2.3.a. Quantification of Adherent Junctions and Apposed Membranes 
 
To characterize and compare TEC morphological changes, cells were 
systematically scanned from low magnification (135 X) to high magnification 
(between 3,600 and 7,200 X).  Fields of cells were visualized with TEM and 
photographed.  The numbers of cells per field were counted, apposed membranes 
between cells traced and measured, desmosomes between cells counted, and 
length of desmosomes measured in electron micrographs which were analyzed 
(measured to scale) using MetaMorph cell analysis computer software (Universal 
Imaging Corporation, Nikon Instruments, Lewisville, TX).  Data variables examined 
included number of cells per field, number of juxtaposed cell membranes, 
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juxtaposed cell membrane length, number of desmosomes, and length of 
desmosomes.  Data was analyzed using chi squared analysis and student’s T test.   
 
 
3.3. RESULTS 
 
TECs maintained in low calcium medium displayed different morphological 
characteristics from TECs maintained in high calcium medium, and these 
morphological characteristics could be induced by elevating medium calcium 
levels.   
 
A minimum medium calcium concentration was required for the establishment 
and maintenance of TEC cultures.  When culture conditions were modified from 
low to high calcium concentrations, thymic cell morphology was dramatically 
altered.  In high calcium (0.188mM) medium, cultured cells were more densely 
populated, forming confluent monolayers lacking intercellular spacing, and were 
resistant to trypsinization (using 0.05% trypsin/EDTA).  This morphological 
change from a partially differentiated spindle-like monolayer to a fully 
differentiated cobblestone-like monolayer was freely inducible in all thymic cell 
cultures maintained in WAJC media by increasing the media calcium content.  
Culture conditions were altered from low calcium media to high calcium media by 
incrementally increasing DMEM supplementation to assess morphological 
changes.  (Figures 3.5. and 3.6.)  Trypsinization at concentrations sufficient to lift 
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cells (0.05%) resulted in detachment of cells in sheets, and induced cellular 
damage (blebbing and cell lysis).  Further, thymic cells maintained in high 
calcium media became quiescent and no longer exhibited logarithmic growth.  
Immortalized TECs established in low calcium media, once exposed to higher 
calcium levels, converted to a morphology similar to primary TECs grown in high 
calcium media.  This differentiated state appeared to be permanent and 
irreversible, as returning cells to the low calcium culture condition after an 18 
hour period in the high calcium condition failed to restore the cellular morphology 
and spacing observed in cells never exposed to high calcium culture conditions.   
 
3.3.1. Light Microscopy: Morphological Analysis of Calcium-Induced Thymic 
Epithelial Cell Changes  
 
As mentioned above, culture conditions were altered from low calcium media to 
high calcium media by incrementally increasing DMEM supplementation.  
Histological characteristics of TECs cultured at both low calcium and high 
calcium concentrations were evaluated by immunocytochemistry for keratin 
distribution and light and electron microscopy to determine the effects of media 
calcium levels on cellular structure and ultrastructure.  These morphological 
analyses were also used to confirm that immortalized TECs retain the ability to 
fully differentiate following exposure to high calcium media.   
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3.3.1.a. Phase Contrast Morphological Analysis of Thymic Epithelial Cell 
Changes To Compare Effects of Differing Culture Conditions on TEC 
Morphology 
 
High calcium GWAJC medium (7.5% DMEM supplemented) has a calcium 
concentration of 0.188 mM.  To further investigate the effects of medium calcium 
levels on TEC morphology, medium calcium levels were incrementally increased 
from 0.098 mM to 0.280 mM in increments of 0.012 mM by adding DMEM.  After 
24 hours, cells were visualized using Hoffman phase contrast microscopy.  As 
opposed to technology behind a normal phase contrast microscope, which allows 
visualization of cells using the interference between a central light path and a 
halo of light around a cell caused by an annular ring, Hoffman phase contrast 
microscopy employs technology that modulates the phase contrast light path with 
a slit lamp effect to produce a three-dimensional image of cells.  The percentage 
of cells transformed from an appearance consistent with cellular proliferation 
(greater intercellular spacing, more three dimensional texture) to an appearance 
consistent with cellular differentiation and decreased proliferation (reduced 
intercellular spacing, more two dimensional texture) was recorded. 
A three dimensional appearance was seen in TECs maintained in low calcium 
while a two dimensional appearance was seen in TECs maintained in high 
calcium, reflecting the flat morphology of cells grown in high calcium medium.  
(Figure 3.1. and 3.2.) 
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aigure 3.1. Hoffman Phase Microscopy of TECs Maintained in Low Calcium 
edium.  Cells have more intercellular spacing and a three dimensional 
ppearance than those maintained in high calcium medium.  135 X. igure 3.2.  Hoffman Phase Microscopy of TECs Maintained in High Calcium 
edium.  Cells have decreased intercellular spacing and a 2 dimensional 
ppearance, indicating their squamous, adherent nature.  135 X. 
ncrementally increasing the medium calcium concentration resulted in an 
lteration of TECs from the proliferative morphology to the non-proliferative 
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morphology.  These results correlate with the earlier immunocytochemical results 
demonstrating that the GWAJC medium containing a high calcium level (0.188 
mM) induces a morphological change in TECs.  (Table 3.1.) 
 
Table 3.1. Effects of Medium Calcium Concentration on TEC Morphology.  Areas 
of altered cells appeared when medium calcium concentrations were between 
0.184 and 0.196 mM.   
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.220 15 
.232 30 
.244 30 
.256 85 
.268 100 
.280 100 
 
0.096 0.144 0.192 0.240 0.288
0
10
20
30
40
50
60
70
80
90
100
Medium Ca++ Conc. (mM)
 o
a
or
ti
(%
 o
f g
ro
w
th
 s
ur
fa
ce
)
 
3.3.1.b. Immunocytochemistry To Compare Effects of Differing Culture 
Conditions on TEC Morphology 
 
Two populations of cells were employed in this investigation.  TEA-3A1 cells 
(LDA TECs) were previously derived, and have been established as an immortal 
line of TECs [132] by Dr. Hayashi at the University of Maryland.  Primary cultures 
of TECs (designated OKTE4-01) were derived in our laboratory using the 
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techniques described above.  Both TEA-3A1 and OKTE4-01 cells were 
maintained in low calcium medium, as described above.  For this study, culture 
conditions for some cells were altered from low calcium medium to high calcium 
medium by increasing the concentration of supplemented Dulbecco’s Modified 
Eagle’s Medium (DMEM) from 2.5% to 7.5%.  (TECs did not thrive in DMEM 
concentrations below 2.5%.)  Because DMEM was originally added to Ca++ free 
WAJC medium (GibcoBRL, Gaithersburg, MD) to introduce a minimal calcium 
level necessary for cell viability (creating low calcium WAJC404A), we used 
DMEM accordingly to further increase calcium levels to make high calcium 
WAJC404A.  DMEM was chosen over serum or other supplements for increasing 
medium calcium levels because of the number of unknown components and 
sometimes intangible effects of serum on the cultured cells.  These four cell 
populations (TEA-3A1, low Ca++; TEA-3A1, high Ca++; OKTE4-01, low Ca++; 
OKTE4-01, high Ca++) were evaluated by light and electron microscopy to 
determine the effects of medium calcium concentration on histological and 
ultrastructural characteristics.  Quantitative analysis of macula adherens density 
was performed on the OKTE4-01 cells.  
 
Immunocytochemistry was used to visualize the keratin IF distribution pattern of 
TECs exposed to low calcium WAJC medium (with 2.5% DMEM) (Figures 3.3. 
and 3.4.) and TECs exposed to high calcium WAJC medium (with 7.5% DMEM) 
(Figures 3.5. and 3.6.).  Evaluation of stained cells demonstrated differences in 
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distribution of keratin IFs between the cells cultured in low vs. high calcium 
media.   
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sigure 3.3. Low Magnification View of TECs in Low Calcium WAJC Medium.  
mmunocytochemical keratin staining demonstrated a diffuse distribution of 
eratin IFs with increased intercellular spacing and spindle-like morphology even 
t confluence.  135 X. 
igure 3.4. Higher Magnification View of TECs in Low Calcium WAJC Medium.  
mmunocytochemical keratin staining demonstrated keratin IFs arranged in a 
eticular pattern through the cytoplasm without visible condensation of filaments 
n any particular area.  Spherical cells were common and in these a darker  
taining pattern was apparent.  640 X. 
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 igure 3.5. Low Magnification View of TECs in High Calcium WAJC Medium.  
mmunocytochemical keratin staining demonstrated decreased intercellular 
pacing with a cobblestoned appearance at confluence.  135 X. 
igure 3.6. Higher Magnification View of TECs in High Calcium WAJC Medium.  
mmunocytochemical keratin staining demonstrated increased specific staining 
ith linear profiles of keratin IFs evident near cell borders. (arrow)  640 X. 
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3.3.2. Transmission Electron Microscopy To Compare Effects of Differing Culture 
Conditions on TEC Morphology  
 
Transmission electron microscopy was used to further characterize and compare 
the nature of TECs cultured in low calcium WAJC media, and TECs cultured in 
low calcium WAJC media and subsequently transferred to high calcium WAJC 
media (supplemented with 7.5% DMEM).  Any steps in the EM processing 
protocol that might expose TECs maintained in low calcium to elevated calcium 
levels were performed following fixation to avoid inadvertent induction of 
morphological changes.  The two cell populations, TECs exposed to high calcium 
and TECs exposed to low calcium, were analyzed by counting cell number, 
number and length of areas of apposed membranes (examples given in Figure 
3.7.), number of desmosomes between cells, and length of each desmosome. 
 
 
 
 
 
 
 
 
 
 
F
a
f1
2
3
igure 3.7. Transmission Electron Microscopy of TECs.  Three cells (1-3) and 
pposed membranes (highlighted by drawn in lines) were counted in a typical 
ield of TECs exposed to low calcium. 
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In total, examination of 87 distinct TEM fields identified 222 cells from high 
calcium cultures (total apposed membrane length of 1489.3µm in 153 discrete 
areas), and assessment of 48 distinct TEM fields identified 124 cells from low 
calcium cultures (total apposed membrane length of 627.3µm in 48 discrete 
areas).   
 
3.3.2.a. Length of Apposed Membranes 
 
Statistics were calculated for 87 fields of high calcium cells and 48 fields of low 
calcium cells.  The average number of cells observed per field was not 
significantly different (2.55±0.10 cells/field, high calcium; 2.58±0.12 cells/field, 
low calcium; p>0.05); however the length of apposed membranes between cells 
differed significantly between the high and low calcium cultured TECs 
(6.59±0.49µm/cell, high calcium; 4.88±0.41µm/cell, low calcium; p<0.02).  These 
results support the subjective finding that TECs maintained in low calcium 
medium appear to retain greater intercellular spacing than TECs maintained in 
high calcium medium.  (Table 3.2.) 
Table 3.2. Analysis of TECs for Juxtaposed Membrane Length.  Number of cells 
per field and length of apposed membranes between cells.  Analysis revealed no 
difference between cells per field but there was a significant difference between 
lengths of apposed membranes between the two cell populations. 
 
 High Ca++ Low Ca++ p* 
n 87 48  
cells/field 2.55 + 0.10 2.58 + 0.12 NS 
apposed 
membrane 
length µm 
6.59+0.49 4.88 + 0.41 p < 0.02 
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3.3.2.b. Number of Desmosomes 
 
Morphological changes were characterized by a quantitative analysis of 
desmosome formation.  In the 222 high calcium cultured cells, a total of 239 
desmosomes were identified, while in the 124 low calcium cultured cells, only 
a single desmosome was observed in all of the juxtaposed cells evaluated.  To 
assess desmosomal density (desmosomes/µm of apposed membrane), the 
number of desmosomes per micrometer of membrane length was calculated 
for each observed region of apposed membrane, and averaged with values 
derived from other regions.  These extrapolations revealed one desmosome 
per 6.23µm of cell membrane (total apposed membrane length/total number of 
desmosomes) in TECs maintained in high calcium medium 
(GWAJC/7.5%DMEM/2%serum).  For statistical evaluation, the number of 
desmosomes per unit membrane length (µm) was calculated for each region 
of apposed membrane examined and averaged to provide a mean value of 
desmosomal density biased by desmosomal distribution within the observed 
membrane regions.  This calculation yielded a value of 0.263±0.035 
desmosomes/µm of apposed membrane (one desmosome per 3.8µm) for 
TECs cultured in high calcium medium vs. 0.001±0.001 desmosomes/µm of 
apposed membrane (one desmosome per 690.7µm) for TECs cultured in low 
calcium medium.  This represented a significant difference between the 
distribution-biased densities of desmosomes in TECs cultured in high vs. low 
calcium medium (p<0.001).  (Table 3.3.) 
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Table 3.3. Analysis of Desmosome/Membrane Relationship Between TECs.  
TECs exposed to high calcium levels had a significant number of 
desmosomes while TECs exposed to low calcium levels had essentially no 
desmosomes. 
 
 High Ca++ Low Ca++ p* 
n 87 48  
cells/field 2.55 + 0.10 2.58 + 0.12 NS 
desmosomes/µm 
membrane 
2.63+0.35 .001 + .001 p<0.001 
 
 
3.3.2.c. Length of Desmosomes 
 
Average desmosome length was approximately 416±19 nm for the high calcium 
TECs, and was 201 nm for the single desmosome observed in low calcium 
TECs.  A valid statistical comparison of desmosome length between the cells 
grown in high calcium and low calcium was not feasible due to the small sample 
size (n=1) of desmosomes in the low calcium condition.  Nevertheless, the single 
desmosome’s 201 nm length was within size ranges documented for normal 
desmosomes.  [220]  (Table 3.4.) 
Table 3.4. Analysis of Desmosome Length in TECs.  There was no significant 
difference between the length of desmosomes in TECs exposed to high calcium 
levels and TECs exposed to low calcium levels.   
 
 High Ca++ Low Ca++ p* 
n 240 1  
desmosome 
length 
0.416 + 0.019 0.201 NS 
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3.4. DISCUSSION 
 
The differences in growth and proliferative characteristics of TECs isolated and 
maintained in medium with varying calcium concentrations appeared to be 
related to irreversible changes in their morphology.  These relationships 
appeared to be especially well demonstrated by the steep rise in morphological 
alteration in the phase contrast microscopy study.  (Table 3.1.).  Also, the almost 
all-or-none phenomenon of desmosome formation as it related to medium 
calcium levels would indicate that desmosome formation is an important 
signature of decreased cellular proliferation in TECs.  While hemidesmosome 
formation has been demonstrated within 5 minutes of exposure to elevated 
calcium levels in other cell types [221], the relationship of desmosome formation 
and TEC exposure to calcium is unique to this project.
138
CHAPTER 4. IMMUNOMODULATION WITH THYMIC EPITHELIAL CELLS 
 
 
4.1. INTRODUCTION 
 
The introduction of "foreign" antigens into the thymus has been shown to 
reeducate the immune system by selectively restricting the T cell repertoire such 
that the "foreign" antigen may be considered "self."  This finding has great 
implications for the potential therapeutic strategies in the prevention of organ graft 
rejection and in autoimmune diseases, particularly Type I diabetes.  Although the 
mechanism by which IT inoculation of antigen or antigenic tissue has not been fully 
elucidated, numerous studies have demonstrated the efficacy of this technique in 
inducing specific unresponsiveness in a host, and have resulted in decreased 
numbers of target-specific effector T cells.  [222] These studies also confirm a 
significant role for the thymus in immune maturation, antigen recognition, and 
induction of specific unresponsiveness (central tolerance).  This has led to the 
development of the hypothesis that cell/tissue grafts within the thymus allow 
presentation of foreign antigens to immature host T cells, resulting in depletion of 
cells bearing TcR specific for the reeducation of the foreign antigen.  The overall 
effect is reeducation of the host immune system leading to specific 
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unresponsiveness.  Recent experimental work in an animal model has shown that 
preconditioning of a transplant recipient by IT injection of donor antigen can induce 
donor-specific unresponsiveness, eliminating the necessity for subsequent long-
term immunosuppression.  This pioneering work described the transplantation of 
allogeneic pancreatic islet tissue into the thymus of streptozotocin (STZ)-induced 
diabetic recipient rats, and reported the induction of unresponsiveness to a 
subsequent, donor-matched, extrathymic islet graft placed at the renal subcapsular 
site.  [223] It was hypothesized that IT placement of allogeneic adult islets 
prevented the rejection of the subsequent islet graft, and the recurrence of the 
recipient’s STZ-induced diabetes, due to tolerogenic presentation of the donor-
specific MHC antigen within the host thymus.   
 
Some studies have compared the effects of intrathymic inoculation to extrathymic 
inoculation.  It has been confirmed that the IT site is specific for tolerance 
induction, whereas neither the renal subcapsular nor the intravenous route of 
inoculation can induce tolerance.  [126, 224]  Authors proposed that IT inoculation 
of cells exposes T cell precursors to B cell-specific autoantigen(s), resulting in 
clonally selective deletion.   
 
In these studies, antilymphocyte serum (ALS) was used to transiently deplete 
peripheral T cells.  The generalized immunosuppressive effect of ALS abates in 
14 to 21 days and permits T cell repopulation through IT maturation of 
lymphocytes.  It has been suggested that alloreactive maturing thymocyte clones 
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encountering their specific target molecule in the host thymus undergo central 
deletion while peripheral alloreactive lymphocytes are eliminated by ALS 
administration.  It is proposed that IT inoculation with a large amount of donor-
specific cells/antigen allows for a more complete central deletion, reducing the 
number of peripherally reactive lymphocytes while the effect of ALS is still 
present.  In a skin model of allograft transplantation using a similar tolerance 
induction mechanism with bone marrow, 21 days passed before a challenge skin 
graft was placed and graft survival was prolonged from 8 days to 24 days with 
treatment.  [128] Similarly, donor-specific unresponsiveness to murine cardiac 
allografts has been induced induced by IT administration of soluble alloantigens.  
[111] Allograft tissue presented intrathymically in this fashion is not recognized as 
foreign and rejection processes are avoided.   
 
This central tolerance induction hypothesis has now been tested in a number of 
rodent models of allogeneic transplantation.  Studies have been conducted using 
pancreatic islet [223, 225], renal [226], cardiac [227-229], skin [230], liver [231, 
232], and small bowel [233] allotransplantation.  Induction of specific 
unresponsiveness has been demonstrated following IT inoculation with whole 
cells, cell clusters (i.e. islets), or soluble cell proteins.  
 
Several studies have shown that the IT inoculation of genetically mismatched 
donor BMCs has been shown to induce long-lasting allogeneic tolerance to 
subsequent grafts.  [128, 234]  Injection of donor-matched bone marrow cells into 
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each lobe of the thymus coadministered with a single intraperitoneal injection of 1 
mL of ALS has been shown to induce tolerance to a variety of tissues [125-127], 
including the “gold standard of transplantation tolerance,” skin.  [128]  (Table 
4.1.) 
Table 4.1. Bone Marrow Transplantation and IT Tolerance Induction.  Donor-
specific tolerance induction to allograft tissue induced by intrathymic bone 
marrow inoculation with single concomitant immunosuppression. 
 
Year Author Intrathymic donor cells Donor Tissue 
1992 Posselt, et al. BM + ALS islets 
1992 Odorico, et al. BM + ALS cardiac 
1993 Matsuura, et al. BM + ALS cardiac 
1993 Campos, et al. BM + ALS liver 
1994 Hara, et al. BM + ALS cardiac 
1995 Alfrey, et al. BM + ALS liver 
1998 Li, et al. BM + tacrolimus lung 
1999 Cober, et al. BM + ALS skin 
2000 Wekerle, et al. BM + anti-CD154 + 
anti-CTLA4 Ig 
skin 
 
 
 
Based upon the results of these previous studies, it was hypothesized that the IT 
administration of genetically mismatched TECs might result in specifically tailored 
immune modification.  To assess this possibility, IT preparations of equivalent 
numbers of TECs or bone marrow cells (BMCs) were used as treatments prior to 
challenges with donor-specific tissue grafts.  Animals received either IT TECs, 
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BMCs, or saline accompanied by an IP injection of either saline or ALS.  After a 
designated in situ period, challenge grafts were removed and analyzed for 
significant differences in rejection responses using a graft rejection scoring 
system.   
 
To establish a baseline to assess immune unresponsiveness in study animals, a 
series of renal subcapsular allografts to recipient rats, biopsied at sequential time 
points, was performed.  This made possible a visual comparison of the 
histological changes between the various study groups.  Those grafts in the 
treatment groups whose histological features appeared to resemble less mature 
stages of acute graft rejection in the control groups could be characterized as 
coming from recipients which experienced some level of immune modification.   
 
 
4.2. MATERIALS AND METHODS 
 
4.2.1. Animals 
 
Both Lewis (Rt1l) and DA rats (Rt1a) were used as donors and recipients (DA to 
Lewis, Lewis to DA challenges) for transplantation studies.  Donors were over 60 
days old and recipients were males 4 to 6 weeks of age.  For baseline graft 
rejection studies, 6 week old DA males received thyroid and pancreatic challenge 
grafts from adult male Lewis donors without concomitant immunosuppression.  
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Grafts were harvested at 2, 4, 6, 8, 10, 12, 14, and 21 days following 
transplantation.   
 
The MHC mismatched TEC inoculum was limited to the spontaneously 
transformed LDA (F1 cross between Lewis and Dark Agouti, Rt1a,l) cell line 
established in the first arm of the project.  Therefore, for parallel studies using 
bone marrow instead of TECs, adult LDA rats were used as bone marrow 
donors.  It was hypothesized that the Rt1a haplotype from IT inoculation of LDA 
(Rt1l/a) TECs into Lewis (Rt1l) recipients would induce donor-specific tolerance to 
DA (Rt1a) allografts.  Likewise, it was hypothesized that the Rt1a haplotype from 
IT inoculation of LDA (Rt1l/a) TECs into DA (Rt1a) recipients would induce donor-
specific tolerance to Lewis (Rt1l) allografts.  Also, it was hypothesized that this 
low responder donor-recipient combination of Lewis to DA strains might have a 
less robust alloresponse than the high responder donor-recipient combination of 
DA to Lewis strains.  [235] Fully allogeneic IT Lewis bone marrow with ALS was 
used as an overall positive control. 
 
4.2.2. Intraperitoneal Injection of Antilymphocyte Serum 
 
Sterile frozen 1 mL ALS (rabbit-anti-rat ALS, Accurate Chemical, Westbury, NY) 
aliquots were thawed at room temperature, aspirated into tuberculin syringes, and 
slowly injected intraperitoneally (IP) into 4 to 6 week old recipients approximately 4 
to 5 hours prior to IT transplantation.  [236] If a group of younger animals appeared 
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to experience a violent reaction to the injection, two separate 0.5 mL injections 
were administered approximately 15 minutes apart.  [237, 238]  Sham controls 
used IP saline as treatments.   
 
4.2.3. Bone Marrow Harvest 
 
Bone marrow donors were anesthetized with isofluorane via general inhalation 
and the lower extremities shaven and washed with 70% ethanol.  An incision was 
made just over the hip joint and extended toward the knee.  Sharp calipers were 
clamped through the tibial plateau to stabilize the proximal tibia.  With downward 
traction on the leg, the acetabulum was disjointed and the femur was removed by 
sharp dissection of knee ligaments.  Muscular tissue was cleaned from the femur 
and both ends were sharply removed with a sterile splicing instrument.  A 12-
gauge needle on a syringe of cold HBSS was used to flush bone marrow cells 
from the bone marrow cavity into a centrifuge tube.  [239] 
 
4.2.4. Intrathymic Transplantation  
 
4.2.4.a. Cell Preparation and Concentration of TECs 
 
As mentioned previously, each confluent T25 flask yielded 1 x 106 TECs.  
Cells were trypsinized and triple washed in Ca++/Mg++ free HBSS, and 
concentrated numbers were disbursed into microfuge tubes for centrifugation 
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(1500 RPM, 5 minutes) and volume adjustment to make 50 microliter aliquots 
containing 5 x 105 TECs per microfuge tube.  
 
4.2.4.b. Cell Preparation and Concentration of BMCs 
 
Bone marrow harvests were consolidated into one centrifuge tube and spun at 
1500 RPM to form a pellet.  The pellet was resuspended in 10 mL of sterile, 
endotoxin free water (Hyclone, Logan, UT) for 30 seconds and then 
centrifuged in 50 mL of HBSS; the supernatant was decanted.  To gauge 
experiments, cell counts were evaluated by cytometric analysis.  Following 
erythrocyte lysis, the number of cells derived from two rat femurs was reduced 
from between 1.3 and 1.5 x 106 to 7 x 105 cells.  Pellets were resuspended in 
enough HBSS to make 50 µl aliquots containing 5 x 105 BMCs per tube.   
 
The same number of TECs and BMCs were prepared for each recipient.  
Cellular inoculates were concentrated via centrifugation to 5 x 105 cells in 50 
microliters of HBSS/1 mL microfuge tube for inoculation of each thymic lobe (2 
tubes per recipient).  [240] [241] [74] [234]   
 
4.2.4.c. Intrathymic Inoculation Procedure 
 
Donor cells (either BMCs or TECs) were prepared and concentrated as 
described.  Recipient rats, aged 4 to 6 weeks, were anesthetized with 
isofluorane via inhalation technique and prepared for surgery.  The neck and 
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upper thorax were shaven and washed with 70% ethanol, and the animal was 
placed supine with the neck extended by placement of a towel roll beneath the 
scapulae.  Forceps were used to lift the skin overlying the trachea and a 
midline incision was created using straight scissors.  Similar to documented 
techniques [242], sharp dissection techniques were used to retract the skin 
laterally, to expose the sternohyoid muscle overlying the trachea, and to incise 
the muscle.  Rongeurs were used to remove the manubrium down to the first 
sternebra.  The two halves of the sternohyoid muscle were further separated 
down to the cut end of the manubrium, revealing the cephalad portion of the 
thymus gland.  A cotton-tipped applicator was used to further delineate the 
edges of the thymus gland.  With a 27-gauge butterfly syringe, the cell 
suspension was gently aspirated and expelled to disperse any settled cells at 
the bottom of the microfuge tube.  The 50 microliter solution containing cells 
for inoculation was finally aspirated into the syringe.  Any liquid at the tip of the 
needle was removed and the solution carefully injected into one lobe of the 
thymus.  As the needle was removed, a sterile cotton tipped applicator was 
used to cover the puncture in the thymus and absorb any leakage.  The 
process was then repeated on the other lobe of the thymus.  Grossly visible 
leakage was recorded as a technical difficulty and considered upon statistical 
analysis.  The feasibility and accuracy of IT injection was initially tested by 
injecting ink into the thymus gland (Figure 4.16.) using the above described 
technique.   
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4.2.4.c.1. Intrathymic Inoculation of TECs 
 
Primary cultured LDA (Rt1l/a hybrid) TECs were transplanted intrathymically 
into 4-6 week old Lewis males (Rt1l).  5 x 105 cells were injected into each 
lobe of the thymus, resulting in a total of 1 x 106 IT TECs.  Concomitantly, 
recipients received either IP saline (1mL, sham control) or anti-lymphocyte 
serum (1mL, rabbit anti-rat ALS, Accurate Chemical, Westbury, NY) for 
peripheral lymphocyte depletion.  
 
Freeze-thawed TECs were prepared by exposing the cells to 4 freeze-thaw 
cycles between liquid nitrogen and a 65°C heating block to supply dead TECs 
(FT-TECs).  (Figure 4.28.)  Cell death was confirmed by a cellular replating 
and incubation technique in supplemented GWAJC medium at 37°C, 5% CO2.   
 
4.2.4.c.2. Intrathymic Inoculation of BMCs 
 
LDA or Lewis BMCs were transplanted intrathymically into 4-6 week old DA or 
Lewis recipients.  5 x 105 cells were injected into each lobe of the thymus, 
resulting in a total of 1 x 106 IT BMCs.   
 
4.2.5. Challenge Grafts—Harvest and Preparation 
 
After a period following IT TEC or BMC inoculation with or without concomitant 
IP ALS, recipients received a challenge graft placed in the renal subcapsular 
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space, and the graft site carefully documented.  (DA recipients received Lewis 
challenge grafts.)  After an in situ period, the graft was recovered, fixed in 
Bouin’s solution, prepared for routine paraffin histology (5µm sections, H&E 
staining) and analyzed histologically for graft rejection.   
 
The harvesting techniques for pancreatic and thyroid tissue challenges were 
similar.  A sterile Petri dish was filled with 25 mL of HBSS (GibcoBRL, 
Gaithersburg, MD) and placed over ice.  Lewis, DA, or LDA rats of sexual 
maturity were used as the source of tissue.  Animals were anesthetized with 
isoflurane via inhalation technique.   
 
4.2.5.a. Challenge Grafts - Pancreas Harvest and Preparation  
 
The abdominal area was shaven and washed with 70% alcohol. Using aseptic 
technique, blunt forceps were used to lift the skin of the right upper quadrant.  
Straight scissors were used to extend a skin incision across to the left upper 
abdomen.  Blunt dissection was used to separate the skin from the underlying 
connective tissue, and the skin was retracted.  The underlying muscular layer 
was lifted with forceps and incised from right to left in a similar fashion.  The 
peritoneum was incised and separated using blunt dissecting techniques.  The 
spleen was lifted with clean blunt forceps and clean scissors were used to 
dissect the tail of the pancreas from the spleen and the greater curvature of the 
stomach.  A fragment of pancreatic tissue was sharply excised and placed in the 
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Hank’s solution over ice.   The animal was either prepared for thyroid tissue 
excision or sacrificed via carbon dioxide asphyxiation.  The pancreatic tissue was 
cleaned of connective tissue, fat, and blood vessels under a dissecting 
stereomicroscope (Hitschfel SZX-ZB9, St. Louis, MO), and then dissected into 2 
mm fragments for immediate transplantation to the renal subcapsule.  The 
unused tissue was discarded.   
 
4.2.5.b. Challenge Grafts - Thyroid Harvest and Preparation  
 
The neck was shaven, and the surgical field was washed with 70% alcohol. 
Using aseptic technique, blunt forceps were used to lift the skin overlying the 
trachea.  Straight scissors were used to extend a skin incision cephalad from the 
jugular notch cranially to the submandibular region.  The scissors were spread to 
separate the skin from the underlying connective tissue, and the skin was 
carefully retracted.  The connective tissue surrounding the each lobe of the 
thyroid gland was separated using a scissors opening technique and blunt 
forceps were used to stabilize the thyroid gland while a fresh pair of curved 
scissors was used to harvest a large fragment of tissue.  The parathyroid glands 
and unwanted material were carefully dissected away and the cleaned thyroid 
tissue was minced to 2 mm fragments and placed in Hank’s solution over ice for 
immediate transplantation to the renal subcapsule.   
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4.2.5.c. Placement of Challenge Grafts 
 
Recipient animals were labeled and identified by metal numbered ear tags 
(National Brand & Tag Company, Newport, KY) to eliminate confusion or 
misidentification, and the recipient animal’s ID number was recorded prior to 
beginning the procedure.  The kidney subcapsule (Serie et al 1983, Hegre et al 
1984) provided a convenient site for easy graft placement.  The animal was 
anesthetized using ether or isofluorane and one or both flanks were shaven with 
an electric shaver.  The area was washed with 70% ethanol, and the animal was 
placed in a lateral decubitus position.   
 
The costal margin was located and used as an anatomical landmark.  The skin 
was opened with scissors at a point slightly inferior to the costal margin.  Blunt 
dissection was used to separate the adipose and loose connective tissue 
underlying the dermis from the underlying lateral muscular wall of the abdominal 
cavity prior to incision of the muscular wall.  This layered dissection was used to 
minimize the development of adhesions.  Irrigation was performed with HBSS. 
 
The kidney was isolated and delivered out of the wound.  A mosquito hemostat 
was applied to the fat pad associated with the renal capsule, stabilizing the 
kidney during placement of the graft tissue.  A #11 blade scalpel was used to 
make a 1-2 mm incision in the renal capsule.  One arm of a blunt forceps, such 
as a #5 eye-dressing forceps, was inserted and angled approximately 
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30 degrees both clockwise and counterclockwise to create a pocket for tissue 
placement, taking care not to injure the underlying renal cortex.  The blunt 
forceps were used to hold the capsule open while other forceps were used to 
advance an appropriately sized intact tissue fragment under the capsule about 1 
cm.  Donor tissue fragments were prepared immediately prior to transplantation 
as described above and stored in cold HBSS over ice.  The capsule was gently 
replaced, and the fragment manipulated through the capsule by gentle pressure 
to prevent the transplanted tissue fragment from slipping out of the subcapsular 
space.  The mosquito hemostats for kidney stabilization were unclamped, and 
the kidney was returned to the body cavity.  Sterile HBSS was used for wound 
irrigation and to replenish lost fluids.  The wound was closed by first 
reapproximating the two edges of the muscle wall incision, and suturing with 4-0 
Vicryl suture (Ethicon, Inc., Somerville, NJ) using simple running suture.  
Subsequently, the skin edges were brought together and stapled with sterile 
wound clips or sutured with nonabsorbable suture in a simple interrupted or 
uninterrupted fashion.  Once the closure of the skin layers was complete, generic 
triple antibiotic ointment was topically applied.   
 
The animal was returned to normal caging after recovery from anesthesia, where 
it was carefully monitored for complications during a one hour recovery period.  
All procedures were documented, and any irregularities noted.   
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4.2.6. Excision and Processing of Grafts 
 
4.2.6.a. Macroscopic Evaluation of Grafted Tissue 
 
At harvest, transplanted tissue was examined macroscopically as part of the 
protocol to assess the host’s immune response.  The graft was evaluated in 
terms of general appearance, visible necrosis, neovascularity, purulence, 
coagulation, and scarring.  The overall assessment was rated as either accepted, 
or partially to completely rejected.  Macroscopic evaluation was included for 
correlation with subsequent histological evaluation, but had no bearing on the 
actual immune scores assessed by histologic evaluation.   
 
4.2.6.b. Renal Subcapsular Graft Excision 
 
Animals were placed under general anesthesia, the surgical site shaven and 
prepped with ethanol, and the skin incised at the same location as the original 
incision.  Blunt and sharp dissection were used to open the layers of the wound, 
separating subcutaneous fat and connective tissue from the underlying muscular 
layer, and noting any excessive adhesion formation, hematoma, or abscess.  The 
previous incision was reopened with scissors, mosquito hemostats were applied, 
and the kidney was delivered through the wound and stabilized.  The graft was 
located based on previous documentation, and macroscopically evaluated as 
described above.  After recording macroscopic observations, the graft area was 
excised using sharp curved scissors to fashion an oval shaped wedge including
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3 mm of kidney cortex with the overlying graft.  An alternative to the scissors 
technique was the use of a #11 scalpel blade (Becton Dickinson and Co., Lincoln 
Park, NJ) to incise the kidney cortex circumferentially around the graft site, 
although the renal capsule tended to slip and distort the graft placement with this 
technique.  The specimen was retrieved with blunt forceps, rinsed in saline 
solution, and placed in Bouin’s fixative solution. 
 
4.2.6.c. Fixation, Embedding, Sectioning and Mounting  
 
Harvested graft tissue was bathed in 5 mL Bouin’s fixative solution for 
approximately 18 to 24 hours.  The Bouin’s solution was then decanted off and 
the tissue was immersed in approximately 25 mL of 70% ethanol.  Ethanol was 
replaced daily for 4 to 5 days to ensure more complete clearing of Bouin’s 
solution from the tissue.  Porous paper embedding bags were labeled 
appropriately, and samples were placed within each bag.  Samples were then 
rinsed twice more, 3 minutes each time, in fresh 70% ethanol, and air bubbles 
were eliminated by piercing the bags with a needle.  A silk tie was stapled to the 
bags which were then hung into a fleaker of fresh 70% ethanol, with continuous 
agitation of the solution by a magnetic stir bar for one hour.  Bathing solutions 
were replaced hourly thereafter with 2 changes of 95% ethanol and 3 changes of 
100% ethanol, resulting in dehydration of the tissue sample.  The sample was 
placed in toluene (3 changes, each an hour long) until tissue translucence was 
confirmed with a flashlight.   
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Paraffin (Surgipath, Richmond, IL) embedding was accomplished with the aid of 
a Sakura Finetech Tissue Tek II tissue processing station.  Tissue samples were 
immersed in three successive paraffin baths, followed by placement of the tissue 
within a mold filled with molten paraffin with the aid of a Leica EG1160 
histological embedding station.  The paraffin block was allowed to cool and 
separated from the mold.  The block was placed in a Leica RM2155 microtome 
and sectioned rapidly until the tissue was encountered.  Chemically etched single 
frosted glass slides (Anapath, Statlab, Lewisville, TX) were labeled with pencil or 
etched with a diamond pen using a numbering system corresponding to 
treatment groups.  Serial tissue sections of 5µm thickness were obtained and 
mounted to the labeled slides using a water bath floatation technique.  The entire 
tissue sample was serially sectioned to ensure that the entire graft could be 
evaluated.  Blocks were stored for later sectioning and referral.    
 
4.2.6.d. Staining for Histological Examination 
 
Harris’ Hematoxylin was prepared as follows.  One hundred grams of aluminum 
potassium sulfate (Sigma, St. Louis, MO) were dissolved in a 2 liter flask 
containing 1 liter of water.  In a 250 mL beaker, 25 mL propylene glycol, 25 mL 
70% ETOH, and 5 gm Hematoxylin (Kodak, C.I. No. 75290, Rochester, NY) were 
combined and stirred at 50-60°C until dissolved.  The two formulations were 
combined at room temperature.  In place of mercuric oxide, 0.5 gm potassium 
iodate was added.  
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For deparaffinization and staining, slides with sections were baked at 60° C and 
washed twice in xylene to clear them of paraffin, and then rehydrated in graded 
ethanol solutions (two washes each of 100% ethanol; then 95% ethanol; then 
85% ethanol).   
 
Rehydrated slides were rinsed in tap water and stained for 15 minutes in filtered 
Harris’ Hematoxylin.  This was followed by a 5 minute water rinse, differentiation 
in acid alcohol, and refining of stain color in ammonia water.  After a final water 
rinse of 10 minutes, slides were dehydrated to 85% ETOH and counterstained to 
the desired intensity with Eosin (Polysciences, Warrington, PA) which had been 
prepared within a week by mixing equal stock solutions of 0.178% eosin Y (C.I. 
No. 45380) and 0.026% phloxine B (C.I. No. 45410), each dissolved in 83.3% 
ETOH.  The working stain was acidified with 0.7 mL glacial acetic acid (EM 
Science, Cherry Hill, NJ) per 150 mL of the mixture.  The dehydration process 
was continued on stained slides through 2 changes each of 95% and 100% 
ethanol and back through 2 washes with xylene before coverslipping with 
Permount mounting medium.   
 
4.2.7. Histological Examination and Immune Scoring of Grafts  
 
Grafts were evaluated using a graft rejection scoring system reflecting: (1) 
allograft viability based upon morphological integrity of the graft, and (2) a graft 
rejection scoring system based upon the mononuclear cell infiltration into the 
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region of the graft.  Scores ranged from 0 to 4, where 0 signified the least altered 
graft viability or the lowest number of mononuclear cells infiltrating the graft; and 
4 signified the most significant reduction in graft viability to the formation of a scar 
and the most significant mononuclear cell destruction of the graft.  (Figure 4.1.)  
The graft scoring system used in the histological analysis of the challenge tissue 
and surrounding graft site has been used in other transplantation study protocols, 
and makes an objective measure of the immunologic response feasible.  (Tables 
4.2. and 4.3.)  As lymphocytic infiltration occurs in focused concentrations, 
accurate cell counts are difficult to obtain based upon 5 µm section samplings 
through grafts measuring between 1 and 2 mm.  The quantification and sizing of 
lymphocytic foci, along with the application of the graft grading system, was 
therefore used to assign graft scores above zero.  Graft fibrosis (Figure 4.2.), 
necrosis (Figure 4.3.), polymorphonuclear cell infiltration (Figure 4.4.), 
macrophage infiltration (Figure 4.5.), and vascularity were also evaluated.   
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Figure 4.1. Graft Rejection and Lymphocytic Infiltration Scoring Systems.  
Overall graft rejection (left column) is scored 0, 1, 2, 3, and 4 from top to bottom; 
graft lymphocytic infiltration (right column) is scored 0, 1, 2, 3, and 4 from top to 
bottom.  Score descriptions can be found in Tables 4.2. and 4.3. Each image = 
100 X. 
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Figure 4.2. Graft Fibrosis.  Eosinophilic collagen fibers replaced viable graft 
tissue as the rejection process ensued 90 X.   
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Graft Necrosis.  Involution of graft structure exceeded the level of 
lymphocytic infiltration expected to cause this extent of graft destruction.  100 X. 
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cigure 4.4. Graft Neutrophilic Infiltration.  Neutrophilic bands are concentrated 
etween nucleated cells in acute stages of graft inflammation. 135 X. igure 4.5. Graft Macrophage Infiltration.  Macrophages and multinucleated giant 
ells phagocytose graft tissue remnants. 240 X. 
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Grafts sometimes contained foreign bodies including fur.  (Figure 4.6.)  When fur 
was seen, it was usually associated with a histological graft appearance 
consistent with late stages of graft rejection, suggesting that its presence 
heightened the immune response by elevating proinflammatory cytokine levels.  
This is not an unexpected finding, as rejected third party grafts can also induce 
rejection of previously accepted donor-matched allografts by localized alteration 
of cytokine milieu.  [243]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
figure 4.6. Graft Foreign Bodies.  White fur from a Lewis rat (top) and brown fur 
rom a DA rat (bottom) are seen within challenge grafts. 240 X. 
161
Lymphocytic infiltration and graft viability (preservation of histological 
architecture) were evaluated, as described above, using separate grading 
systems based on criteria for allograft evaluation developed by Hegre and 
Ketchum.  (Hegre et al 1984)  (Figure 4.1.) 
 
Grafts of pancreatic and thyroid fragments were histologically examined and 
assigned graft scores based upon lymphocytic infiltration of the graft, and relative 
immune-related destruction of graft tissue by the following sets of criteria:  
 
Table 4.2. Lymphocytic Infiltration Scoring System.  Scores of 0 to 4 were 
assigned based upon presence and size of lymphocytic foci.   
 
Lymphocytic 
infiltration Score Description 
0 Graft site free of lymphocytic proliferation, allowing for a few scattered lymphocytes. 
1 
Graft site with one or more small distinct lymphocytic 
infiltrates containing between 10 and 30 cells. 
2 
Graft site with one or more distinct lymphocytic infiltrates 
containing 40 or more cells. 
3 
Graft site with several large lymphocytic infiltrates with 
some overlap or extensive infiltration throughout. 
4 
Graft without almost complete, indistinct lymphocytic 
infiltration obscuring normal graft tissue. 
 
Table 4.3. Allograft Viability Scoring System.  Scores of 0 to 4 were assigned 
based upon histological architecture. 
 
Allograft  
Viability Score Description 
0 Viable graft, no evidence of immune involvement 
1 Viable graft, structurally intact tissue with limited mononuclear infiltrate 
2 
Immune response, with a largely intact graft with evidence of 
mononuclear infiltrate and minimal evidence of graft 
destruction 
3 
Immune response, with recognizable tissue with significant 
mononuclear infiltrate and evident significant 
destruction of graft tissue 
4 Rejection, remnant scar tissue only, with complete resolution of mononuclear infiltrate 
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4.2.7.a. Statistical Analysis 
 
Fisher’s Exact Probability Test was initially used to identify statistically significant 
overall differences in outcome among smaller treatment groups.  The chi squared 
test was also used to determine the statistical significance of the qualitative 
preliminary data between preliminary treatment groups.  The student’s T test was 
then used to evaluate differences between the graft scores of individual 
treatment groups, with a one-way ANOVA for comparisons between numbers of 
groups.  [244]  Graphpad Prism 4 and GraphPad InStat (GraphPad Software, 
San Diego, CA) computer software programs were used for statistical outputs. 
 
 
4.3. RESULTS  
 
4.3.1. The Natural History of Allograft Rejection: Temporal Studies in the Course 
of Immune Rejection  
 
As described in Chapter 1, the immunologic response to graft rejection differs 
from the natural response to graft placement, i.e. inflammatory response 
associated with unavoidable surgical trauma, such as in the case of an autograft.  
These graft rejection events are dependent upon factors such as the extent of 
the surgical wound, immunocompetence of the recipient, histocompatibility 
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between the donor and recipient, cellular composition of the graft, antibody 
formation following engraftment, and immunosuppressive regimens. 
 
Almost no immune response to allogeneic transplantation occurs 2 days 
following graft placement.  (Figure 4.7.)  There is retention of pancreatic acinar 
structure and minimal lymphocytic infiltration.   
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Pancreatic Graft 2 Days Following Allogeneic Transplantation.  
Tissue demonstrates normal pancreatic acinar structure and a minimal number of 
infiltrating mononuclear cells.  120 X. 
Day 2
 
By Day 4 following allogeneic transplantation, there is a significant change in 
graft morphology with loss of basophilic staining pancreatic acini.  (Figure 4.8.)  
Ductal elements are still supported by an intact, eosinophilic staining basal 
lamina, making it still evident that this is glandular tissue.  Compared to the day 2 
graft with minimal lymphocytic infiltration, there is some mild perivascular 
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lymphocytic infiltration.  There is no evidence of scarring or deposition of fibrotic 
tissue.   
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igure 4.8. Pancreatic Graft 4 days Following Allogeneic Transplantation.  
ormal acinar appearance is lost but ductal elements remain supported by an 
osinophilic basal lamina.  Mild mononuclear cell infiltration.  120 X. 
imilar findings to the 4 day pancreatic graft are seen in this thyroid graft at 7 
ays.  (Figure 4.9.) Follicular elements are seen, and there is increased 
ymphocytic infiltration compared to the 2 day graft.  Loss of tissue density 
etween the follicular elements and replacement with lightly eosinophilic fibers 
ignify early fibrotic changes.  
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 Day 7 
 
 
 
 
 
 
 
Figure 4.9. Thyroid Graft 7 Days Following Allogeneic Transplantation.  Follicular 
elements of thyroid glandular tissue remain while lymphocytic infiltration ensues 
along fibrotic areas of the graft.  115 X. 
 
By day 10 following allotransplantation, pancreatic ductal elements are losing 
structural integrity, suggested by loss of the smooth appearance to the ductal 
lumen.  (Figure 4.10.)  This may be due to lack of support from the disintegrating 
basal lamina.  There is increased lymphocytic infiltration around the ductal 
elements compared to the 4 and 7 day grafts, occupying loose fibrotic areas.   
 
 
 
 
 
 
 
 
Day 10  10 
Figure 4.10. Pancreatic Graft 10 Days Following Allogeneic Transplantation.  
Ductal lumina appear less well preserved and lymphocytic infiltration continues to 
destroy the graft.  125 X. 
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Tissue destruction continues until basal laminae are no longer evident after 12 
days.  (Figure 4.11.)  Lymphocytes and macrophages predominate.  
Neovascularization is also noted.  This tissue is no longer identifiable as 
glandular in structure.  Much of the tissue has been replaced by lightly 
eosinophilic staining collagen fibers.   
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igure 4.11. Pancreatic Graft 12 days Following Allogeneic Transplantation.  
uctal elements are replaced by eosinophilic collagen fibers while lymphocytic 
nfiltration destroys graft viability.  125 X. 
t 14 days, the majority of the graft takes on a lightly eosinophilic, fibrotic 
ppearance but there is still a moderate lymphocytic infiltrate.  (4.12.) 
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nigure 4.12. Pancreatic Graft 14 Days Following Allogeneic Transplantation.  A 
ew lymphocytic foci remain at the junction between the graft and the renal 
ubcapsule.  Eosinophilic collagen fibers account for the majority of the graft.  
00 X. 
Day 14
inally, by day 21, all that remains of the graft is a scar devoid of nuclei.  (Figure 
.13.)  Paucity of lymphocytes in the area indicate that the immunologic process 
f rejection has resolved.   
Day 21
igure 4.13. Pancreatic Graft 21 Days Following Allogeneic Transplantation.  A 
c
o
ar of eosinophilic collagen is all that remains of the tissue graft which overlies 
rmal kidney tissue.  Lymphocytic infiltration has resolved. 100 X. 
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Graft score categories of overall graft rejection and lymphocytic infiltration were 
plotted, and this reflected the expected natural history of the immunologic 
response to allotransplantation.  (Figure 4.14.)   
 
 
 
 
 
 
 
 
 
Figure 4.14. Lymphocytic Infiltration Scores in the Natural History of Graft 
Rejection.  Lymphocytic infiltration was elevated 2 days post transplant, and 
peaked at 8 days post transplant.   
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Figure 4.15.  Graft Rejection Scores in the Natural History of Graft Rejection.  
Graft rejection rose and became relatively steady past day 4. 
The Natural History of
Allograft Rejection
0 2 4 6 8 10 12 14
0
1
2
3
4
Days Post Transplant
R
ej
ec
tio
n 
sc
or
e
169
Rejection scores were similar from days 4 through 14, and therefore not as 
useful for comparing graft scores in treatment groups.  Averages of combined 
rejection and lymphocytic infiltration scores were not as physiologically relevant 
but fit a more bell shaped distribution (not shown) with a peak between 8 and 10 
days.  The findings in the natural history of graft rejection helped to outline the 
time frames chosen for challenge graft harvesting to determine a treatment-
related shift in graft immune response from the normal response.   
 
4.3.2. Allogeneic Transplantation from DA to Lewis Rats  
 
As mentioned in the Materials and Methods, 4 to 6 week old recipients received a 
total IT inoculation of 1 x 106 LDA BMCs or TECs, or 50 µL saline, with a 
concomitant intraperitoneal injection of 1 cc ALS or saline.   
 
Successful IT injection with retention of inoculum was easily established and 
documented using India ink, as described in p. 142.   
 
 
 
 
 
 
Figure 4.16. Adolescent Rat Thymus Following India Ink Inoculation.  The 
intrathymic injection technique was tested for accuracy using an ink injection.   
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After a treatment to challenge period of 10 days, DA challenge grafts of thyroid 
and pancreatic tissue fragments were placed in the renal subcapsule.  DA Grafts 
were harvested for processing and analysis after 21 days in situ.  Any technical 
difficulties were recorded.  This was referred to as the “10/21” time frame. 
 
To determine whether the in situ period had an effect on graft recovery studies, 
the treatment to challenge frame was extended to 21 days and the in situ 
challenge time was reduced to 10 days.  This was referred to as the “21/10” time 
frame. 
 
To control for sensitization, syngeneic Lewis graft responses were evaluated 
following IT TEC and IP ALS or saline on the 21/10 time frame. 
 
The DA to Lewis transplantation experiments are summarized in Table 4.4. 
Table 4.4. DA to Lewis Challenge Grafts Following Varied IT Treatments.  Lewis 
recipients received either IP ALS or saline and either IT cells or saline for 
tolerance induction studies. 
 
Group Donor Recipient IT inoculum ALS Challenge 
(Days post Rx) 
Harvest  
(days post-
challenge) 
1 DA Lew saline N 10 21 
2 DA Lew saline Y 10 21 
3 DA Lew LDA BMC Y 10 21 
4 DA Lew LDA BMC N 10 21 
5 DA Lew LDA TEC Y 10 21 
6 DA Lew LDA TEC N 10 21 
7 DA Lew LDA TEC Y 21 10 
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Figure 4.17. DA to Lewis Control Groups.  There was a statistically significant 
elevation (ANOVA, p<0.02) in lymphocytic infiltration in the ALS/ LDA BMC 
(positive control, group 3) compared to negative controls (groups 1, 2 and 4).  
There were no statistically significant differences among the negative control 
groups (1, 2 and 4).   
 
 
A one-way ANOVA of the control groups revealed significant overall differences 
between the groups with a p<0.02.  A Dunn’s multiple comparison post-test 
revealed no significant differences between the negative control groups, 
indicating that ALS alone or BMCs alone did not exert statistically significant 
immunomodulatory effects compared to saline.  There were significant 
differences (p<0.05) between group 3 (positive control, ALS + BMCs, mean 
lymphocytic infiltration 2.1+0.27, n=13) and negative controls, including group 1 
(saline + saline, mean lymphocytic infiltration 0.83+0.65, n=6, p<0.05) and group 
4 (saline + BMCs, mean lymphocytic infiltration 0.63+0.26, n=8, p=.002).  The 
immunological effects of intrathymic LDA BMCs (group 4) were significantly 
enhanced by the addition of IP ALS to the BMC protocol.  Of interest, there was 
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no significant difference between group 3 and group 2 (ALS + saline, mean 
lymphocytic infiltration 1.5+0.87, n=4, p NS) in a 10/21 time frame.  The ALS only 
group was also used to control for the effects of IT BMCs.  The brief IT 
reeducation period and lingering effects of ALS during the in situ challenge 
period might have been the cause of these results, and the impetus behind the 
protocol switch to the 21/10 time frame.   
 
The saline negative control and the IP ALS/IT LDA BMC positive control were 
used as direct comparisons to the treatment group of IT LDA TECs with 
concomitant IP ALS.  (Figure 4.18)  As mentioned previously, the period from 
ALS administration and IT inoculation to challenge graft placement was either 21 
or 10 days, and the in situ graft period was either 10 or 21 days, respectively.  
These time periods were evaluated for their significance and to highlight any 
outcomes between the treatment groups as related to the period of thymic 
reeducation.   
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Figure 4.18. DA to Lewis Experimental Groups.  The degree of 
immunomodulation was significantly higher (ANOVA, p=0.006) in the positive 
control group (3, ALS+BMCs) compared to the IP ALS/IT TEC treatment groups 
(5 and 7).  Group 6 (saline+TECs) was associated with immunomodulation not 
significantly different from group 3, suggesting a physiological role for TECs.   
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A one-way ANOVA including group 3 (positive control) and experimental TEC 
treatment groups revealed statistically significant differences between the groups 
(p=.006).  A Dunn’s multiple comparison post-test revealed significantly higher 
mean graft lymphocytic infiltration scores between group 3 (ALS+BMCs) and the 
treatment groups 5 (ALS+TECs, 10/21 time frame, mean lymphocytic infiltration 
0.86+0.25, n=12, p<0.05) and 7 (ALS+TECs, 21/10 time frame, mean 
lymphocytic infiltration 0.63+0.32, n=4, p<0.05).  There were no significant 
differences among any of the TEC treatment groups despite differences in time 
frames, and despite the addition of ALS to the TEC treatment protocol.  This was 
different from the effect of adding ALS to the BMC treatment protocol, which 
resulted in a synergistic immunomodulatory effect, even though the ALS came 
from the same source.  Of interest, there was not a statistically significant 
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difference between group 3 and group 6 (saline+TECs, mean lymphocytic 
infiltration 1.6+0.34, n=17, p<0.05), suggesting that IT TECs have significant 
immunomodulatory effects when administered without ALS.  However, group 6 
was not significantly different from group 1 (saline control) in host 
immunomodulation (not shown, p NS).  This was confirmed by a t-test between 
the two groups.  Therefore, the potential clinical significance of IT TEC 
inoculation remains limited due to the lack of statistical significance when 
comparing the TEC group with the saline negative control. 
 
Overall, when compared directly, it appeared that TECs alone were as effective 
as BMCs with concurrent ALS administration, suggesting a physiologic role for IT 
injected TECs.  The determine the safety of IT TEC inoculation, syngeneic Lewis 
recipients were treated with IT LDA TECs without concomitant ALS.  (Figure 
4.19.) 
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Figure 4.19. The Effect of Allogeneic IT TECs on Syngeneic Grafts.  IT 
inoculation of LDA TECs resulted in reduced graft lymphocytic infiltration 
(average score 0), indicating no deleterious effects in syngeneic recipients. 
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Cases in which technical difficulties led to leakage of the TEC inoculum into the 
mediastinal cavity were recorded.  Not shown, a comparison between the IT TEC 
inoculations without technical difficulties and those with technical difficulties 
(“leaks”) revealed a statistically significant (p<0.05) loss of graft viability.  The 
relevance of these results appears dimmed by the lack of significant change in 
graft lymphocytic infiltration or rejection scores between the groups.   
 
4.3.3. Allogeneic Transplantation from Lewis to DA Rats   
 
Strain-dependent differences have been reported to affect the success of 
allograft survival following IT inoculation of donor BMCs with concomitant ALS.  
[245]  The Rt1a haplotype of DA rats has been reported to induce a stronger 
response to allograft placement compared to the Rt1l haplotype of Lewis.  A 
combination of rat strains which results in such a response is referred to as a 
“high responder” combination.  [235]  Therefore, the DA to Lewis transplantation 
direction was reversed to create a “low responder” combination.  This was done 
to highlight any observed modulations in the immune response following the 
hypothesis that TECs might induce donor-specific tolerance.   
 
Recipients aged 4 to 6 weeks received an IT inoculation of 1 x 106 LDA BMCs or 
TECs, or 50 µL saline, with a concomitant IP injection of 1 cc ALS or saline.   
The negative control group was treated with IP and IT saline.  As a control for IT 
cellular immunomodulation, animals received IP ALS and saline as a treatment.  
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After a treatment to challenge period of 21 days, Lewis challenge grafts of thyroid 
and pancreatic tissue fragments were placed in the renal subcapsule.  Lewis 
grafts were harvested for processing and analysis after 10 days in situ.  Again, 
any technical difficulties were recorded. The Lewis to DA experiments are 
summarized in Table 4.5.   
Table 4.5. Lewis to DA Challenge Grafts Following Varied IT Treatments.  DA 
recipients received either IP ALS or saline and either IT cells or saline for 
tolerance induction studies. 
 
Group Donor Recipient IT inoculum ALS Challenge 
(Days post Rx) 
Harvest  
(days post-
challenge) 
1 Lew DA saline N 21 10 
2 Lew DA saline Y 21 10 
3 Lew DA Lew BMC Y 21 10 
4 Lew DA LDA BMC Y 21 10 
5 Lew DA LDA TEC Y 21 10 
6 Lew DA LDA TEC N 21 10 
7 Lew DA LDA FT-TEC Y 21 10 
 
To control for the tolerance inducing capacity of the partially mismatched Rt1 
haplotype, Lewis BMCs (Rt1l) (ALS/Lew BM) were substituted for LDA BMCs 
(Rt1l/a) for the IT treatment with IP ALS in a 21/10 time frame (ALS/LDA BM).   
 
The target experimental group was given ALS and TECs (ALS/TEC).  To control 
for a physiological role for TECs as opposed to a purely antigenic role, freeze-
thawed LDA TECs were injected intrathymically with IP ALS in a 21/10 time 
frame.  (Figure 4.20.) 
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Figure 4.20. Hoffman Phase Microscopy of Freeze-Thawed TECs.  TECs 
immediately following 4 freeze-thaw cycles; cells were injected intrathymically as 
a negative control to confirm a physiologic role for live TECs.  260 X. 
 
To control for an allogeneic Lewis to DA response and for graft necrosis, 
syngeneic DA controls were included in a 21/10 time frame, as were syngeneic 
Lewis controls.   
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Figure 4.21. Lewis to DA Control Groups.  As expected, compared to the saline 
control (group 1), IP ALS without an IT cellular treatment (group 2) did not 
significantly modulate the host immune system.  Compared to negative control 
groups (1 and 2), group 3 (ALS+Lewis BMCs) and group 4 (ALS+LDA BMCs) 
resulted in reductions in mean lymphocytic infiltration of the grafts (ANOVA, 
p=0.08).   
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As a positive control, allogeneic BMCs were injected intrathymically with a 
concomitant IP injection of ALS.  A one-way ANOVA of the Lewis to DA control 
groups revealed not quite statistically significant overall differences between the 
groups (p=0.08).  However, a selected Dunns analysis revealed the mean 
lymphocytic infiltration for group 1 (saline control, mean lymphocytic infiltration 
1.78+0.47, n=10) to be statistically different from group 3 (ALS+Lewis BMCs, 
n=6, p=0.01), indicating that Lewis BMCs resulted in significant modulation of the 
host immune system.  The reversed direction of graft scores from high to low in 
the positive control was felt to reflect the 21/10 time frame as it related to the 
natural history of graft rejection.  Though appearing to reduce lymphocytic 
infiltration to some degree, the lack of statistically significant immunomodulation 
by group 4 (ALS+LDA BMCs, mean lymphocytic infiltration 0.9+0.41, n=6) 
compared to group 1 (p NS) may have been related to strain specific differences 
in the allograft response, or it may have been a function of the new 21/10 time 
frame.  In this specific strain combination, the inclusion if a Lewis-Dark Agouti 
hybrid bone marrow plus ALS treatment group was more experimental when 
compared to the use of fully allogeneic Lewis bone marrow plus ALS as a 
positive control treatment group, although there was no statistically significant 
difference in the mean lymphocytic infilration scores between group 4 to group 3.  
The comparison of group 4 to group 2 (ALS+saline, mean lymphocytic infiltration 
1.5+0.6, n=8, p NS) was included to control for the effects of IT LDA bone 
marrow, suggesting that the addition of ALS to the IT BMC treatment regimen 
was not as effective in immunomodulating the host immune system in this low 
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responder strain combination, compared to the DA to Lewis strain combination.  
The difference in the mean lymphocytic infiltration scores between group 2 and 
group 3 approached statistical significance (p=0.07), suggesting a physiologic 
role for IT Lewis BMCs in DA recipients and a synergistic role for ALS in host 
immunomodulation when combined with fully allogeneic Lewis BMCs.  
 
The immunomodulatory effects of IT LDA TECs were compared to those of IT 
Lewis and LDA BMCs.   
 
 
 
 
 
 
 
 
 
Figure 4.22. Lewis to DA Experimental Groups.  Immunomodulation as 
demonstrated by reduced lymphocytic infiltration scores was higher (ANOVA, 
p=0.07) in the positive control group (3, ALS+Lewis BMCs) compared to the IP 
ALS/IT TEC treatment groups (5 and 6).  Treatment groups 5 and 6 were not 
significantly different from group 4 (ALS+LDA BMCs).  Group 7 (ALS+FT-TECs) 
showed the least immunomodulation compared to saline controls (not shown).   
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A one-way ANOVA of the Lewis to DA experimental groups comparing the 
immunomodulatory effects of groups 5 and 6 (IT TEC treatment groups with ALS, 
mean lymphocytic infiltration 1.0+0.33, n=14, or without ALS, mean lymphocytic 
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infiltration 0.88+0.3, n=11) to those of groups 3 (ALS+Lewis BMCs) and 4 
(ALS+LDA BMCs) revealed statistically not quite significant overall differences 
(p=0.07).  Using Dunn’s multiple comparison test to compare groups 4, 5, and 6 
to group 3, there was no significant difference between the use of ALS and live 
LDA TECs or the use of LDA BMCs with concomitant ALS administration in the 
Lewis to DA strain combination.  There was a statistically significant difference 
between group 3 and group 7 (ALS+IT freeze-thawed TECs, mean lymphocytic 
infiltration 2.33+0.67, n=6, p<0.01), reflecting the difference between 
physiologically active BMCs and dead cells such as TECs.  The lack of 
significant differences between the immunomodulatory response to freeze-
thawed TECs with ALS vs. the saline control group further suggests a 
physiological role for both live TECs and BMCs in this experimental model.  
Although a comparison between recipients receiving live TECs and ALS vs. 
recipients receiving freeze-thawed TECs and ALS did not quite reach statistical 
significance (p=0.7), these findings are suggestive of a physiological role for the 
TECs as opposed to a simply antigenic role.   
 
As with the majority of experiments, graft rejection score inconsistencies within 
the treatment groups made those scores unreliable indicators of host 
immunomodulation.  Therefore, mean lymphocytic scores were used.  Overall, 
the Lewis to DA allotransplantation studies revealed the lowest mean 
lymphocytic infiltration scores in the positive control group (ALS+Lew BMCs), 
similar results between experimental groups (ALS+LDA TECs vs. ALS+LDA 
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BMCs), and similar results between negative controls (saline control vs. ALS + 
freeze-thawed TECs).  These results were exactly opposite the results of DA to 
Lewis allotransplantation studies, where highest mean lymphocytic infiltration 
scores occurred in the positive control group (ALS+LDA BMCs), and the lowest 
scores occurred in the negative control groups.  A striking similarity between the 
groups, however, was the placement of the TEC treatment groups somewhere in 
the middle between positive and negative controls.  Intrathymic TECs with 
concomitant intraperitoneal ALS immunomodulated graft lymphocytic infiltration 
scores when compared to saline controls, but not with any statistical significance 
in either strain direction.  Additionally, a comparison between treatment with IT 
TECs and ALS vs. ALS alone failed to demonstrate a statistically significant 
physiologic role for TECs in the Lewis to DA strain combination.  Perhaps this 
reflects the relatively reduced synergistic effect of ALS with IT cellular treatments 
in the Lewis to DA transplants.   
 
The results of the above transplantation studies may be meaningful from an 
educational standpoint, but they may not become clinically relevant if 
immunomodulatory responses are strain dependent.  Therefore, it was 
hypothesized that the differences in treatment responses were related to strain 
combinations.   
 
4.3.3.a. DA Syngeneic and Lewis Syngeneic Graft Controls  
 
Syngeneic and allogeneic transplant results were compared.  (Figure 4.23)
182
Strain Studies
Lew-Lew DA-DA LDA-DA LDA-Lew Lew-DA DA-Lew
0.0
0.5
1.0
1.5
2.0
2.5
Donor/recipient combinations
Ly
m
ph
oc
yt
ic
 in
fil
tr
at
io
n
 
 
 
 
 
 
 
Figure 4.23. Untreated Groups in Various Strain Combinations.  LDA to DA 
transplants and Lewis to DA transplants resulted in stronger alloresponses, 
providing a plausible explanation for differences between the immunomodulatory 
responses using reversed strain combinations.     
 
Syngeneic grafts were included as controls for host immunomodulation.  Both 
graft rejection scores and lymphocytic infiltration scores were significantly lower 
in the control groups as compared to the Lewis to DA allograft group.  (Figure 
4.24 and 4.25)  Not shown, the graft rejection score was 2.83+0.44 for the Lewis 
syngeneic group and 3.33+0.25 for the DA syngeneic group, significantly lower 
than the Lewis to DA allograft group at 3.67+0.22, p<0.05. 
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Figure 4.24.  Lewis to Lewis Syngeneic vs. Lewis to DA Allogeneic Transplants.  
Syngeneic Lewis challenge grafts had statistically significant reductions in graft 
lymphocytic infiltration compared to allogeneic challenge grafts. 
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Figure 4.25. DA to DA Syngeneic vs. Lewis to DA Allogeneic Transplants.  
Syngeneic DA challenge grafts had statistically significant reductions in graft 
lymphocytic infiltration compared to allogeneic challenge grafts. 
 
To further analyze the findings, the strain direction was directly compared to 
determine whether a “high responder” strain combination was the cause of these 
differences in allogeneic response.  There was found to be no significant 
difference between the DA to Lewis compared to the Lewis to DA TEC/ALS 
treatment group in a 21/10 time frame.   
 
 
4.4. DISCUSSION 
 
The transplantation studies used to plot the natural history of allograft rejection 
served to put in perspective the results of the experimental transplantation 
studies.  The original 10/21 time frame, where animals received IP ALS and IT 
inoculation with a 10 day time period before challenge graft placement to the 
RSC that remained in situ for a period of 21 days, was chosen because of its 
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expected success.  The results indicating that TECs were not as effective as 
hypothesized led to a shift in the time frame to the 21/10 day protocol.  
Although some of the results were suggestive of immunomodulation by TECs, 
the null hypothesis was disproven.  One reason might have been the effect of 
prolonged in vitro culture of TECs prior to their use.  Repeated trypsinization at 
cellular passaging could have resulted in down regulation of surface antigen 
molecule expression, particularly MHC antigens, making the cells less 
tolerogenic.  Since BMCs had neither been cultured for a prolonged period in 
vitro nor exposed to trypsinization, down regulation of surface antigenicity 
would not have been likely.  The trypsinization of BMCs would have been an 
educational control, but would not have been clinically applicable since BMCs 
in current pre-transplantation tolerance induction protocols are not exposed in 
such a way.  Another reason for the lack of robust tolerance inducing capacity 
in TECs might have been their proposed dual role in both positive and 
negative T cell selection.  [246] Foreign TECs might be effective in eliminating 
MHC mismatched clones in the host via negative selection while also 
recruiting donor-matched clones via positive selection.  The end result would 
have been void due to this dual role.  The results of these transplantation 
studies are further discussed in Chapter 5.  
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CHAPTER 5.  
DISCUSSION AND OVERVIEW 
 
 
Successful organ, tissue, or cell transplantation is dependent on two primary 
factors: 1) achieving technical success, which maximizes tissue/organ 
engraftment and survival, and 2) avoiding immune rejection of the graft.  
Previous transplant protocols have focused on minimizing deleterious immune 
responsiveness, and allograft rejection, by either minimizing graft 
immunogenicity or by modifying the host immune environment by systemically 
suppressing immunoreactivity.   
 
Interest in the thymus, and thymic induction of central tolerance, has increased 
over the last several years as a consequence of studies demonstrating the 
induction of immunological tolerance following the placement of donor antigen 
within a host thymus with concomitant depletion of the peripheral lymphocyte 
population.  In the initial landmark report, isolated pancreatic islets of 
Langerhans, transplanted to the thymus of adolescent rats with a concomitant 
single dose of anti-lymphocyte serum, were challenged after 200 days of graft 
residence by a second graft of donor-matched pancreatic islets placed in the 
renal subcapsular space [247].  Apparent immunological tolerance was 
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observed, as indicated by the failure of the host to reject the challenge islet graft.  
This tolerance was proven to be donor-specific because of the rejection of third 
party control grafts.  Subsequently, numerous other studies have reported similar 
outcomes using a variety of cell types and/or antigen sources as the IT inoculum 
[121, 124, 126, 127, 129, 248-251].  It was hypothesized from these studies that 
the IT administration of novel antigens resulted in immune reeducation and 
specific tolerance to the introduced antigens.  These reports stimulated 
significant interest in the thymus and the thymic cells involved in this process, 
including the TEC.  The epithelial nature of TECs would suggest that these cells 
would be highly amenable to culture and to in vitro manipulation.  To show the 
efficacy of this paradigm, the feasibility of TEC isolation and proliferative culture 
had to be demonstrated and established.  TECs were isolated and cultured from 
neonatal thymi of several rat strains.  The cells were manipulated for extensive 
characterization in differing culture conditions.  Valuable information was 
gathered regarding the establishment, maintenance, and manipulation of primary 
keratinocyte cultures.   
 
 
5.1. THYMIC EPITHELIAL CELL CHARACTERISTICS 
 
A continuous cell line of TECs was necessary for disproving the null hypothesis 
that IT inoculation of TECs with concomitant ALS would induce donor-specific 
tolerance.  It was soon discovered that these cells could not be easily established 
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in primary culture, and this led to investigations on these limitations.  Initial 
attempts using mammalian cell culturing techniques in commonly used media 
formulations for epithelial culture led to the outgrowth of scattered, slow 
proliferating cells that mostly resembled fibroblasts.  Literature review on the 
primary culture establishment of specialized epithelial cells (keratinocytes) 
pointed towards the supplementation of medium with various growth factors 
(insulin-like growth factor, bovine pituitary extract) and the reduction/removal of 
serum from the medium.  The combined focus of previous experience with 
primary culture of other cell types and further literature searches finally pointed to 
references [252] which alluded to the low calcium culture methods that eventually 
led to successful establishment of a rat TEC line.   
 
Calculations of the calcium levels in the medium varieties that were initially used 
for this project showed them to be significantly higher than the calcium levels 
maintained in reported keratinocyte permissive media formulations.  In 
retrospect, the inability to easily trypsinize those higher calcium cultured cells that 
were able to attach to the growth surface, the limited proliferative capacity of the 
cells, and the early differentiation of the cells into a dendritic phenotype 
suggested an interrelated cause--calcium levels were suspected.  
 
Histologic techniques used to identify the cells as TECs demonstrated the 
presence of structures and proteins (desmosomes and keratin IFs) characteristic 
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of epithelial-derived keratinocytes.  This led to the question of why these 
particular keratinocytes would not proliferate in culture. 
 
Following a low calcium, serum free method for establishing primary TECs in 
culture proved difficult despite correspondence with authors who reported ease 
of culture.  Attempts to recapitulate experiments using the reported components 
(approximately 70 additives) were technically difficult due to the trace 
concentrations necessary.  To assist the learning process, Dr. Jun Hayashi at the 
University of Maryland generously donated a sample of the custom formulation, 
WAJC, to the laboratory.  The TEA-3A1 cell line was derived from neonates of 
the LDA strain of rat (Lewis/Dark Agouti cross) [132] and is of the same genetic 
background as the new line of TECs derived in this study.  Not coincidentally, the 
use of WAJC medium in the initial establishment of primary cultures of rat TECs 
was limited to the LDA strain.  As presented in the results section on primary 
culture isolation of TECs (Chapter 2), thymic tissue isolated from the other rat 
strains did not respond as favorably as thymic tissue from LDA rats.  The LDA rat 
cell line for this project, designated OKTE4-01, was compared to the TEA-3A1 
cell line by examining for cytokeratin content and structural elements.  The 
presence of desmosomes and tonofilament bundles is typical and characteristic 
of epithelial cells, and the ultrastructural visualization of these structures allowed 
these thymus-derived cells to be characterized as TECs.  These cells appeared 
identical in morphology and cellular proliferation to the LDA TEC cell line 
established for this project.  While the OKTE4-01 cell cultures spontaneously 
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transformed, it was a struggle to obtain a monolayer of cells from the other strain.  
It was hypothesized that the ability to establish rat TEC primary culture might be 
strain specific.  Further, it was hypothesized that the morphological nature and 
proliferative capacity of TECs was calcium related.   
 
Indeed, it was demonstrated that TECs maintained in medium containing low 
calcium levels expressed significant differences from TECs maintained in 
medium containing high calcium.  Specifically, proliferative capacity, morphologic 
appearance, intercellular spacing, and macula adherens density were found to 
be dependent upon calcium levels in the media.  (Chapter 3)  
 
The information gained from these findings was applied to primary culture 
techniques.  It was hypothesized that the failure of DA TECs to attach early in 
the process of the in vitro isolation and culture using the low-calcium GWAJC 
medium could be due to lack of calcium-dependent cellular attachment.  When 
the medium calcium concentrations were increased, DA thymic tissue 
responded as expected—there was adequate tissue attachment to the tissue 
growth surface.  Unfortunately, when medium with higher calcium 
concentrations was used, the attached DA tissue would adhere so tightly to 
the surface that trypsinization was nearly impossible due to lifting of cells in 
sheets.  Within a short time frame, approximately 7-10 days, the DA cells 
consistently assumed a terminally differentiated, dendritic appearance.  After 
many attempts to grow the cells in different types of media with different 
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supplements, the idea to establish attachment to the growth surface early in 
the primary culture establishment process with higher calcium medium 
followed by the withdrawal and replacement of medium with lower calcium 
medium resulted in the successful culture isolation of DA rat TECs.  This 
technique of early high calcium culture followed by a switch to low calcium 
culture was applied to the other strains of thymic tissue and resulted in 
successful culture establishment of primary TECs.  As part of this project, 
primary rat TEC cultures were derived from several different strains.  It is 
hypothesized that the application of this new method of high to low calcium 
medium switch technique could lead to the successful primary culture 
establishment of many other types of keratinocytes in varying strains and 
species.   
 
Thymic epithelial cell lines, both OKTE4-01 and TEA-3A1, grown in WAJC 
medium supplemented with 2.5% DMEM were highly proliferative (with doubling 
times of ≈48hrs), and were readily passaged via light trypsinization (0.05%).  
Increasing medium calcium concentration induced a distinct change in cell 
morphology, including the approximation of cell boundaries, and the formation of 
increased areas of cell contact.  Upon examination with electron microscopy, 
cells maintained in high calcium medium appeared more closely spaced, with 
confluent TECs closely apposed to adjacent cells and spread evenly across the 
growth surface.  Cells maintained in low calcium medium appeared more widely 
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spaced, with visible gaps between adjacent cells and fewer regions of closely 
apposed TECs.   
 
As stated above, the in vitro maintenance of the new OKTE4-01 cell line, as 
well as the TEA-3A1 line, required a significantly reduced medium calcium 
concentration to 0.098mM, which was achieved using WAJC404A medium 
supplemented with 2.5% DMEM.   (DMEM alone has a calcium concentration 
of 1.815 mM.)  Previous studies have reported using Nutrient Mixture (Ham’s) 
F12, whose calcium levels are already extremely low (0.299mM calcium) in 
comparison to other media, to achieve the low calcium levels required for 
successful TEC culture [149, 157].  However, culture of both OKTE4-01 and 
TEA-3A1 in Ham’s F12 resulted in conversion of the cultured cells to a non-
proliferative state, displaying closely approximated adherent cell boundaries 
and increased adherence to the growth surface similar to that observed in our 
TEC populations cultured in high calcium WAJC404A medium. 
 
These observations indicate that increased desmosome formation results from 
increased medium calcium concentrations, and would explain the strong 
adherence characteristics, both between cells and to the growth surface, 
demonstrated by cells maintained in high calcium conditions.  This is the first 
instance in which the calcium-dependent morphological changes in TECs 
have been quantified and statistically analyzed.  These calcium-dependent 
adherence characteristics may not be limited to thymic epithelium only.  
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Desmosome formation in mouse epidermal keratinocytes was documented 
ultrastructurally just one to two hours following elevations in medium calcium 
levels.  [221] An unexpected finding upon TEM examination of TECs 
maintained in low calcium medium was the presence of laminar, whorled and 
curvilinear cytoplasmic densities.  These structures were found near keratin 
IFs and were thought to be immature keratin protein structures.  Their 
significance was not determined, although future studies using labeling 
techniques in combination with electron microscopy might be useful in 
determining their composition. 
 
Numerous studies demonstrate induction of desmosome formation and cell 
differentiation by increasing extracellular calcium levels [253] In fact, a 
“dramatic reorganization” was shown to occur concurrently between 
microtubules, microfilaments, and keratin IFs only hours after cell culture 
medium calcium changes in human epidermal keratinocytes [254].  Many 
studies attempt to demonstrate that calcium induced cell differentiation 
mechanisms are not all-or-none phenomena [255].  While the observations 
presented here indicate that once exposed to higher levels of calcium, cells 
form adherent junctions with other cells that cannot be reversed, in some 
epithelial cell cultures it may be of value to reduce medium calcium 
concentrations with the intent of decreasing intercellular adhesion to allow for 
increased cell proliferation.   
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Serendipitously, the LDA rat thymic tissue culture isolation and maintenance in 
GWAJC as described in the techniques section resulted in spontaneous 
transformation into the OKT4-01 cell line, allowing a constant supply of TECs for 
the remainder of this project.  Additionally, the OKT4-01 cell line allowed for the 
focused studies on calcium-dependent cellular changes and served as a control 
cell for comparison with the TECs from other rat strains.  The evaluation of the 
effects of calcium on TECs revealed that TECs maintained in high calcium media 
became highly differentiated and did not exhibit logarithmic growth, while TECs 
maintained in low calcium media supplemented with specific growth factors could 
be used to maintain these partially differentiated cells at high mitotic frequency in 
vitro.  It was also an important finding that a minimum calcium level was 
necessary for TEC establishment and maintenance.   
 
Based on the irreversible nature of changes induced by high calcium exposure, 
we have concluded that our ability to passage these cells was based primarily on 
initial culture conditions, strain of donor tissue, and lack of exposure to calcium, 
rather than on the passaging protocol.  This could explain why a limited number 
of thymus-derived epithelial cell lines have been documented among humans, 
mice, and rats.  [214, 256-261].    
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5.2. GENERATION OF IMMUNOLOGIC UNRESPONSIVENESS TO 
INTRATHYMIC TRANSPLANTATION OF ALLOGENEIC TISSUE 
 
Due to their organ of origin and their hypothesized role in the process of 
immune education, modified TECs were considered excellent candidate cells 
for induction of immune tolerance in models of autoimmunity and/or 
transplantation.  Statistical analysis of the graft scores in allograft recipients 
pretreated with IT TECs and ALS comparing negative controls (sham 
experiments) and positive controls (IT BMCs and ALS) reflected some 
reduction in lymphocytic infiltration, effectively shifting the time course of graft 
rejection to the left (reducing the expected level of rejection at a given time 
point).  However, numerical values did not reach statistical significance to 
support the hypothesis that TECs and ALS would be better candidates than 
BMCs and ALS for inducing donor-specific tolerance, despite changing the 
treatment to challenge time frame, changing the in situ challenge graft time 
frame, altering the type of donor tissue to avoid autolysis, switching from a 
high responder to a low responder strain combination, and increasing 
treatment group sizes.  The comparison between positive and negative control 
groups did reach statistical significance with p values < 0.3, indicating that the 
IT inoculation of cells previously proven to induce donor-specific tolerance was 
effective in this particular animal model of allograft rejection.  A comparison 
between the donor-specific tolerance inducing capacity of living and non-living 
TECs with ALS also did not reach statistical significance, despite the fact that 
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non-living TECs were also not significantly more effective than saline in 
inducing donor-specific tolerance.  In many of the transplantation experiments, 
p values reached near statistical significance, suggesting a dual role for TECs 
that might have confounded the results.  If both positive and negative 
tolerance induction mechanisms were in effect, one would have expected 
equivalent results.  Following peripheral lymphocyte depletion, allogeneic 
TECs injected intrathymically might be retaining immature T cell clones 
specific for the allogeneic MHC, thus actually sensitizing the host.  
Simultaneously, they might be inducing tolerance in the host by eliminating T 
cells that are reactive to the new “self” antigens, thus buffering the 
sensitization, producing an overall neutral effect.   
 
Evidence of sensitization, as demonstrated by accelerated graft rejection, was 
not seen in the transplant recipients.  This could be related to the dual role of 
foreign IT TECs, or the immunoprivileged graft site.  The relatively placid effect 
of TECs compared to BMCs might actually be of benefit when considering the 
use of TECs as a platform cell for gene therapeutic techniques.  The effects of 
genetically altered TECs on the host immune system have yet to be evaluated.   
 
Terminal differentiation of cells exposed to high calcium levels in vivo might 
also affect the results of TEC transplantation to the host thymus.  Specifically, 
inoculating TECs that were originally maintained in low calcium in vitro 
conditions into relatively high calcium in vivo conditions might have resulted in 
terminal differentiation of these proposed immunomodulatory cells, inhibiting a 
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physiologic role.  In view of the sensitivity of TECs to calcium levels, gene 
therapeutic protocols employing higher calcium levels might have negative 
effects on the physiologic role of TECs. 
 
Another possible explanation for the less than statistically significant results 
was the use of TECs derived from an F1 hybrid rat strain due to limitations in 
cell supply.  Future studies might involve a different animal model with the 
unlimited availability of fully allogeneic TECs. 
 
 
5.3. GENETIC TRANSFECTION OF THYMIC EPITHELIAL CELLS 
 
Integrating gene therapy techniques with IT transplantation of TECs could 
provide a potential transgene platform for transfection of novel antigens and 
subsequent IT transplantation of genetically altered TECs to modify host 
immunity.  Sufficient numbers of TECs were made available by early experiments 
to pave the way for future gene transfer studies.  As a sideline to transplantation 
studies, the feasibility of TECs to serve as such a vehicle for the delivery of novel 
genes was investigated using various gene therapeutic techniques.  TECs were 
transfected with green and red fluorescent protein reporter genes using liposome 
techniques and electroporation, and with humanized green fluorescent protein 
using adenoviral-associated vectors with transient expression encoded proteins 
with all gene therapy technique applications.   
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5.4. ROLE OF TECs FOLLOWED BY A SECOND GRAFT 
 
TECs are normal thymic residents, representing a significant portion of the 
cells which constitute the stroma of the thymus.  Although their precise 
function has not been definitively elucidated, it is known that TECs are 
involved in the process of T cell development and immune education.  
Experimental evidence indicates that TECs are involved in the process of 
positive thymic selection, which selects a population of immature T cells for 
retention within the thymus based on the ability of their TcR to interact with 
self-recognizing MHC proteins expressed on TECs [62, 263, 264].  Other 
reports suggest an ability of TECs to act as an APC within the thymus, and to 
present antigens to maturing thymocytes in the process of negative selection, 
in which T cell subsets with a high affinity for self-MHC antigen are selected 
and deleted, thereby excluding cells capable of recognizing and responding to 
autologous antigens from the peripheral immune repertoire.  [62, 73, 265, 
266].  Some reports go so far as to ascribe both positive and negative 
selection functions to TECs, with functional effects determined by the cellular 
location within the thymus [99, 267], or by the degree of expression of MHC 
antigens [268].  Almost all nucleated cells, TECs included, express MHC Class 
I antigen, and as APCs, TECs also express MHC Class II molecules.  The 
objective of this project was to employ in vitro TECs most closely mimicking an 
in vivo functional role.  Hence, the effects of donor-MHC-specific tolerance 
induction studies were expected to potentially reveal new information about 
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how TECs function in the immune response and clonal selection.  While it has 
been shown that interferon gamma (IFN-γ) can induce the upregulation of 
MHC Class I and II molecules on TECs [269], this was felt to be less reflective 
of usual in vivo conditions.  Additionally, a direct comparison between the 
effects of unaltered IT allogeneic bone marrow with concomitant 
immunosuppression and the effects of unaltered IT allogeneic TECs with 
concomitant immunosuppression is a novel approach, and altering the TECs 
with IFN-γ might be interesting as a focus for future experiments. 
 
As with any treatment, significant potential complications may occur in 
performing IT cellular transplants for tolerance induction.  One complication 
considered was accelerated graft rejection.  In one background study, it was 
shown that IT injection of purified liver and spleen derived allogeneic dendritic 
cells (DC) “…plus a single dose of ALS did not prolong allogeneic islet graft 
function but rather induced accelerated rejection of islet allografts” 
administered intraportally.  [240]  
 
Intrathymic inoculation of LDA TECs prior syngeneic Lewis challenges were used 
to control for accelerated graft rejection, and no such response was found.    
 
This project took advantage of the high mitotic frequency and proliferative 
capacity of culture immortalized TECs for a continuous supply of cells to use in 
transplantation experiments investigating the ability of TECs to induce donor-
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MHC specific tolerance to subsequent allografts, a novel approach towards to 
tolerance induction because of the inherent nature of the TECs.  Successful 
transplantation and gene transfer experiments using TECs derived from primary 
culture were performed once cells were established.  These studies appeared to 
demonstrate the modulation of host immunity, with reduced allograft rejection 
following IT TEC transplantation.  Despite indications of modified immunity, 
success, as gauged by complete protection of the challenge graft from immune 
destruction, was not achieved.  Initial essays at transfection of a novel gene into 
these cells demonstrated definite expression of the reporter gene in primary 
cultures of TECs.  However, stable transfer of novel genes to these sensitive 
primary cell lines will require further optimization.  The immunomodulatory 
capacity of transgenic TECs upon IT transplantation will be the focus of a future 
project. 
 
The above works, while unique in revealing potentially widespread 
applications of conditions associated with primary epithelial culture, TECs from 
many different strains, and the donor-specific tolerance inducing capacity of 
TECs, served as precursors towards the development of a treatment paradigm 
combining IT transplantation with gene therapy to allow introduction and 
prolonged expression of antigens within the thymus.  The application of gene 
therapy to TECs destined for IT inoculation for tolerance induction is also a 
novel approach. 
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The use of cultured-isolated MHC-mismatched TECs for host IT inoculation as 
a model to induce donor-specific tolerance is a unique approach.  Since the 
inception of this project, a research group at the Tohoku University School of 
Medicine in Japan chose to investigate the effects of IT thymic stromal cell 
transplantation in a mouse model of allogeneic skin transplantation, 
demonstrating prolongation of graft survival. [269]   
 
Combining gene therapy with IT transplantation using a unique cell type, the 
TEC, is hypothesized to serve as a means to introduce immunogenic proteins 
into the thymus of a host.  Once successful TEC transfection protocols can be 
established, follow-up studies would include IT transplantation of TECs 
transfected with genes encoding specific novel antigens and investigations 
into the successful expression of these genes within the thymic environment.  
An indirect measure of gene expression would be an assessment of 
modification of host immunity following IT transplantation of genetically 
modified TECs.  Further investigations would be necessary to optimize the 
preliminary TEC transfection results before going forward with such an 
ambitious project.   
 
“Donor/recipient MHC class II matching permits survival of experimental 
allografts without permanent immunosuppression, but is not clinically 
applicable due to the extensive polymorphism of this locus.” [95] The 
transplantation tolerance induction arm of this project using MHC mismatched 
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TECs served as a precursor towards the use of IT transplantation of 
genetically modified TECs expressing novel donor MHC molecules for 
induction of graft specific tolerance in virtually any population of 
transplantation recipients.  Since TECs are amenable to culture techniques, 
they were hypothesized to provide an appropriate transgene platform for the 
transfection of novel antigens and subsequent transplantation of altered cells.  
Based on the finding that the majority of transplant rejection is due to an MHC 
Class I mismatch between the donor and the recipient, using donor-matched 
TECs transfected with a mismatched MHC Class I specific gene sequence for 
IT inoculation might provide insight into transplantation tolerance induction 
mechanisms.  Follow-up studies would investigate the ability of TECs 
transfected with a gene sequence encoding a specific antigen and inoculated 
into the thymus to induce antigen specific tolerance.  In these experiments, 
genetically modified syngeneic TECs transplanted to the thymic 
microenvironment would be assessed regarding their ability to present a 
foreign antigen to the developing immune system of a young recipient, 
resulting in permanent modification of host immunity.  Host specific TECs 
would be transfected with the gene encoding a specific antigen and injected IT 
following a single IP injection of ALS.  Finally, the immune response to 
subsequent peripheral administration of this antigen would be viewed as a 
reflection of central tolerance induction.   
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The most successful donor-specific tolerance induction strategies would benefit 
graft recipients suffering from various comorbidities associated with non-donor-
specific immunosuppressive drug regimens.  The clinical relevance and 
practicality of this approach in the prevention and treatment of immune diseases 
and hypersensitivity states is yet to be determined, but as researchers continue 
to discover and genetically sequence the autoantigens responsible for the 
development of specific autoimmune diseases, the feasibility of using such an 
approach becomes more realistic.  For example, IT transgenic TEC expression of 
autoantigens targeted by the immune system in type I diabetes mellitus could 
induce tolerance to these autoantigens, resulting in the prevention of the immune 
mediated destruction of insulin producing pancreatic beta cells.  Most ambitious, 
due to the risk of inadvertently exposing a healthy recipient to a serious lifelong 
autoimmune disease, is the idea of applying a combination of IT tolerance 
induction strategies combined with gene therapy to potentially be used as a 
cellular vaccine in children to prevent the early onset of autoimmune diseases 
such as autoimmune thyroiditis or diabetes. 
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Procedure or Event Date Surgeon or Scientist 
Limb and tooth tr.  Late 1700’s John Hunter 
Xenogeneic skin tr.  Late 1700’s G. Baronio 
First skin autograft 1823 Carl Bunger 
Allograft tr.  1863 Paul Bert 
Skin allografts 1880’s Astley Cooper 
Corneal tr. Late 1800’s Edward Zim 
Surgical tr. techniques Early 1900’s Alexis Carrel, Charles Guthrie 
Renal tr. (dogs/goats) 1902  
Skin allograft 1908 Jacques Louis Reverdin 
Cadaveric knee joint replacement  1908 Eric Lexer 
First blood transfusions 1918  
United States Navy Tissue Bank  1949  
x-radiation  1950’s Main and Prehn 
Living-related human kidney tr. 
between identical twins 
1954 Joseph E. Murray, David Hume, 
Harrison, Merrill 
Histocompatibility system  1958 Jean Dausset 
Non-twin kidney tr.  1959 Joseph E. Murray 
Heart valve tr.  1962  
Cadaveric kidney tr.   1962 David Hume 
Liver tr.   1963 Thomas Starzl 
Lung tr. 1963 James Hardy 
Kidney-pancreas tr. 1966  
Human heart tr.  1967 Christian Bernard 
Pancreas tr. 1966 Richard C. Lillehei, William D. Kelly 
Cryopreservation  1970’s  
Living related pancreas tr.   1979  
Heart-lung tr.   1981 Norman Shumway, Bruce Reitz 
Cyclosporine 1982 Clinical use 
Artificial heart tr. 1982  
Single-lung tr. 1983  
Cyclosporine  1983 FDA approval 
Heart-liver tr. 1984 Thomas Starzl 
Baboon to human heart tr.  1984  
Establishment of UNOS 1984  
Double lung tr. 1987  
Partial lung tr. 1991  
Small intestine tr. 1991  
Split-liver tr. 1996  
Islet tr.   1999 James Shapiro, Edmonton protocol 
Table A. Historical Events in Transplantation.  List of major events from late 18th 
century through the 21st century.  tr. = transplantation
205
CITATIONS 
 
1. Tilney, N.L., Transplantation and Transplantation Biology: From Legend to 
Reality, in Transplantation Biology: Cellular and Molecular Aspects, N.L. 
Tilney, Editor. 1996, Lippincott-Raven Publishers: Philadelphia. p. 1-10. 
2. Cryobiogenics, Xenotransplantation: History of Transplantation. 2000. 
3. Medawar, P.B., Memoir of a thinking radish. 1986: Oxford. p. Oxford 
University Press. 
4. Hume, D.M., J.P. Merrill, and B.F. Miller, Experiences with renal 
homotransplantation in the human: report of nine cases. J Clin Invest, 
1955. 34: p. 327-382. 
5. Van der Werf, W.J., et al., Procurement, preservation, and transport of 
cadaver kidneys. Surgical Clinics of North America, 1998. 78(1): p. 41-54. 
6. Southard, J.H. and F.O. Belzer, Organ preservation. Annual Review of 
Medicine, 1995. 46: p. 235-47. 
7. Brent, L.B. and R.A. Sells, Notes on the history of tissue and organ 
transplantation., in Organ transplantation: current clinical and 
immunological concepts. 1989, Balliere Tindall: London. 
8. Kuss, R. and P. Bourget, An illustrated history of organ transplantation. 
1992, Sandoz Laboratories: Rueil-Malmaisson, France. 
9. Saunders, J.B., A conceptual history of transplantation, in Transplantation, 
J.S. Najarian and R.L. Simmons, Editors. 1972, Lea and Febiger: 
Philadelphia. p. 3-25. 
10. Bloodbook, The history of blood transfusion in medicine, Bloodbook.com, 
Information for Life. 2004, not reported. 
11. Mollison, P.L. and P. Engelfriet, Blood transfusion. Seminars in 
Hematology, 1999. 36(4 Suppl 7): p. 48-58. 
12. Keck, B.M., et al., Worldwide thoracic organ transplantation: a report from 
the UNOS/ISHLT International Registry for Thoracid Organ 
Transplantation. Clinical Transplants, 1999: p. 35-49. 
13. Gonzalez-Posada, J.M., et al., Immunosuppression with sirolimus, 
cyclosporine, and prednisone in renal transplantation. Transplantation 
Proceedings, 2002. 34(1): p. 99. 
14. Fisher, J.S., E.S. Woodle, and J.R.J. Thistlethwaite, Kidney 
transplantation: graft monitoring and immunosuppression. World Journal 
of Surgery, 2002. 26(2): p. 185-93. 
15. Wilkinson, A., Progress in the clinical application of immunosuppressive 
drugs in renal transplantation. Curr Opinion in Nephrology & Hypertension, 
2001. 10(6): p. 763-70. 
206
16. Mosimann, F., et al., Twelve years of liver transplantation in Lausanne. 
Revue Medicale de la Suisse Romande, 2001. 121(2): p. 95-9. 
17. Goddard, S. and D.H. Adams, New approaches to immunosuppression in 
liver transplantation. J Gastroenterol Hepatol, 2002. 17(2): p. 116-26. 
18. Gebhardt, B.M. and W. Shi, Experimental corneal allograft rejection. 
Immunologic Research, 2002. 25(1): p. 1-26. 
19. Korossis, S.A., J. Fisher, and E. Ingham, Cardiac valve replacement: a 
bioengineering approach. Biomed Mater Eng, 2000. 10(2): p. 83-124. 
20. Murdoch, T.B., et al., Methods of human islet culture for transplantation. 
Cell Transplant, 2004. 13(6): p. 605-17. 
21. Juang, J.H., et al., Beneficial influence of glycemic control upon the growth 
and function of transplanted islets. Diabetes, 1994. 43(11): p. 1334-9. 
22. Gupta, S. and J.R. Chowdhury, Hepatocyte transplantation: back to the 
future. Hepatology, 1992. 15: p. 156-161. 
23. Mito, M. and M. Kusano, Hepatocyte transplantation in man. Cell 
Transplant, 1993. 2: p. 65-74. 
24. Schumacher, I.K., T. Okamato, and B.H. Kim, Transplantation of 
conditionally immortalized hepatocytes to treat hepatic encephalopathy. 
Hepatology, 1996. 24: p. 337-342. 
25. Jensen, P.E., Mechanisms of antigen presentation. Clin Chem Lab Med, 
1999. 37(3): p. 179-86. 
26. Ketchum, R.J., et al., Failure of nonimmunogenic islet allografts to induce 
donor-specific immunological unresponsiveness. Cell Transplantation, 
1994. 3(2): p. 179-86. 
27. Wilkinson, B., J.J. Owen, and E.J. Jenkinson, Factors regulating stem cell 
recruitment to the fetal thymus. Journal of Immunology, 1999. 162(7): p. 
3873-81. 
28. Vicente, A., et al., Histogenesis of the epithelial component of rat thymus: 
an ultrastructural and immunohistological analysis. Anatomical Record, 
1996. 244(4): p. 506-19. 
29. Shortman, K. and L. Wu, Early T lymphocyte progenitors. Annual Reviews 
of Immunology, 1996. 14: p. 29-47. 
30. Duijvestijn, A.M. and E.C.M. Hoefsmit, Ultrastructure of the rat thymus: the 
micro-environment of T-lymphocyte maturation. Cell Tissue Res, 1981. 
218: p. 279-92. 
31. Hwang, W.S., et al., Ultrastructure of the rat thymus.  A transmission, 
scanning electron microscope, and morphometric study. Laboratory 
Investigation, 1974. 31: p. 473-487. 
32. Von Gaudecker, B., et al., Immunohistochemical characterization of the 
thymic microenvironment.  A light-microscopic and ultrastructural 
immunocytochemical study. Cell Tissue Res, 1986. 244: p. 403-412. 
207
33. Von Gaudecker, B., Functional histology of the human thymus. Anat 
Embryo, 1991. 183: p. 1-15. 
34. Hogquist, K.A., S.C. Jameson, and M.J. Bevan, The ligand for positive 
selection of T lymphocytes in the thymus. Current Opinion in Immunology, 
1994. 6(2): p. 273-8. 
35. Milicevic, Z. and N.M. Milicevic, Ultrastructure of different types of thymic 
epithelial cells in normal and cyclosporin-A-treated rats. Anatomy & 
Embryology, 1997. 196(2): p. 171-83. 
36. von Gaudecker, B., et al., Immunohistochemical characterization of the 
thymic microenvironment. A light-microscopic and ultrastructural 
immunocytochemical study. Cell & Tissue Research, 1986. 244(2): p. 403-
12. 
37. Kasai, M., et al., Difference in antigen presentation pathways between 
cortical and medullary thymic epithelial cells. European Journal of 
Immunology, 1996. 26(9): p. 2101-7. 
38. Lo, D., et al., Thymic stromal cell specialization and the T-cell receptor 
repertoire. Immunologic Research., 1997. 16(1): p. 3-14. 
39. van Ewijk, W., et al., Thymic microenvironments, 3-D versus 2-D? 
Seminars in Immunology., 1999. 11(1): p. 57-64. 
40. Naquet, P., M. Naspetti, and R. Boyd, Development, organization and 
function of the thymic medulla in normal, immunodeficient or autoimmune 
mice. Seminars in Immunology, 1999. 11(1): p. 47-55. 
41. Bonomo, A. and P. Matzinger, Thymus epithelium induces tissue-specific 
tolerance. Journal of Experimental Medicine, 1993. 177(4): p. 1153-64. 
42. Surveyor, G.A. and D.R. Brigstock, Immunohistochemical localization of 
connective tissue growth factor (CTGF) in the mouse embryo between 
days 7.5 and 14.5 of gestation. Growth Factors, 1999. 17(2): p. 115-24. 
43. Freitas, C.S., et al., Epidermal growth factor modulates fetal thymocyte 
growth and differentiation. Developmental Immunology, 1998. 5(3): p. 169-
82. 
44. Rosenheimer-Goudsmid, N., et al., p53 and thymic 'death by neglect': 
thymic epithelial cell-induced apoptosis of CD4+8+ thymocytes is p53-
independent. Cell Death & Differentiation., 2000. 7(3): p. 241-9. 
45. Moulian, N., et al., Functional Fas expression in human thymic epithelial 
cells. Blood, 1999. 93(8): p. 2660-70. 
46. Chen, W.F., et al., Multiple types of cytokines constitutively produced by 
an established murine thymic epithelial cell line. European Cytokine 
Network., 1992. 3(1): p. 43-52. 
47. Coutinho, A., et al., The role of thymic epithelium in the establishment of 
transplantation tolerance. Immunological Reviews., 1993. 133: p. 225-240. 
208
48. Ashton-Rickardt, P., et al., Evidence for a differential avidity model of T 
cell selection in the thymus. Cell, 1994. 76(4): p. 651-63. 
49. Zhao, Y., et al., Skin graft tolerance across a discordant xenogeneic 
barrier. [see comments]. Nature Medicine, 1996. 2: p. 11. 
50. Tomatis, L. and L. Wang, The presence of lymphocytes in long term 
cultures of newborn mouse thymic epithelium. Proc Soc Exp Biol Med., 
1965. 120(2): p. 472-80. 
51. Zinkernagel, R.M. and P.C. Doherty, Restrictionof in vivo T cell-mediated 
cytotoxicity in lymphocytic choriomeningitis within a syngeneic or 
semiallogeneic system. Nature, 1974. 248: p. 701-710. 
52. Berg, L.J., A.M. Pullen, and B. Fazekas De St. Groth, Antigen/MHC-
specific T cells are preferentially exported fromthe thymus in the presence 
of their MHC ligand. Cell, 1989. 58(1035-46). 
53. Delaney, J.R., et al., Differences in the level of expression of class I major 
histocompatibility complex proteins on thymic epithelial and dendritic cells 
influence the decision of immature thymocytes between positive and 
negative selection. Proceedings of the National Academy of Science, 
U.S.A., 1998. 95: p. 5235-40. 
54. Zinkernagel, R.M., et al., Restriction specificities, alloreactivity, and 
allotolerance expressed by T cells from nude mice reconstituted with H-2-
compatible or -incompatible thymus grafts. Journal of Experimental 
Medicine, 1980. 151(2): p. 376-99. 
55. Manickasingham, S.P. and C.R.E. Sousa, Mature T cell seeks antigen for 
meaningful relationship in lymph node. Immunology, 2001. 102: p. 381-
386. 
56. Jenkinson, E.J., J.J. Owen, and R. Aspinall, Lymphocyte differentation 
and major histocompatibility copmlex antigen expression in the embryonic 
thymus. Nature, 1980. 284: p. 177-9. 
57. Sprent, J., Fundamental Immunology. T lymphocytes and the thymus, 
1993(W.E. Paul, ed.): p. 75. 
58. Boyd, R.L., et al., The thymic microenvironment. Immunology Today, 
1993. 14: p. 445-59. 
59. Jameson, S.C., K.A. Hogquist, and M.J. Bevan, Positive selection of 
thymocytes. Annual Review of Immunology, 1995. 13: p. 93-126. 
60. Kisielow, P. and H. von Boehmer, Development and selection of T cells: 
facts and puzzles. Adv Immunol, 1995. 58: p. 87-209. 
61. James, S.C., K.A. Hogquist, and M.J. Bevan, Positive selection of 
thymocytes. Annual Reviews of Immunology, 1996. 13: p. 93-126. 
62. Benoist, C. and D. Mathis, Positive selection of the T cell repertoire: where 
and when does it occur? Cell, 1989. 58(6): p. 1027-33. 
209
63. Vukmanovic, S., The molecular jury: deciding whether immature 
thymocyte should live or die. Journal of Experimental Medicine, 1996. 184: 
p. 305-9. 
64. Johnston, R.J., Current concepts: Immunology, monocytes and 
macrophages. N Engl J Med, 1988. 318: p. 747-752. 
65. Pavlovic, D., et al., Effect of interferon-gamma and glucose on major 
histocompatibility complex class I and class II expression by pancreatic 
beta- and non-beta-cells. J Clin Endocrinol Metab, 1997. 82(7): p. 2329-
36. 
66. Nickoloff, B.J. and L.A. Turka, Immunological functions of non-
professional antigen-presenting cells: new insights from studies of T-cell 
interactions with keratinocytes. Immunology Today, 1994. 15: p. 464-469. 
67. Fritsch, P., E. Diem, and H. Honigsmann, Langerhans cells in cell culture: 
Survival and identification. Arch. Dermatol. Forsch., 1973. 248: p. 123. 
68. Setum, C.M., et al., The potency of splenic dendritic cells as alloantigen 
presenters in vivo. Quantitation of the number of cells required to achieve 
graft rejection. Transplantation, 1990. 49(6): p. 1175-7. 
69. Jansen, A., et al., Immunohistochemical characterization of monocytes-
macrophages and dendritic cells involved in the initiation of the insulitis 
and beta-cell destruction in NOD mice. Diabetes, 1994. 43: p. 667-674. 
70. Steinman, R.M., et al., Identification of a Novel Cell Type in Peripheral 
Lymphoid Organs of Mice: V. Purification of Spleen Dendritic Cells, New 
Surface Markers, and Maintenance In Vitro. J. Exp. Med, 1979. 149: p. 1-
16. 
71. Speiser, D.E., et al., Positive and negative slection of T cell receptor V 
beta domains controlled by distinct cell populations in the thymus. Journal 
of Experimental Medicine, 1989. 170: p. 2165-70. 
72. van Ewijk, W., E.W. Shores, and A. Singer, Crosstalk in the mouse 
thymus. Immunology Today, 1994. 15: p. 214-17. 
73. Speiser, D.E., et al., Positive and negative selection of T cell receptor V 
beta domains controlled by distinct cell populations in the thymus. Journal 
of Experimental Medicine, 1989. 170(6): p. 2165-70. 
74. Saoudi, A., et al., The thymus contains a high frequency of cells that 
prevent autoimmune diabetes on transfer into prediabetic recipients. 
Journal of Experimental Medicine, 1996. 184(6): p. 2393-8. 
75. Bodey, B., et al., Molecular biological ontogenesis of the thymic reticulo-
epithelial cell network during the organization of the cellular 
microenvironment. In Vivo, 1999. 13(3): p. 267-94. 
76. Goldrath, A.W. and M.J. Bevan, Selecting and maintaining a diverse T-cell 
repertoire. Nature, 1999. 402: p. 255-262. 
210
77. Stumbles, P.A. and W.J. Penhale, IDDM in rats induced by thymectomy 
and irradiation. Diabetes, 1993. 42: p. 571-578. 
78. Fukuma, K., et al., Immunologic and clinical studies on murine 
experimental autoimmune gastritis induced by neonatal thymectomy. 
Gastroenterology, 1988. 94: p. 247-283. 
79. Modigliani, Y., et al., Establishment of tissue-specific tolerance is driven by 
regulatory T cells selected by thymic epithelium. Eur J Immunol, 1996. 26: 
p. 1807-1815. 
80. Fowell, D. and D.W. Mason, Evidence that the T cell repertoire of normal 
rats contains cells with the potential to cause diabetes.  Characterization 
of the CD4+ T cell subset that inhibits this autoimmune potential. Journal 
of Experimental Medicine, 1993. 177: p. 627-636. 
81. Fowell, D., et al., eds. The role of subsets of CD4+ T cells in 
autoimmunity. T cell Subsets in Infections and Autoimmune Diseases., ed. 
D. Chadwick and C. Cardew. 1996, John Wiley & Sons, Ltd. 173-182. 
82. Kyewski, B.A., C.G. Fathman, and R.V. Rouse, Intrathymic presentation of 
circulating non-MHC antigens by medullary dendritic cells. An antigen-
dependent microenvironment for T cell differentiation. Journal of 
Experimental Medicine, 1986. 163(2): p. 231-46. 
83. Kirkpatrick, C.D., Duke Hospital Admits to Botching Transplant, in Duke 
Herald Sun. 2003. 
84. Aalamian, Z., Reducing adverse effects of immunosuppressive agents in 
kidney transplant recipients. Prog Transplant., 2001. 11(4): p. 271-82. 
85. Karamehic, J., et al., Review of immunosuppressive drugs in organ 
transplantation. Medicinski Arhiv, 2001. 55(4): p. 243-5. 
86. Pastural, M., M. Abtahi, and P. Lang, The benefits of new 
immunosuppressive treatments in adult kidney transplantation. Presse 
Med, 2002. 31(9): p. 421-6. 
87. Weber, M., et al., Single center analysis of mycophenolate mofetil and 
Neoral/prednisone therapy for prophylaxis of rejection in African-American 
and Caucasian transplant recipients. Transplantation Proceedings, 1997. 
29(1-2): p. 338-9. 
88. Vogelsang, G.B. and S. Arai, Mycophenolate mofetil for the prevention 
and treatment of graft-versus-host disease following stem cell 
transplantation: preliminary findings. Bone Marrow Transplantation, 2001. 
27(12): p. 1255-62. 
89. Levy, G.A., Long-term immunosuppression and drug interactions. Liver 
Transplantation, 2001. 7(11 Supp 1): p. S53-9. 
90. Parleviet, K.J. and P.T. Schellekens, Monoclonal antibodies in renal 
transplantation: a review. Transplant Immunology, 1992. 5(4): p. 234-46. 
211
91. Dedrick, R.L., P. Walicke, and M. Garovoy, Anti-adhesion antibodies 
efalizumab, a humanized anti-CD11a monoclonal antibody. Transplant 
Immunology, 2002. 9(2): p. 181-6. 
92. Chandraker, A., H. Azuma, and K. Nadeau, Late blockade of T cell 
costimulation interrupts progression of experimental chronic allograft 
rejection. J Clin Invest, 1998. 101(11): p. 2309-18. 
93. Ilan, Y., et al., Induction of central tolerance by intrathymic inoculation of 
adenoviral antigens into the host thymus permits long-term gene therapy 
in Gunn rats. Journal of Clinical Investigation, 1996. 98(11): p. 2640-7. 
94. Jolicoeur, C., D. Hanahan, and K.M. Smith, T cell tolerance toward a 
transgenic beta cell antigen and transcription of endogenous pancreatic 
genes in thymus. Proceedings of the National Academy of Science, 
U.S.A., 1994. 91: p. 6707-6711. 
95. Sonntag, K.C., et al., Tolerance to solid organ transplants through transfer 
of MHC class II genes. Journal of Clinical Investigation, 2001. 107(1): p. 
33-4. 
96. Sykes, M., D.H. Saches, and A.W. Nienhuis, Specific prolongation of skin 
graft survival following retroviral transduction of bone marrow with an 
allogeneic major histocompatibility complex gene. Transplantation, 1993. 
55: p. 197. 
97. Modigliani, Y., et al., Establishment of tissue-specific tolerance is driven by 
regulatory T cells selected by thymic epithelium. Eur J Immunol, 1996. 
26(8.): p. 1807-15. 
98. Kappler, J.W., M. Roehm, and P. Marrack, T cell tolerance by clonal 
elimination in the thymus. Cell, 1987. 49: p. 273-280. 
99. Sprent, J., et al., T-cell selection in the thymus. Princess Takamatsu 
Symposia, 1988. 19: p. 127-36. 
100. Ge, Q. and C. W.F., Effect of murine thymic epithelial cell line (MTEC1) on 
the functional expression of CD4(+)CD8(-) thymocyte subgroups. 
International Immunology, 2000. 12(8): p. 1127-33. 
101. Kasai, M., et al., Difference in antigen presentation pathways between 
cortical and medullary thymic epithelial cells. European Journal of 
Immunology, 1996. 26: p. 2101-7. 
102. Mueller, D.L., M.K. Jenkins, and R.H. Schwartz, Clonal expansion versus 
functioanl clonal inactivation: a costimulatory signalling pathway 
determines the outcome of T cell antigen receptor occupancy. Annual 
Reviews of Immunology, 1989. 7: p. 445-480. 
103. Ohashi, P.S., et al., Ablation of "tolerance" and induction of diabetes by 
virus infection of viral antigen transgenic mice. Cell, 1991.: p. 305-317. 
212
104. LeDouarin, N., et al., Evidence for a thymus-dependent form of tolerance 
that is not based on elimination or anergy of reactive T cells. 
Immunological Reviews., 1996. 149: p. 35-54. 
105. Zilberman, Y., et al., Apoptosis of thymic lymphoma clones by thymic 
epithelial cells: a putative model for 'death by neglect'. Immunology 
Letters, 1999. 67(2): p. 95-104. 
106. Cairns, L., F.S. Rosen, and Y. Borel, Mice naturally tolerance to C5 have 
T cells that suppress the response to this antigen. European Journal of 
Immunology, 1986. 16: p. 1277-1282. 
107. Oluwole, S.F., et al., Induction of peripheral tolerance by intrathymic 
inoculation of soluble antigens: evidence for the role of host antigen-
presenting cells and suppressor cell mechanism. Cellular Immunology, 
1995. 162: p. 33-41. 
108. Odorico, J.S., et al., Examination of the mechanisms responsible for 
tolerance induction after intrathymic inoculation of allogeneic bone 
marrow. Annals of Surgery, 1993. 218(4): p. 525-31; discussion 31-3. 
109. Egwuagu, C.E., P. Charukamnoetkanok, and I. Gery, Thymic expression 
of autoantigens correlates with resistance to autoimmune disease. Journal 
of Immunology, 1997. 159(7): p. 3109-12. 
110. Haller, G.W., et al., Thymic transplantation across an MHC class I barrier 
in swine. Journal of Immunology, 1999. 163(7): p. 3785-92. 
111. Chowdhury, N.C., et al., Donor-specific unresponsiveness to murine 
cardiac allografts induced by intrathymic-soluble alloantigens is dependent 
on alternate pathway of antigen presentation. Journal of Surgical 
Research, 1995. 59: p. 91-6. 
112. Oluwole, S.F., et al., Induction of transplantation tolerance to rat cardiac 
allografts by intrathymic inoculation of allogeneic soluble peptides. 
Transplantation, 1993. 56(6): p. 1523-7. 
113. Behrens, D., et al., Donor-derived soluble MHC antigens plus low-dose 
cyclosporine induce transplantation unresponsiveness independent of the 
thymus by down-regulating T cell-mediated alloresponses in a rat 
transplantation model. Transplantation, 2001. 72(12): p. 1974-82. 
114. Ohajekwe, O.A., et al., Transplantation tolerance to rat cardiac and islet 
allografts by posttransplant intrathymic inoculation of soluble alloantigens. 
Transplantation, 1995. 60(10): p. 1139-43. 
115. Niederkorn, J.Y. and E. Mayhew, Phenotypic analysis of oral tolerance to 
alloantigens: evidence that the indirect pathway of antigen presentation is 
involved. Transplantation, 2002. 73(9): p. 1493-500. 
116. Posselt, A.M., et al., Intrathymic islet transplantation in the spontaneously 
diabetic BB rat. Annals of Surgery, 1991. 214: p. 363-71, Discussion 371-
3. 
213
117. Posselt, A.M., et al., Prevention of autoimmune diabetes in the BB rat by 
intrathymic islet transplantation at birth. Science, 1992. 256(5061): p. 
1321-4. 
118. Brayman, K.L., et al., Evaluation of intrathymic islet transplantation in the 
prediabetic period. Surgery, 1992. 112: p. 319. 
119. Brayman, K.L., et al., Intrathymic islet allografts prevent hyperglycemia 
and autoimmune beta-cell destruction in BB rats following transplantation 
in the prediabetic period. Transplantation Proceedings, 1993. 25: p. 284-5. 
120. Posselt, A.M., et al., Intrathymic inoculation of islets at birth prevents 
autoimmune diabetes and pancreatic insulitis in the BB rat. 
Transplantation Proceedings, 1993. 25(1 Pt 1): p. 301-2. 
121. Brayman, K.L., et al., Evaluation of intrathymic islet transplantation in the 
prediabetic period. Surgery, 1992. 112(2): p. 319-26. 
122. Fritz, R.B. and M.L. Zhao, Thymic expression of myelin basic protein 
(MBP). Activation of MBP-specific T cells by thymic cells in the absence of 
exogenous MBP. Journal of Immunology, 1996. 157(12): p. 5249-53. 
123. Posselt, A.M., et al., Induction of donor-specific unresponsiveness by 
intrathymic islet transplantation. [see comments]. Science, 1990. 
249(4974): p. 1293-5. 
124. Remuzzi, G., et al., Kidney graft survival in rats without 
immunosuppressants after intrathymic glomerular transplantation. Lancet, 
1991. 337(8744): p. 750-2. 
125. Posselt, A.M., et al., Promotion of pancreatic islet allograft survival by 
intrathymic transplantation of bone marrow. Diabetes, 1992. 41(6): p. 771-
5. 
126. Odorico, J.S., et al., Induction of donor-specific tolerance to rat cardiac 
allografts by intrathymic inoculation of bone marrow. Surgery, 1992. 
112(2): p. 370-6; discussion 376-7. 
127. Campos, L., et al., Prolonged survival of rat orthotopic liver allografts after 
intrathymic inoculation of donor-strain cells. Transplantation, 1993. 55(4): 
p. 866-70. 
128. Cober, S.R., M.A. Randolph, and W.P. Lee, Skin allograft survival 
following intrathymic injection of donor bone marrow. Journal of Surgical 
Research, 1999. 85(2): p. 204-8. 
129. Odorico, J.S., et al., Promotion of rat cardiac allograft survival by 
intrathymic inoculation of donor splenocytes. Transplantation, 1993. 55(5): 
p. 1104-7. 
130. Hager, B., J.R. Bickenbach, and P. Fleckman, Long-term culture of murine 
epidermal keratinocytes. Journal of Investigative Dermatology., 1999. 
112(6): p. 971-6. 
214
131. Colic, M., et al., Heterogeneity of rat thymic epithelium defined by 
monoclonal anti-keratin antibodies. Thymus, 1988. 12(2): p. 123-30. 
132. Piltch, A., P. Naylor, and J. Hayashi, A cloned rat thymic epithelial cell line 
established from serum-free selective culture. In Vitro Cellular & 
Developmental Biology, 1988. 24(4): p. 289-93. 
133. McKeehan, W.L., P.S. Adams, and M.P. Rosser, Direct mitogenic effects 
of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown 
pituitary factors and possibly prolactin, but not androgen, on normal rat 
prostate epithelial cells in serum-free, primary cell culture. Cancer 
Research, 1984. 44(5): p. 1998-2010. 
134. Hager, B., J.R. Bickenbach, and P. Fleckman, Long-term culture of murine 
epidermal keratinocytes. Journal of Investigative dermatology, 1999. 
112(6): p. 971-6. 
135. Rheinwald, J.G. and H. Green, Serial cultivation of strains of human 
epidermal keratinocytes: the formation of keratinizing colonies from single 
cells. Cell., 1975. 6(3): p. 331-43. 
136. Compton, C.C., et al., Skin regenerated from cultured epithelial autografts 
on full-thickness burn wounds from 6 days to 5 years after grafting. 
Laboratory Investigation, 1989. 60: p. 600-612. 
137. Rouabhia, M., et al., Optimization of murine keratinocyte culture for the 
productionof graftable epidermal sheets. Journal of Dermatology, 1992. 
19: p. 325-334. 
138. Brown, O.A., et al., Thymulin stimulates prolactin and thyrotropin release 
in an age-related manner. Mechanisms of Ageing & Development, 1998. 
104(3): p. 249-62. 
139. Brown, O.A., et al., Growth hormone-releasing activity of thymulin on 
pituitary somatotropes is age dependent. Neuroendocrinology, 1999. 
69(1): p. 20-7. 
140. Bach, J.F. and M. Dardenne, Thymulin, a zinc-dependent hormone. 
Medical Oncology & Tumor Pharmacotherapy, 1989. 6(1): p. 25-9. 
141. Cohen, S., et al., Feedback regulation of the secretion of a thymic 
hormone (thymulin) by human thymic epithelial cells in culture. Thymus, 
1986. 8(3): p. 109-19. 
142. De Mello-Coelho, V., et al., Role of prolactin and growth hormone on 
thymus physiology. Developmental Immunology, 1998. 6(3-4): p. 317-23. 
143. Nakagawa, M., et al., Thymocyte proliferation-inducing activity of high 
molecular weight fraction from the culture supernatant of thymic epithelial 
cell line established from normal rat thymus. Cellular & Molecular Biology, 
1996. 42(2): p. 199-207. 
144. Bodey, B., B. Bodey, Jr., and H.E. Kaiser, Cell culture observations of 
human postnatal thymic epithelium: an in vitro model for growth and 
215
humoral influence on intrathymic T lymphocyte maturation. In Vivo, 1996. 
10(5): p. 515-26. 
145. Vacca, A., et al., Thrombospondin-1 is a mediator of the neurotypic 
differentiation induced by EGF in thymic epithelial cells. Experimental Cell 
Research, 1999. 248(1): p. 79-86. 
146. Hennings, H., et al., Calcium regulation of growth and differentiation in 
mouse epidermal cells in culture. Cell, 1980. 19: p. 245-254. 
147. Nieburgs, A.C., et al., In vitro growth and maintenance of two 
morphologically distinct populations of thymic epithelial cells. Cellular 
Immunology, 1985. 90(2): p. 439-50. 
148. Small, M., L. Barr-Nea, and M. Aronson, Culture of thymic epithelial cells 
from mice and age-related studies on the growing cells. European Journal 
of Immunology, 1984. 14(10): p. 936-42. 
149. Farr, A.G., D.J. Eisenhardt, and S.K. Anderson, Isolation of murine thymic 
epithelium and an improved method for its propagation in vitro. Anatomical 
Record, 1986. 216(1): p. 85-94. 
150. Eshel, I., N. Savion, and J. Shoham, Analysis of thymic stromal cell 
subpopulations grown in vitro on extracellular matrix in defined medium. I. 
Growth conditions and morphology of murine thymic epithelial and 
mesenchymal cells. Journal of Immunology, 1990. 144(5): p. 1554-62. 
151. Chaproniere, D.M. and W.L. McKeehan, Serial culture of single adult 
human prostatic epithelial cells in serum-free medium containing low 
calcium and a new growth factor from bovine brain. Cancer Research, 
1986. 46: p. 819-24. 
152. Sacks, P.G., et al., In vitro modulation of differentiation by calcium organ 
cultures of human and murine epithelial tissue. In Vitro Cellular & 
Developmental Biology, 1985. 21: p. 99-107. 
153. Wolff, J.A. and J. Lederberg, An early history of gene transfer and therapy. 
Human Gene Therapy, 1994. 1994(5): p. 465. 
154. Yuspa, S.H., et al., Clonal growth of mouse epidermal cells in medium 
with reduced calcium concentration. Journal of Investigative dermatology, 
1981. 76: p. 144-146. 
155. Christensson, B., et al., In vitro culture of human thymic epithelial cells in 
serum-free media. APMIS, 1989. 97(10): p. 926-34. 
156. van de Wijngaert, F.P., et al., Heterogeneity of epithelial cells in the 
human thymus. An ultrastructural study. Cell & Tissue Research, 1984. 
237(2): p. 227-37. 
157. Itoh, T., Establishment of an epithelial cell line from rat thymus. American 
Journal of Anatomy., 1979. 156(1): p. 99-104. 
216
158. Kurz, B., et al., Rat thymic epithelial cells in vitro and in situ: 
characterization by immunocytochemistry and morphology. Cell & Tissue 
Research, 1996. 283(2): p. 221-9. 
159. Chaproniere, D.M. and M.M. Webber, Dexamethasone and retinyl acetate 
similarly inhibit and stimulate EGF- or insulin-induced proliferation of 
prostatic epithelium. Journal of Cellular Physiology, 1985. 122(2): p. 249-
53. 
160. Argiles, A., et al., Regulation of human renal adenocarcinoma cell growth 
by retinoic acid and its interactions with epidermal growth factor. Kidney 
Int., 1994. 45(1): p. 23-31. 
161. Pazirandeh, A., et al., Paracrine glucocorticoid activity produced by mouse 
thymic epithelial cells. FASEB Journal, 1999. 13(8): p. 893-901. 
162. Jondal, M., A. Pazirandeh, and S. Okret, Different roles for glucocorticoids 
in thymocyte homeostasis? Trends Immunol., 2004. 25(11): p. 595-600. 
163. Masuda, A., et al., Dexamethasone-induced changes in morphology and 
keratin organization of rat thymic epithelial cells in primary culture. 
Experimental Cell Research, 1985. 160(2): p. 343-55. 
164. Fischer, S.M., et al., Improved conditions for murine epidermal cell culture. 
In Vitro., 1980. 16(2): p. 180-8. 
165. Bertolero, F., et al., Mouse epidermal keratinocytes. Clonal proliferation 
and response to hormones and growth factors in serum-free medium. Exp 
Cell Res., 1984. 155(1): p. 64-80. 
166. Bertolero, F., et al., Effects of serum and serum-derived factors on growth 
and differentiation of mouse keratinocytes. In Vitro Cell Dev Biol., 1986. 
22(7): p. 423-8. 
167. Oku, H., et al., Further optimization of culture method for rat keratinocytes: 
titration of glucose and sodium chloride. In Vitro Cell Dev Biol Anim., 1999. 
35(2): p. 67-74. 
168. Rosenthal, D.S., et al., A human epidermal differentiation-specific keratin 
gene is regulated by calcium but not negative modulators of differentiation 
in transgenic mouse keratinocytes. Cell Growth and Differentiation, 1991. 
2: p. 107-113. 
169. Roop, D.R., et al., Keratin gene expression in mouse epidermis and 
cultured epidermal cells. Proceedings of the National Academy of 
Sciences of the United States of America., 1983. 80(3): p. 716-20. 
170. Chaproniere, D.M. and W.L. McKeehan, Serial culture of single adult 
human prostatic epithelial cells in serum-free medium containing low 
calcium and a new growth factor from bovine brain. Cancer Res., 1986. 
46(2): p. 819-24. 
217
171. Fernandez, E., et al., Establishment and characterization of cloned human 
thymic epithelial cell lines. Analysis of adhesion molecule expression and 
cytokine production. Blood, 1994. 83(11): p. 3245-54. 
172. Sakai, Y., et al., Expression of proto-oncogenes and tumor suppressor 
genes in in vitro cell lines derived from a thymus, thymoma, and malignant 
thymoma of rats. Nagoya Journal of Medical Science, 1993. 55(1-4): p. 
125-30. 
173. Masuda, A., K. Ohtsuka, and M. Matsuyama, Establishment of functional 
epithelial cell lines from a rat thymoma and a rat thymus. In Vitro Cellular 
& Developmental Biology, 1990. 26(7): p. 713-21. 
174. Glimcher, L.H., et al., Functional activity of a transformed thymic epithelial 
cell line. Scandinavian Journal of Immunology, 1983. 17(1): p. 1-11. 
175. Watt, S.M., et al., Human thymic epithelial cells are frequently transformed 
by retroviral vectors encoding simian virus 40. Cellular Immunology, 1991. 
138(2): p. 456-72. 
176. Watt, S.M., et al., Adhesion receptors are differentially expressed on 
developing thymocytes and epithelium in human thymus. Experimental 
Hematology, 1992. 20(9): p. 1101-11. 
177. Melo, L.G., et al., Gene therapy strategy for long-term myocardial 
protection using adeno-associated virus-mediated delivery of heme 
oxygenase gene. Circulation, 2002. 105(5): p. 602-7. 
178. Knechtle, S.J., et al., Direct MHC class I complementary DNA transfer to 
thymus induces donor-specific unresponsiveness, which involves multiple 
immunologic mechanisms. Journal of Immunology, 1997. 159(1): p. 152-8. 
179. Wood, K.J. and T.G. Prior, Gene therapy in transplantation. Curr Opin Mol 
Ther., 2001. 3(4): p. 390-8. 
180. Behara, A.M., A.J. Westcott, and P.L. Chang, Intrathymic implants of 
genetically modified fibroblasts. FASEB Journal, 1992. 6(10): p. 2853-8. 
181. Vassalli, G., Gene therapy of heart transplantation. Rev Med Suisse 
Romande., 2002. 122(3): p. 145-8. 
182. Wood, K.J., The induction of tolerance to alloantigens using MHC class I 
molecules. Current Opinion in Immunology, 1993. 5(5): p. 759-62. 
183. Ma, J., H. Iwaki, and K. Kikuchi, Five novel monoclonal antibodies to 
thymic epithelial cell surface antigens in rats. Chin Med J (Engl). 2002. 
115(8): p. 1186-90. 
184. Pavlovic, M.D., et al., Two novel monoclonal antibodies reactive with 
different components of the rat thymic epithelium. Thymus, 1993. 21(4): p. 
235-46. 
185. Savino, W. and M. Dardenne, Developmental studies on expression of 
monoclonal antibody-defined cytokeratins by thymic epithelial cells from 
218
normal and autoimmune mice. Journal of Histochemistry & Cytochemistry, 
1988. 36(9): p. 1123-9. 
186. Dalloul, A.H., et al., Human thymic epithelial cells produce interleukin-3. 
Blood, 1991. 77(1): p. 69-74. 
187. Freysdottir, J. and M.A. Ritter, Antibodies to human thymic epithelium form 
part of the murine autoreactive repertoire. Dev Immunol., 2001. 8(2): p. 
75-93. 
188. Farr, A.G., et al., Medullary epithelial cell lines from murine thymus 
constitutively secrete IL-1 and hematopoietic growth factors and express 
class II antigens in response to recombinant interferon-gamma. Cellular 
Immunology, 1989. 119(2): p. 427-44. 
189. Savino, W., S. Berrih, and M. Dardenne, Thymic epithelial antigen, 
acquired during ontogeny and defined by the anti-p19 monoclonal 
antibody, is lost in thymomas. Laboratory Investigation, 1984. 51(3): p. 
292-6. 
190. Savino, W. and M. Dardenne, Immunohistochemical studies on a human 
thymic epithelial cell subset defined by the anti-cytokeratin 18 monoclonal 
antibody. Cell & Tissue Research, 1988. 254(1): p. 225-31. 
191. Takahashi, T., et al., Immunohistological analysis of thymic tumors with 
PE-35 monoclonal antibody reactive with medullary thymic epithelium. 
Cancer Research, 1988. 48(7): p. 1896-903. 
192. Takeuchi, T., et al., A new monoclonal antibody to human subcapsular 
thymic epithelial cells. Virchows Archiv - A, Pathological Anatomy & 
Histopathology, 1991. 419(2): p. 147-51. 
193. Chan, W.C., et al., Thymoma: an immunohistochemical study. American 
Journal of Clinical Pathology, 1984. 82(2): p. 160-6. 
194. Kraus, V.B., et al., Demonstration of phenotypic abnormalities of thymic 
epithelium in thymoma including two cases with abundant Langerhans 
cells. American Journal of Pathology, 1988. 132(3): p. 552-62. 
195. Chung, D.H., et al., A monoclonal antibody to cell surface antigen of 
human thymic epithelial cell. Journal of Korean Medical Science, 1994. 
9(1): p. 47-51. 
196. Colic, M., et al., Immunohistochemical characterization of rat thymic non-
lymphoid cells. I. Epithelial and mesenchymal components defined by 
monoclonal antibodies. Immunology, 1988. 65(2): p. 277-84. 
197. Defresne, M.P., et al., The ER-TR4 monoclonal antibody recognizes 
murine thymic epithelial cells (type 1) and inhibits their capacity to interact 
with immature thymocytes: immuno-electron microscopic and functional 
studies. Histochemistry, 1994. 101(5): p. 355-63. 
219
198. Hirokawa, K., et al., Analysis of the thymic microenvironment by 
monoclonal antibodies with special reference to thymic nurse cells. 
Thymus, 1986. 8(6): p. 349-60. 
199. Izon, D.J. and R.L. Boyd, The cytoarchitecture of the human thymus 
detected by monoclonal antibodies. Human Immunology, 1990. 27(1): p. 
16-32. 
200. Kaneshima, H., et al., Thymic epithelial reticular cell subpopulations in 
mice defined by monoclonal antibodies. Laboratory Investigation, 1987. 
56(4): p. 372-80. 
201. Rouse, R.V., et al., Monoclonal antibodies reactive with subsets of mouse 
and human thymic epithelial cells. Journal of Histochemistry & 
Cytochemistry, 1988. 36(12): p. 1511-7. 
202. Van Vliet, E., M. Melis, and W. Van Ewijk, Monoclonal antibodies to 
stromal cell types of the mouse thymus. European Journal of Immunology, 
1984. 14(6): p. 524-9. 
203. Vollger, L.W., et al., Thymocyte binding to human thymic epithelial cells is 
inhibited by monoclonal antibodies to CD-2 and LFA-3 antigens. Journal of 
Immunology, 1987. 138(2): p. 358-63. 
204. Colic, M., et al., Ontogeny of rat thymic epithelium defined by monoclonal 
anticytokeratin antibodies. Developmental Immunology, 1990. 1: p. 67-75. 
205. Colic, M., et al., Heterogeneity of rat thymic epithelium defined by 
monoclonal anti-keratin antibodies. Thymus., 1988-1989. 12(2): p. 123-30. 
206. De Maagd, R.A., et al., The human thymus microenvironment: 
heterogeneity detected by monoclonal anti-epithelial cell antibodies. 
Immunology, 1985. 89: p. 152-7. 
207. Kampinga, J., et al., The rat thymus microenvironment: subsets of thymic 
epithelial cells defined by monoclonal antibodies. Transplantation 
Proceedings, 1987. 19: p. 3171-74. 
208. Cirne-Lima, E.O., W. van Ewijk, and W. Savino, Cortical and medullary 
phenotypes within a mouse thymic epithelial cell line. In Vitro Cellular & 
Developmental Biology. Animal, 1993. 29A(6): p. 443-5. 
209. Parvaz, P., et al., Study of a monoclonal antibody specific to epithelial 
cells of mammalian thymuses. Journal of Clinical & Laboratory 
Immunology, 1989. 30(3): p. 135-9. 
210. Hsu, S.M., L. Raine, and H. Fanger, A comparative study of the 
peroxidase-antiperoxidase method and an avidin-biotin complex method 
for studying polypeptide hormones with radioimmunoassay antibodies. 
American Journal of Clinical Pathology, 1981. 75(5): p. 734-8. 
211. Hsu, S.M., L. Raine, and H. Fanger, Use of avidin-biotin-peroxidase 
complex (ABC) in immunoperoxidase techniques: a comparison between 
220
ABC and unlabeled antibody (PAP) procedures. Journal of Histochemistry 
& Cytochemistry, 1981. 29(4): p. 577-80. 
212. Lumsden, R.D., J.A. Oaks, and R.R. Mills, Mitochondrial oxidation of 
diaminobenzidine and its relationship to the cytochemical localization of 
tapeworm peroxidase. Journal of Parasitology, 1969. 55(6): p. 1119-33. 
213. Burns, J., Background staining and sensitivity of the unlabelled antibody-
enzyme (PAP) method. Comparison with the peroxidase labelled antibody 
sandwich method using formalin fixed paraffin embedded material. 
Histochemistry, 1975. 43(3): p. 291-4. 
214. Colic, M., et al., Rat thymic epithelial cells in culture constitutively secrete 
IL-1 and IL-6. International Immunology, 1991. 3(11): p. 1165-74. 
215. Bodey, B. and H.E. Kaiser, Cell culture observations of human postnatal 
thymic epithelium: an in vitro model for growth and humoral influence on 
intrathymic T lymphocyte maturation. In Vivo, 1996. 10(5): p. 515-26. 
216. Jones, J.C., et al., Dynamic aspects of the supramolecular organization of 
intermediate filament networks in cultured epidermal cells. Cell Motility., 
1982. 2(3): p. 197-213. 
217. Mattey, D.L. and D.R. Garrod, Calcium-induced desmosome formation in 
cultured kidney epithelial cells. Journal of Cell Science., 1986. 85: p. 95-
111. 
218. Watt, F.M., D.L. Mattey, and D.R. Garrod, Calcium-induced reorganization 
of desmosomal components in cultured human keratinocytes. Journal of 
Cell Biology., 1984. 99(6): p. 2211-5. 
219. O'Keefe, E.J., R.A. Briggaman, and B. Herman, Calcium-induced 
assembly of adherens junctions in keratinocytes. Journal of Cell Biology., 
1987. 105(2): p. 807-17. 
220. Burns, T.R., et al., Desmosomes of epithelial malignant mesothelioma. 
Ultrastructural Pathology, 1988. 12(4): p. 385-8. 
221. Hennings, H. and K.A. Holbrook, Calcium regulation of cell-cell contact 
and differentiation of epidermal cells in culture. An ultrastructural study. 
Experimental Cell Research., 1983. 143(1): p. 127-42. 
222. Jones, N.D., et al., Deletion of alloantigen-reactive thymocytes as a 
mechanism of adult tolerance induction following intrathymic antigen 
administration. European Journal of Immunology, 1997. 27(7): p. 1591-
600. 
223. Posselt, A.M., et al., Induction of donor-specific unresponsiveness by 
intrathymic islet transplantation. Science, 1990. 249(4974): p. 1293-1295. 
224. Posselt, A.M., et al., Intrathymic inoculation of islets at birth prevents 
autoimmune diabetes and pancreatic insulitis in the BB rat. 
Transplantation Proceedings, 1993. 25(1 Pt 1): p. 301-2. 
221
225. Oluwole, O.O., et al., Indirect allorecognition in acquired thymic tolerance: 
induction of donor-specific permanent acceptance of rat islets by adoptive 
transfer of allopeptide-pulsed host myeloid and thymic dendritic cells. 
Diabetes., 2001. 50(7): p. 1546-52. 
226. Remuzzi, G., et al., Kidney graft survival in rats without 
immunosuppressants after intrathymic glomerular transplantation. Lancet, 
1991. 337: p. 750. 
227. Oluwole, S., N. Chowdhury, and R. Fawwaz, Induction of donor-specific 
unresponsiveness to rat cardiac allografts by intrathymic injection of UV-B-
irradiated donor spleen cells. Transplantation., 1993. 55: p. 1389. 
228. Garrovillo, M., A. Ali, and S.F. Oluwole, Indirect allorecognition in acquired 
thymic tolerance: induction of donor-specific tolerance to rat cardiac 
allografts by allopeptide-pulsed host dendritic cells. Transplantation., 
1999. 68(12): p. 1827-34. 
229. Oluwole, S.F., et al., Induction of transplantation tolerance to rat cardiac 
allografts by intrathymic inoculation of allogeneic souble peptides. 
Transplantation, 1993. 56: p. 1523-7. 
230. Ohzato, H. and A.P. Monaco, Induction of specific unresponsiveness 
(tolerance) to skin allografts by intrathymic donor-specific splenocyte 
injection in antilymphocyte serum-treated mice. Transplantation., 1992. 
54: p. 1090-5. 
231. Knechtle, S.J., et al., Direct MHC class I complementary DNA transfer to 
thymus induces donor-specific unresponsiveness, which involves multiple 
immunologic mechanisms. Journal of Immunology, 1997. 159(1): p. 152-8. 
232. Knechtle, S.J., et al., Induction of specific tolerance by intrathymic 
injection of recipient muscle cells transfected with donor Class I major 
histocompatibility complex. Transplantation., 1994. 57: p. 990. 
233. Chowdhury, J.R., R. Fawwaz, and S. Oluwole, Induction of donor-specific 
tolerance to rat cardiac and small bowel allografts by intrathymic 
inoculation of donor T-cells. Journal of Surgical Research, 1993. 54(368). 
234. Alfrey, E.J., et al., Tolerance induced by direct inoculation of donor antigen 
into the thymus in low and high responder rodents. Transplantation, 1995. 
59(8): p. 1171-6. 
235. Fiedor, P., et al., Dependence of acquired systemic tolerance to rat islet 
allografts induced by intrathymic soluble alloantigens on host 
responsiveness, MHC differences, and transient immunosuppression in 
the high responder recipient. Transplantation, 1997. 63(2): p. 279-83. 
236. Chester, C.H., M. Sykes, and D.H. Sachs, The recovery of resistance to 
alloengraftment following lethal irradiation and administration of T cell-
depleted syngeneic bone marrow. Transplantation Biology Section, 
222
National Cancer Institute, Bethesda, Maryland 20892., 1989. 4(2): p. 195-
200. 
237. Davis, R.C., S.R. Cooperband, and J.A. Mannick, Preparation and in vitro 
assay of effective and ineffective antilymphocyte sera. Surgery, 1969. 
66(1): p. 58-64. 
238. Henderson, R.F., et al., Effect of blood leucocyte depletion on the 
inflammatory response of the lung to quartz. Toxicol Appl Pharmacol, 
1991. 109(1): p. 127-36. 
239. Renkonen, R., Bone Marrow Transplantation in the Rat V. Lymphoid Cell 
Subsets in the Target Organs During Acute Graft-Versus-Host Disease. 
Transplantation, 1986. 41(6): p. 704-8. 
240. Chaib, E., et al., Does intrathymic injection of alloantigen-presenting cells 
before islet allo-transplantation prolong graft survival? Transplant 
International, 1994. 7 Suppl 1: p. S423-5. 
241. Ohzato, H. and A.P. Monaco, Induction of specific unresponsiveness 
(tolerance) to skin allografts by intrathymic donor-specific splenocyte 
injection in antilymphocyte serum-treated mice. Transplantation, 1992. 
54(6): p. 1090-5. 
242. Waynforth, H.B., Experimental and Surgical Technique in the Rat. 1980, 
Academic Press, A subsidiary of Harcourt Brace Janovich. 
243. Kover, K. and W.V. Moore, Initiation of rejection of established islet 
allografts by third-party thyroid allografts and splenic dendritic cells. 
Diabetes, 1991. 40(6): p. 754-8. 
244. Marks, R.G., Analyzing Research Data: The Basics of Biomedical 
Research Methodology. 1982, Malibar,FL: Robert E. Krieger Publishing 
Company. 
245. Walker, K.G., et al., Strain-dependent differences in prolongation of rat 
cardiac allograft survival after intrathymic injection of donor bone marrow 
and ALS treatment. Transplant Immunology, 1996. 4(2): p. 177-9. 
246. Hugo, P., et al., Thymic epithelial cell lines that mediate positive selection 
can also induce thymocyte clonal deletion. Journal of Immunology, 1994. 
152(3): p. 1022-31. 
247. Posselt, A.M., et al., Induction of donor-specific unresponsiveness by 
intrathymic islet transplantation. Science, 1990. 249(4974): p. 1293-5. 
248. Posselt, A.M., et al., Intrathymic islet transplantation in the spontaneously 
diabetic BB rat. Annals of Surgery, 1991. 214(4): p. 363-71; discussion 
371-3. 
249. Brayman, K.L., et al., Intrathymic islet allografts prevent hyperglycemia 
and autoimmune beta-cell destruction in BB rats following transplantation 
in the prediabetic period. Transplantation Proceedings, 1993. 25(1 Pt 1): 
p. 284-5. 
223
250. Oluwole, S.F., et al., Effectiveness of intrathymic inoculation of soluble 
antigens in the induction of specific unresponsiveness to rat islet allografts 
without transient recipient immunosuppression. Transplantation, 1994. 
58(10): p. 1077-81. 
251. Oluwole, S.F., et al., Induction of peripheral tolerance by intrathymic 
inoculation of soluble alloantigens: evidence for the role of host antigen-
presenting cells and suppressor cell mechanism. Cellular Immunology, 
1995. 162(1): p. 33-41. 
252. Sun, L., et al., Thymocytes stimulate metabolism of arachidonic acid in rat 
thymic epithelial cells. Cellular Immunology, 1990. 131(1): p. 86-97. 
253. Rice, R.H. and H. Green, Presence in human epidermal cells of a soluble 
protein precursor of the cross-linked envelope: activation of the cross-
linking by calcium ions. Cell., 1979. 18(3): p. 681-94. 
254. Zamansky, G.B., U. Nguyen, and I.N. Chou, An immunofluorescence 
study of the calcium-induced coordinated reorganization of microfilaments, 
keratin intermediate filaments, and microtubules in cultured human 
epidermal keratinocytes. Journal of Investigative Dermatology., 1991. 
97(6): p. 985-94. 
255. Jones, J.C. and K.A. Grelling, Distribution of desmoplakin in normal 
cultured human keratinocytes and in basal cell carcinoma cells. Cell 
Motility & the Cytoskeleton., 1989. 13(3): p. 181-94. 
256. Hays, E.F. and T.R. Beardsley, Immunologic effects of human thymic 
stromal grafts and cell lines. Clinical Immunology & Immunopathology., 
1984. 33(3): p. 381-90. 
257. Hibi, T., et al., Establishment of epithelial cell lines from human and 
mouse thymus immortalized by the 12S adenoviral E1a gene product. 
Thymus, 1991. 18(3): p. 155-67. 
258. Tamir, M., et al., Thymus-derived stromal cell lines. International Journal 
of Cell Cloning., 1987. 5(4): p. 289-301. 
259. Mori, K., et al., A novel MHC class I-related molecule expressed on mouse 
thymic stroma cells and mature lymphocytes. Immunogenetics, 1991. 
33(2): p. 101-7. 
260. Colic, M., et al., Adhesion molecules involved in the binding and 
subsequent engulfment of thymocytes by a rat thymic epithelial cell line. 
Immunology, 1994. 83(3): p. 449-56. 
261. Ransom, J., et al., Lymphokine-mediated induction of antigen-presenting 
ability in thymic stromal cells. Journal of Immunology, 1987. 139(8): p. 
2620-8. 
262. Lebkowski, J.S., et al., Adeno-associated virus: a vector system for 
efficient introduction and integration of DNA into a variety of mammalian 
cell types. Molecular & Cellular Biology, 1988. 8(10): p. 3988-96. 
224
263. Jenkinson, E.J., J.J. Owen, and R. Aspinall, Lymphocyte differentiation 
and major histocompatibility complex antigen expression in the embryonic 
thymus. Nature, 1980. 284(5752): p. 177-9. 
264. Berg, L.J., et al., Antigen/MHC-specific T cells are preferentially exported 
from the thymus in the presence of their MHC ligand. Cell, 1989. 58(6): p. 
1035-46. 
265. Kyewski, B.A., C.G. Fathman, and H.S. Kaplan, Intrathymic presentation 
of circulating non-major histocompatibility complex antigens. Nature, 1984. 
308(5955): p. 196-9. 
266. Kyewski, B.A., Seeding of thymic microenvironments defined by distinct 
thymocyte-stromal cell interactions is developmentally controlled. Journal 
of Experimental Medicine, 1987. 166(2): p. 520-38. 
267. Delaney, J.R., et al., Differences in the level of expression of class I major 
histocompatibility complex proteins on thymic epithelial and dendritic cells 
influence the decision of immature thymocytes between positive and 
negative selection. Proceedings of the National Academy of Sciences of 
the United States of America, 1998. 95(9): p. 5235-40. 
268. Lo, D., et al., Thymic stromal cell specialization and the T-cell receptor 
repertoire. Immunologic Research, 1997. 16(1): p. 3-14. 
269. Itoh, T., et al., Establishment of a mouse thymic epithelial cell line, IT-
76MHC and a brief review on cultured thymic epithelial cells. Cellular & 
Molecular Biology, 2001. 47(1): p. 1-18. 
 
 
 
 
 
225
VITA 
 
Sandra Soraya Sands 
 
Candidate for the Degree of 
 
Doctor of Philosophy 
 
 
Dissertation: THYMIC EPITHELIAL CELL TRANSPLANTATION TO THE HOST 
THYMUS: STUDIES IN IMMUNOMODULATION AND 
TOLERANCE INDUCTION 
 
Major Field: Biomedical Sciences 
 
Biographical:  
 
 Personal Data: Born April 13, 1976 to a proud father, Marcus Sands, a 
U.S. immigrant, and a hard working mother, Gail Sands, the daughter of 
U.S. immigrants.   
 
 Education: Premedical education at Southern Nazarene University in 
Bethany, Oklahoma.  Received Doctor of Osteopathy degree from 
Oklahoma State University College of Osteopathic Medicine (OSU-COM) 
in May 1997.  Completed the requirements for the Doctor of Philosophy 
degree through the Department of Anatomy and Cell Biology at Oklahoma 
State University Center for Health Sciences (OSU-CHS) in May, 2005.   
 
Experience:  
 
Premedical education supported by medical transcription work 1989 to 
1993; summer 1994 research fellowship during medical school (1993-
1997), 1997-1998 traditional rotating intern Tulsa Regional Medical Center 
(TRMC), 1998 to 1999 neurosurgery resident (TRMC), Histology, Gross 
Anatomy, and Neuroanatomy teaching assistant Fall 1999 to Spring 2002, 
2002-2004 family medicine resident (TRMC), 2004 small group facilitator 
OSU-COM, and graduate research assistant, OSU-CHS Department of 
Anatomy and Cell Biology, 1999 to 2005. 
226
Name: Sandra Sands Date of Degree:    May, 2005 
 
Institution: Center for Health Sciences, Oklahoma State University 
Location: Tulsa, Oklahoma 
Title of Study: THYMIC EPITHELIAL CELL TRANSPLANTATION TO THE HOST THYMUS: 
STUDIES IN IMMUNOMODULATION AND TOLERANCE INDUCTION 
Pages in Study: 225              Candidate for the Degree of Doctor of Philosophy 
 
Major Field: Biomedical Sciences 
 
Scope and Method of Study: This study’s purpose was to determine whether thymic epithelial 
cells (TECs) would work in a pre-transplantation intrathymic tolerance induction regimen, 
necessitating investigations on the establishment of a primary TEC line, characterization of 
the response of TECs to varying medium conditions, and investigation of immunologic effects 
of intrathymic TEC transplantation on the natural history of graft rejection in an allogeneic rat 
transplantation model.  The efficacy of bone marrow has been established in a regimen of 
pre-transplant tolerance induction.  It was hypothesized that isolated TECs might be better 
candidates.  Primary tissue culture techniques were used to establish TECs from different rat 
strains.  Light immunocytochemistry and transmission electron microscopy were used to 
evaluate the effects of varying medium conditions on cellular morphology and differentiation.  
Allotransplantation following intrathymic cellular inoculation with histological analysis of 
challenge grafts examined the tolerance inducing capacity of TECs.  Multiple techniques 
tested the feasibility of gene therapeutic techniques on TECs 
 
Findings and conclusions: Rat TECs were established from 4 different strains of inbred rats, one 
of which became a cell line.  Light immunocytochemistry revealed cytokeratin intermediate 
filament expression, and electron microscopy revealed both cytokeratin intermediate 
filaments and desmosomes.  Quantification of morphological changes revealed 1 
desmosome per 6.24 µm of cell membrane in high calcium grown cells, and virtually no 
desmosomes in low calcium grown cells (p < 0.03).  Intrathymic transplantation experiments 
revealed a reduction in graft mean lymphocytic infiltration from 1.78+0.47 in the negative 
control groups (intrathymic saline, IP saline; n=10) and 1.50+0.60 (intrathymic saline, IP ALS; 
n=8) to 0.25+.25 (p < 0.01) in the positive control group (intrathymic bone marrow + ALS; 
n=8), and a reduction in graft mean lymphocytic infiltration to 1.00+0.31 in the experimental 
group (intrathymic TEC, IP ALS; n=16), p value > 0.05.  Overall, the results revealed that IT 
inoculation of TECs results in some immunomodulation, although not reaching the same 
effectiveness as bone marrow.  This project served as the predecessor to a future project 
using genetically modified intrathymic TECs in a new paradigm for allogeneic tolerance 
induction.  Initial transfection of TECs resulted in positive expression of reporter genes.   
 
 
 Robert J. Ketchum, Ph.D. 
Advisor’s Approval:            
 
 
